<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001155.pub2" GROUP_ID="MUSKEL" ID="055999082413023750" MERGED_FROM="" MODIFIED="2011-07-08 11:50:12 -0400" MODIFIED_BY="[Empty name]" REVIEW_NO="C004-R" REVMAN_SUB_VERSION="5.1.2" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2011-07-08 11:50:12 -0400" MODIFIED_BY="[Empty name]">
<TITLE>Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women</TITLE>
<CONTACT>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director, Cardiovascular Research Methods Centre</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology and Community Medicine</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-07-08 11:12:01 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director, Cardiovascular Research Methods Centre</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology and Community Medicine</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14918" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ann</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cranney</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ancranney@ohri.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Rheumatology</DEPARTMENT>
<ORGANISATION>Ottawa Hospital</ORGANISATION>
<ADDRESS_1>1053 Carling Ave</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4E9</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-798-5555 ext: 16804</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5409" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Joan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Peterson</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jpeterson@ohri.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Epidemiology Unit</DEPARTMENT>
<ORGANISATION>Ottawa Civic Hospital / Loeb Research Institute</ORGANISATION>
<ADDRESS_1>1053 Carling Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4E9</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 ext: 8279</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 761 5351</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13F0E8D782E26AA201A9DC553296B984" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Michel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Boucher</LAST_NAME>
<SUFFIX/>
<POSITION>Research Officer/ Interim Manager</POSITION>
<EMAIL_1>MichelB@CCOHTA.CA</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>HTA Development Canadian Agency for Drugs and Technologies in Health (CADTH)</ORGANISATION>
<ADDRESS_1>865 Carling Ave</ADDRESS_1>
<ADDRESS_2>Suite 600</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1S 5S8</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-226-2553 X 232</PHONE_1>
<PHONE_2/>
<FAX_1>613-226-5392</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5440" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Beverley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shea</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bevshea@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>CIET, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart St.</ADDRESS_1>
<ADDRESS_2>Room 312</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562 5800 ext: 8571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13312" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Vivian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Welch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>vivian.welch@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street, Room 206</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562-5800 ext: 2921</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="84E856DE82E26AA20104C58EF03F20CE" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Doug</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Coyle</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Scientist</POSITION>
<EMAIL_1>dcoyle@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiology and Community Medicine</DEPARTMENT>
<ORGANISATION>Ottawa Health Research Institute</ORGANISATION>
<ADDRESS_1>451 Smyth Rd.</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1H 8M5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 X 8690</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5465</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5474" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tugwell</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Medicine &amp; Epidemiology and Community Medicine, Canada Research Chair in Health Equity</POSITION>
<EMAIL_1>tugwell.bb@uottawa.ca</EMAIL_1>
<EMAIL_2>kerry.obrien@uottawa.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 ext: 1945</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-05-27 23:41:19 -0400" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="14" MONTH="11" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="11" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="11" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2011-07-08 11:50:12 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2011-07-08 11:50:12 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>Responses to queries about:</P>
<P>1. clincal and non-clinical fractures</P>
<P>2. NNT calculation.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-07-08 11:42:43 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2011-07-08 11:42:43 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="1" YEAR="2011"/>
<DESCRIPTION>
<P>Amendments in Figure 6: Summary of Findings for Secondary Prevention</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2011-01-19 23:09:53 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Absolute event rates included in the Plain language summary.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-01-19 23:11:45 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.CMSG ID C004-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Ottawa Hospital Research Institute</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Canadian Agency for Drugs and Technologies in Health</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-12 15:40:17 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-08-12 15:40:17 -0400" MODIFIED_BY="[Empty name]">
<TITLE>Alendronate for preventing fractures caused by osteoporosis in postmenopausal women</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-12 15:40:17 -0400" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effect of alendronate for preventing fractures (broken bones) caused by osteoporosis.<BR/>
<BR/>
<B>In women who have already been diagnosed with low bone density, putting them at risk for a fracture, or have already had a fracture in the bones of their spine, alendronate:</B>
</P>
<P>- may prevent fractures in the spine, hip or wrist, or in bones other than the spine.</P>
<P>
<B>In women whose bone density is closer to normal, or who may not yet have had a fracture in the bones of their spine, alendronate:</B>
</P>
<P>- probably prevents fractures in the spine</P>
<P>- probably leads to no difference in fractures of the hip, wrist or bones other than the spine.</P>
<P>We often do not have precise information about side effects and complications. This is particularly true for rare but serious side effects. Possible side effects may include digestive problems such as injury to the throat, esophagus and stomach and, less commonly, reduced blood supply to the jaw bone, which causes the bone tissue to break down.<BR/>
<BR/>
<B>What is osteoporosis and what is alendronate?</B>
<BR/>Bone is a living, growing part of your body. Throughout your lifetime, new bone cells grow and old bone cells break down to make room for the new, stronger bone. When you have osteoporosis, the old bone breaks down faster than the new bone can replace it. As this happens, the bones lose minerals (such as calcium). This makes bones weaker and more likely to break even after a minor injury, like a little bump or fall. Women are more likely to get osteoporosis after menopause.<BR/>
<BR/>Alendronate belongs to the class of drugs called bisphosphonates. It is a type of medication that slows down the cells that break down the old bone.<BR/>
<BR/>
<B>The best estimate of what happens to women that have already been diagnosed with low bone density or have already had a fracture in the bones of their spine:</B>
</P>
<P>Fracture of the spine</P>
<P>              - 12 out of 100 women had a fracture when taking a placebo</P>
<P>              - 6 out of 100 women had a fracture when taking alendronate</P>
<P>Fracture in the hip or wrist</P>
<P>               - 2 out of 100 women had a fracture when taking a placebo</P>
<P>               - 1 out of 100 women had a fracture when taking alendronate</P>
<P>Fractures in bones other than the spine</P>
<P>               - 9 out of 100 women had a fracture when taking a placebo</P>
<P>               - 7 out of 100 women had a fracture when taking alendronate</P>
<P>
<B>The best estimate of what happens to women whose bone density is closer to normal or who may not yet have had a fracture in the bones of their spine:</B>
</P>
<P>Fracture of the spine</P>
<P>                - 3 out of 100 women had a fracture when taking a placebo</P>
<P>                - 1 out of 100 women had a fracture when taking alendronate</P>
<P> Fractures in bones other than the spine:</P>
<P>                 - 1 out of 100 women had a hip fracture when taking a placebo</P>
<P>                 - 1 out of 100 women had a hip fracture when taking alendronate<BR/>
<BR/>
</P>
<P>               - 3 out of 100 women had a wrist fracture when taking a placebo</P>
<P>                 - 4 out of 100 women had a wrist fracture when taking alendronate</P>
<P> </P>
<P>                - 13 out of 100 women had a fracture somewhere other than the spine when taking a placebo</P>
<P>                 - 12 out of 100 women had a fracture somewhere other than the spine when taking alendronate</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Osteoporosis is an abnormal reduction in bone mass and bone deterioration leading to increased fracture risk. Alendronate belongs to the bisphosphonate class of drugs, which act to inhibit bone resorption by interfering with the activity of osteoclasts.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the efficacy of alendronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched CENTRAL, MEDLINE and EMBASE for relevant randomized controlled trials published between 1966 to 2007.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Women receiving at least one year of alendronate, for postmenopausal osteoporosis, were compared to those receiving placebo and/or concurrent calcium/vitamin D. The outcome was fracture incidence.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We undertook study selection and data abstraction in duplicate. We performed meta-analysis of fracture outcomes using relative risks and a &gt; 15% relative change was considered clinically important. We assessed study quality through reporting of allocation concealment, blinding and withdrawals.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Eleven trials representing 12,068 women were included in the review.</P>
<P>Relative (RRR) and absolute (ARR) risk reductions for the 10 mg dose were as follows. For vertebral fractures, a significant 45% RRR was found (RR 0.55, 95% CI 0.45 to 0.67). This was significant for both primary prevention, with 45% RRR (RR 0.55, 95% CI 0.38 to 0.80) and 2% ARR, and secondary prevention with 45% RRR (RR 0.55, 95% CI 0.43 to 0.69) and 6% ARR. For non-vertebral fractures, a significant 16% RRR was found (RR 0.84, 95% CI 0.74 to 0.94). This was significant for secondary prevention, with 23% RRR (RR 0.77, 95% CI 0.64 to 0.92) and 2% ARR, but not for primary prevention (RR 0.89, 95% CI 0.76 to 1.04). There was a significant 40% RRR in hip fractures (RR 0.60, 95% CI 0.40 to 0.92), but only secondary prevention was significant with 53% RRR (RR 0.47, 95% CI 0.26 to 0.85) and 1% ARR. The only significance found for wrist was in secondary prevention, with a 50% RRR (RR 0.50 95% CI 0.34 to 0.73) and 2% ARR. </P>
<P>For adverse events, we found no statistically significant differences in any included study. However, observational data raise concerns regarding potential risk for upper gastrointestinal injury and, less commonly, osteonecrosis of the jaw.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>At 10 mg per day, both clinically important and statistically significant reductions in vertebral, non-vertebral, hip and wrist fractures were observed for secondary prevention ('gold' level evidence, www.cochranemsk.org). We found no statistically significant results for primary prevention, with the exception of vertebral fractures, for which the reduction was clinically important ('gold' level evidence).</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Osteoporosis is in part a natural consequence of aging in postmenopausal women (<LINK REF="REF-Hodsman-2002" TYPE="REFERENCE">Hodsman 2002</LINK>). It is a skeletal disorder characterized by decreased bone mass, and deterioration in microarchitecture of bone resulting in an increased risk of fracture (<LINK REF="REF-NIH-Consensus-2001" TYPE="REFERENCE">NIH Consensus 2001</LINK>).</P>
<P>The most common consequences of osteoporosis are fractures of the hip, wrist and vertebrae (<LINK REF="REF-Hodsman-2002" TYPE="REFERENCE">Hodsman 2002</LINK>). "Bone strength reflects the integration of two main features: bone density and bone quality" (<LINK REF="REF-Brown-2002" TYPE="REFERENCE">Brown 2002</LINK>). The clinical indicator of bone quality is a patient's history of a fragility fracture. A fragility fracture is a fracture caused by an injury that would be insufficient to fracture normal bone (e.g. a fall from a standing height or less)(<LINK REF="REF-Brown-2002" TYPE="REFERENCE">Brown 2002</LINK>). The preferred method of evaluating bone density is the measurement of bone mineral density (BMD) of the spine and hip by Dual Energy X-ray Absorptiometry (DXA), which can be used to assess response to therapy (<LINK REF="REF-Hanley-2003" TYPE="REFERENCE">Hanley 2003</LINK>).</P>
<P>The interpretation of BMD results is based on comparison of a patient's BMD with the mean value for a young adult population. The "T-score" is the number of standard deviations (SDs) above or below the mean BMD for normal young adults (<LINK REF="REF-Brown-2002" TYPE="REFERENCE">Brown 2002</LINK>). The World Health Organization (WHO) Study Group on Osteoporosis defined osteoporosis as "a hip BMD level of more than 2.5 SDs below the mean BMD for young, white, adult women" (<LINK REF="REF-WHO-1994" TYPE="REFERENCE">WHO 1994</LINK>). Using the WHO definition, approximately 30% of postmenopausal women have osteoporosis (<LINK REF="REF-Kanis-1994" TYPE="REFERENCE">Kanis 1994</LINK>; <LINK REF="REF-WHO-1994" TYPE="REFERENCE">WHO 1994</LINK>). It should be noted that there are limitations associated with the WHO definition. The predictive value of BMD measurement for fracture varies depending on the site selected, database used for comparison and the technology used. Furthermore, T-scores do not provide a good basis to establish comparable diagnostic thresholds between different regions of interest and different bone mass measurement techniques (<LINK REF="REF-Black-2001" TYPE="REFERENCE">Black 2001</LINK>). As a result, between-site and technique variability introduces potential for misclassification and inappropriate treatment of some individuals.</P>
<P>Osteoporosis can be detected by BMD measurement or diagnosed by presence of osteoporosis-related fractures. The presence of pre-existing osteoporotic fractures is an important risk factor for future fractures (<LINK REF="REF-Hodsman-2002" TYPE="REFERENCE">Hodsman 2002</LINK>). It is reported that 25% of women aged 80 have had at least one vertebral fracture (<LINK REF="REF-Melton-1989" TYPE="REFERENCE">Melton 1989</LINK>). <LINK REF="REF-Cauley-2000" TYPE="REFERENCE">Cauley 2000</LINK> demonstrated excess mortality in women who have experienced a clinical vertebral fracture. The cumulative lifetime fracture risk for a 50-year-old woman with osteoporosis is stated to be as high as 60% (<LINK REF="REF-Cummings-1989" TYPE="REFERENCE">Cummings 1989</LINK>). As a result, effective fracture prevention would have a major impact on morbidity and a smaller but important impact on mortality in these women.</P>
<P>Osteoporosis-related morbidity is associated with significant medical and social consequences (<LINK REF="REF-Brown-2002" TYPE="REFERENCE">Brown 2002</LINK>). The major source of morbidity and mortality from osteoporosis is attributed to hip fractures. Hip fractures are not only associated with an increased mortality risk, but also influence long-term function and independence. Fifty percent of women who sustain a hip fracture do not return to their previous functional state and become dependent on others for their daily activities (<LINK REF="REF-Brown-2002" TYPE="REFERENCE">Brown 2002</LINK>). The mortality associated with hip fractures in older women may be as high as 20% in the first year (<LINK REF="REF-Cauley-2000" TYPE="REFERENCE">Cauley 2000</LINK>). This excess mortality may not be directly attributable to the hip fracture, but to comorbid conditions (<LINK REF="REF-Browner-1996" TYPE="REFERENCE">Browner 1996</LINK>; <LINK REF="REF-Cooper-1993" TYPE="REFERENCE">Cooper 1993</LINK>). </P>
<P>Prevention and treatment of osteoporosis can be complex, due to the multifactorial etiology of the disorder. Anabolic therapies directed at increasing bone formation, such as teriparatide (recombinant human parathyroid hormone (1-34))(<LINK REF="REF-Shukla-2003" TYPE="REFERENCE">Shukla 2003</LINK>) are available and very expensive; however, most currently available osteoporosis drugs are anti-resorptive agents that act to decrease bone turnover. Anti-resorptive drugs include the bisphosphonates (e.g. etidronate, alendronate and risedronate). They are recommended as first-line preventive agents in postmenopausal women with low BMD, and as first-line agents for the treatment of postmenopausal women with osteoporosis (<LINK REF="REF-Brown-2002" TYPE="REFERENCE">Brown 2002</LINK>). </P>
<P>Bisphosphonates are stable analogues of naturally occurring pyrophosphates. The mechanism of action of these drugs is to inhibit bone resorption through their effects on osteoclast function (<LINK REF="REF-Brown-2002" TYPE="REFERENCE">Brown 2002</LINK>). Bisphosphonates are poorly absorbed and avidly taken up by bone on active sites of resorption. Alendronate is a second generation nitrogen containing bisphosphonate which is administered daily or once weekly (depending on formulation) and does not impair bone mineralization at doses that maximally inhibit bone resorption (<LINK REF="REF-Rodan-1993" TYPE="REFERENCE">Rodan 1993</LINK>). The recommended doses for the prevention and treatment of osteoporosis in postmenopausal women are 5 mg/day (35 mg/week) or 10 mg/day (70 mg/week). Alendronate at 10 mg/day or greater, relative to control, has been shown to increase bone mineral density by 7.48% (95% CI, 6.12 to 8.85) after two to three years of treatment in the lumbar spine; 5.60% (95%CI, 4.80 to 6.39) after three to for years in the hip and 2.08% (95% CI, 1.53 to 2.63) after two to four years in the forearm (<LINK REF="REF-Cranney-2002" TYPE="REFERENCE">Cranney 2002</LINK>). At 5 mg/day, bone mineral density was increased by 5.81% (95% CI, 4.32 to 6.29) after two to three years in the spine, 4.64% (95%CI, 4.27 to 5.01) after three to four years in the hip and 1.83% (95% CI, 1.47 to 2.20) after three to four years in the forearm. (<LINK REF="REF-Cranney-2002" TYPE="REFERENCE">Cranney 2002</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of this systematic review was to assess the clinical efficacy of alendronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women receiving these agents, compared with untreated women over a follow-up period of at least one year.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomized controlled trials (RCTs) with a duration of at least one year were included in this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included only post-menopausal women, and accepted both primary and secondary prevention trials. A hierarchy was used to define primary versus secondary prevention according to the information available. We selected a definition of primary and secondary prevention that gave more weight to study inclusion criteria, than baseline statistics. That is, if the inclusion criteria restricted the population to women whose bone density was at least 2 SD values below the peak bone mass, or the inclusion criteria restricted the population to women who had experienced previous vertebral compression fractures, then the trial was considered a secondary prevention study. If such inclusion criteria were not provided, then the baseline statistics were considered as follows: (a) we considered the trial as primary prevention if the average T-score (and SD) was such that it included women whose bone density was within 2 SD of the mean, or if the prevalence of vertebral fracture at baseline was less than 20%; and (b) when these data were not available, we considered a trial as secondary prevention if the average age was above 62 years.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Treatment: Alendronate at any dose.<BR/>Comparators: No treatment (including placebo or calcium and/or vitamin D). If the study used calcium and/or vitamin D controls, these same treatments would have to be given concurrently in the alendronate treatment groups.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Incidence of fractures, including vertebral, non-vertebral, hip and wrist fractures.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The Cochrane Collaborative approach for identifying randomized controlled trials (RCTs) as described by <LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>, and modified for the Cochrane Musculoskeletal Group, guided our literature search. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE® (1966 to November 2004), Current Contents® and citations of relevant articles. No language restrictions were applied to the search strategy. The actual literature search was conducted in three stages. The first stage was the basis for our systematic review published in 2002 (<LINK REF="REF-Cranney-2002" TYPE="REFERENCE">Cranney 2002</LINK>) and the second and third stages involved updating the search. The first search, for the period 1966-99, included CENTRAL, MEDLINE®, EMBASE® and Current Contents®. This was followed by a MEDLINE® search for the time period 1999-November 2004. This MEDLINE search was confirmed by a parallel literature search that was conducted for a companion bisphosphonate economic report (<LINK REF="REF-CADTH-2006" TYPE="REFERENCE">CADTH 2006</LINK>). For the final update (2004 - February 2007), we searched CENTRAL, MEDLINE and EMBASE.</P>
<P>
<B>Literature search for MEDLINE using OVID interface<BR/>
</B>
<BR/>1. osteoporosis, postmenopausal/<BR/>2. osteoporosis/<BR/>3. osteoporosis.tw.<BR/>4. exp bone density/<BR/>5. bone loss$.tw.<BR/>6. (bone adj2 densit$).tw.<BR/>7. or/2-6<BR/>8. menopause/<BR/>9. post-menopaus$.tw.<BR/>10. postmenopaus$.tw.<BR/>11. or/8-10<BR/>12. 7 and 11<BR/>13. 1 or 12<BR/>14. alendronate/<BR/>15. alendronate.tw,rn.<BR/>16. fosamax.tw.<BR/>17. aminohydroxybutane bisphosphonate.tw.<BR/>18. or/14-17<BR/>19. 13 and 18<BR/>20. meta-analysis.pt,sh.<BR/>21. (meta-anal: or metaanal:).tw.<BR/>22. (quantitativ: review: or quantitativ: overview:).tw.<BR/>23. (methodologic: review: or methodologic: overview:).tw.<BR/>24. (systematic: review: or systematic: overview).tw.<BR/>25. review.pt. and medline.tw.<BR/>26. or/20-25<BR/>27. 19 and 26<BR/>28. clinical trial.pt.<BR/>29. randomized controlled trial.pt.<BR/>30. tu.fs.<BR/>31. dt.fs.<BR/>32. random$.tw.<BR/>33. (double adj blind$).tw.<BR/>34. placebo$.tw.<BR/>35. or/28-34<BR/>36. 19 and 35</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Selection of studies<BR/>
</B>Two reviewers examined each title generated from the search and identified potentially eligible articles, for which we obtained the abstracts. For abstracts consistent with study eligibility, the full article text was obtained. Overall, we only considered for inclusion studies for which findings were published, either as full article or abstract.</P>
<P>
<B>Data abstraction strategy</B>
<BR/>Two independent reviewers abstracted all information and data using standardized data abstraction forms, with a third reviewer verifying the data. Abstraction included information on pertinent methodological aspects of the study design, characteristics of the participants, the specific dose of the study drug used and the outcomes assessed (e.g. number of vertebral, non-vertebral, hip and wrist fractures). For fracture data, we considered all reported fractures (whether clinical or radiographic). </P>
<P>For the yearly data, our unit of analysis was number of patients sustaining a fracture. If an article reported yearly data, we used the time points available. For baseline denominators, we used the same baseline denominator for each time point. For follow-up denominators, we used any yearly follow-up number of patients reported in the article, if available. If these were not available, we assumed a uniform drop-out rate for each year and calculated the denominators by determining the proportion of subjects that would have remained at the end of the year in question based on the number of withdrawals over the course of the study. If an article reported only end of study outcomes, these were used for our analysis with the exception of outcomes for which the numerator was zero for both treatment groups. In these instances, we included the outcome (with any necessary adjustments for follow-up denominators) for the earlier years in the duration of the study. For example, if a trial reported zero hip fractures for both treatment arms at the end of year three, we would also include in our analysis zero hip fractures for that trial at years one and two. <BR/> <BR/>For person year data, the unit of analysis, if available, was number of fractures. When these data were not available (i.e. in the majority of cases), we used the number of women sustaining a fracture. For denominators, we multiplied the number of women followed by the length of the study. For radiographic vertebral fractures, we used the number of women with available radiographs, if the number was reported in the article. For clinical fractures, we estimated the number of women followed over the duration of the study by taking the mean of the baseline and follow-up denominators.</P>
<P>
<B>Strategy for quality assessment<BR/>
</B>Two reviewers assessed each eligible RCT for quality based on allocation concealment. Research has shown that lack of adequate allocation concealment is associated with bias (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>), and studies can be judged on the method of allocation concealment. The method for assigning participants to interventions should be robust against patient and clinician bias, and its description should be clear. The reviewers were required to indicate whether allocation concealment was adequate (A), unclear (B), or inadequate (C) as per The Cochrane Collaboration criteria as follows.</P>
<P>Adequate: The following are some approaches that can be used to ensure adequate concealment schemes: centralized or pharmacy-controlled randomization, pre-numbered or coded identical containers which are administered serially to participants; on-site computer system combined with allocations kept in a locked unreadable computer file that can be accessed only after the characteristics of an enrolled participant have been entered or sequentially numbered; or sealed, opaque envelopes. Other approaches may include those similar to ones listed previously, along with reassurance that the person who generated the allocation scheme did not administer it.</P>
<P>Inadequate: Approaches to allocation concealment that are considered inadequate include: alternation, use of case record numbers, dates of birth or day of the week and any procedure that is entirely transparent before allocation, such as an open list of random numbers.</P>
<P>Unclear: When studies do not report any concealment approach, adequacy should be considered unclear. Examples include merely stating that a list or table was used, only specifying that sealed envelopes were used and reporting an apparently adequate concealment scheme in combination with other information that leads the reviewer to be suspicious.</P>
<P>In addition, blinding and loss to follow-up were assessed. </P>
<P>
<B>Data analysis<BR/>
</B>For the analysis of fractures (i.e. vertebral, non-vertebral, hip and wrist), the relative risk (RR) of fracture was calculated. The methods we used for pooling the results are described elsewhere (<LINK REF="REF-Fleiss-1993" TYPE="REFERENCE">Fleiss 1993</LINK>). The pooled or weighted RRs, using the general inverse variance method for the weights were calculated. For the pooled results, site-specific 95% confidence intervals (CIs) were calculated for vertebral, non-vertebral, hip and wrist fractures, and we tested for association using a chi-square test procedure, taking P value &lt; 0.05 for presence of statistical association. Statistically significant risk reductions were considered to be clinically important if a 15% or greater relative benefit was shown. We also tested for homogeneity using a chi-square test procedure, taking the specific cut-off for presence of statistical heterogeneity as P value = 0.10 ( <LINK REF="REF-Fleiss-1993" TYPE="REFERENCE">Fleiss 1993</LINK>). In the event of significant heterogeneity, a random-effects model was used. </P>
<P>If the relative risk reduction (RRR) was significant (P value &lt; 0.05), then the absolute risk reduction (ARR) and number needed to treat (NNT) were calculated. For these calculations, we based the five-year risk of fracture in the untreated population on the FRACTURE Index (FI)(<LINK REF="REF-Black-2001" TYPE="REFERENCE">Black 2001</LINK>), and the lifetime and five-year age-specific risks in the untreated population on the model by Doherty et al. (<LINK REF="REF-Doherty-2001" TYPE="REFERENCE">Doherty 2001</LINK>) for predicting osteoporotic fractures in postmenopausal women (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>Trials varied as to the length of treatment (e.g. one to four years) and the number of patients available for study at the start of treatment (i.e. baseline denominator) compared to those available at different time points during the trial (i.e. follow-up denominators). The base case taken for the review of fractures considered the data available for the longest period of time for the treatment in the trial (i.e. "all years") and used the baseline denominators for the number of patients in the trial. </P>
<P>Data was initially pooled broadly across primary and secondary trials. The overall analysis was also considered using person-years of observation. In addition, we conducted subgroup analysis for: 1) primary versus secondary, 2) treatment duration and 3) treatment dose. Furthermore, we conducted sensitivity analysis for: 1) baseline denominators versus follow-up denominators, 2) fixed versus random effects model and 3) baseline vertebral fracture rate. For the last sensitivity analysis, recall that the vertebral fracture criteria for a trial to be considered secondary was a prevalence of vertebral fracture at baseline of greater than 20%. A sensitivity analysis using different vertebral fracture rates (i.e. 100%, &gt; 80%, &gt; 60%, &gt; 40%, &gt; 20%) without the BMD and age criteria was conducted. Such sensitivity analysis allowed evaluating whether the effect of bisphosphonates on the secondary prevention of osteoporotic fractures varied, depending on how strictly secondary prevention was defined.</P>
<P>
<B>Grading of evidence<BR/>
</B>We graded results for the primary analyses using the system described in <I>Evidence-based Rheumatology</I> (<LINK REF="REF-Tugwell-2004" TYPE="REFERENCE">Tugwell 2004</LINK>), as recommended by the Musculoskeletal Group.</P>
<P>Platinum: <BR/>To achieve the platinum level of evidence, a published systematic review that has at least two randomized controlled trials each satisfying the following is required: <BR/>- sample sizes of at least 50 per group - if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome;<BR/>- blinding of patients and assessors for outcomes; <BR/>- handling of withdrawals &gt; 80% follow up (imputations based on methods such as Last Observation Carried Forward (LOCF) are acceptable); <BR/>- concealment of treatment allocation. </P>
<P>Gold: <BR/>The gold level of evidence requires at least one randomized clinical trial meeting all of the following criteria for the major outcome(s) as reported: <BR/>- sample sizes of at least 50 per group - if they do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome; <BR/>- blinding of patients and assessors for outcomes; <BR/>- handling of withdrawals &gt; 80% follow up (imputations based on methods such as LOCF are acceptable); <BR/>- concealment of treatment allocation. </P>
<P>Silver: <BR/>The silver level of evidence requires a randomized trial that does not meet the above criteria for gold or platinum ranking, or evidence from at least one study of non-randomized cohorts that did and did not receive the therapy, or evidence from at least one high-quality case-control study. A randomized trial with a 'head-to-head' comparison of agents would be considered silver level ranking unless a reference were provided to a comparison of one of the agents to placebo showing at least a 20% relative difference. </P>
<P>Bronze:<BR/>The bronze level of evidence requires at least one high-quality case series without controls (including simple before/after studies in which patients act as their own control) or a conclusion derived from expert opinion based on clinical experience without reference to any of the foregoing (for example, argument from physiology, bench research or first principles). </P>
<P>
<B>Clinical relevance tables<BR/>
</B>Clinical relevance tables were compiled under "additional tables" to improve the readability of the review. Results were presented within the context of both the study population and moderate-/high-risk women from the population at large. The number needed to treat (NNT) was calculated using the relative risk (RR) in combination with either the risk of fracture in the control group, or the five-year FRACTURE Index (<LINK REF="REF-Black-2001" TYPE="REFERENCE">Black 2001</LINK>). To do this, the Visual Rx NNT calculator (<LINK REF="REF-Cates-2004" TYPE="REFERENCE">Cates 2004</LINK>) was used. The weighted absolute risk difference was calculated using the risk difference (RD) statistic in RevMan and RR-1 was used to calculate the relative percent change (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>In addition, for the outcomes of vertebral and hip fractures we prepared Summary of Findings tables using the GRADE criteria from the GRADE working group (<LINK REF="REF-GRADE-2004" TYPE="REFERENCE">GRADE 2004</LINK>), (<LINK REF="FIG-22" TYPE="FIGURE">Figure 22</LINK>; <LINK REF="FIG-23" TYPE="FIGURE">Figure 23</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<B>
<BR/>Quantity of research available<BR/>
</B>The literature search revealed 1203 citations as depicted in <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>. Of these, 85 articles were retrieved for further review. A total of 74 articles were excluded for various reasons, including lack of appropriate control group (19)(<LINK REF="STD-Black-2003" TYPE="STUDY">Black 2003</LINK>; <LINK REF="STD-Body-2002" TYPE="STUDY">Body 2002</LINK>; <LINK REF="STD-Chailurkit-2003" TYPE="STUDY">Chailurkit 2003</LINK>; <LINK REF="STD-Davas-2003" TYPE="STUDY">Davas 2003</LINK>; <LINK REF="STD-Evio-2004" TYPE="STUDY">Evio 2004</LINK>; <LINK REF="STD-Iwamoto-2004" TYPE="STUDY">Iwamoto 2004</LINK>; <LINK REF="STD-Kushida-2004" TYPE="STUDY">Kushida 2004</LINK>; <LINK REF="STD-Luckey-2004" TYPE="STUDY">Luckey 2004</LINK>; <LINK REF="STD-Palomba-2002" TYPE="STUDY">Palomba 2002</LINK>; <LINK REF="STD-Rittmaster-2000" TYPE="STUDY">Rittmaster 2000</LINK>; <LINK REF="STD-Rizzoli-2002" TYPE="STUDY">Rizzoli 2002</LINK>; <LINK REF="STD-Rozkydal-2003" TYPE="STUDY">Rozkydal 2003</LINK>; <LINK REF="STD-Sahota-2000" TYPE="STUDY">Sahota 2000</LINK>; <LINK REF="STD-Sambrook-2004a" TYPE="STUDY">Sambrook 2004a</LINK>; <LINK REF="STD-Schnitzer-2000" TYPE="STUDY">Schnitzer 2000</LINK>; <LINK REF="STD-Simon-2002" TYPE="STUDY">Simon 2002</LINK>; <LINK REF="STD-Sosa-2002" TYPE="STUDY">Sosa 2002</LINK>; <LINK REF="STD-Tiras-2000" TYPE="STUDY">Tiras 2000</LINK>; <LINK REF="STD-Vasikaran-1995" TYPE="STUDY">Vasikaran 1995</LINK>); lack of fracture outcome (25)(<LINK REF="STD-Aki-2003" TYPE="STUDY">Aki 2003</LINK>; <LINK REF="STD-Boivin-2000" TYPE="STUDY">Boivin 2000</LINK>; <LINK REF="STD-Bouxsein-1999" TYPE="STUDY">Bouxsein 1999</LINK>; <LINK REF="STD-Chailurkit-2003" TYPE="STUDY">Chailurkit 2003</LINK>; <LINK REF="STD-Chavassieux-1997" TYPE="STUDY">Chavassieux 1997</LINK>; <LINK REF="STD-Cummings-2000" TYPE="STUDY">Cummings 2000</LINK>; <LINK REF="STD-Dobnig-2006" TYPE="STUDY">Dobnig 2006</LINK>; <LINK REF="STD-Gonnelli-2002" TYPE="STUDY">Gonnelli 2002</LINK>; <LINK REF="STD-Ho-2005" TYPE="STUDY">Ho 2005</LINK>; <LINK REF="STD-Johnell-2002" TYPE="STUDY">Johnell 2002</LINK>; <LINK REF="STD-Kung-2000" TYPE="STUDY">Kung 2000</LINK>; <LINK REF="STD-Lau-2000" TYPE="STUDY">Lau 2000</LINK>; <LINK REF="STD-McClung-1998" TYPE="STUDY">McClung 1998</LINK>; <LINK REF="STD-Nenonen-2005" TYPE="STUDY">Nenonen 2005</LINK>; <LINK REF="STD-Ravn-1999a" TYPE="STUDY">Ravn 1999a</LINK>; <LINK REF="STD-Ravn-1999b" TYPE="STUDY">Ravn 1999b</LINK>; <LINK REF="STD-Rhee-2006" TYPE="STUDY">Rhee 2006</LINK>; <LINK REF="STD-Rossini-2000" TYPE="STUDY">Rossini 2000</LINK>; <LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK>; <LINK REF="STD-Stepan-1999" TYPE="STUDY">Stepan 1999</LINK>; <LINK REF="STD-Tutuncu-2005" TYPE="STUDY">Tutuncu 2005</LINK>; <LINK REF="STD-Uusi_x002d_Rasi-2003" TYPE="STUDY">Uusi-Rasi 2003</LINK>; <LINK REF="STD-van-der-Poest-2000" TYPE="STUDY">van der Poest 2000</LINK>; <LINK REF="STD-Yen-2000" TYPE="STUDY">Yen 2000</LINK>; <LINK REF="STD-Yildirim-2005" TYPE="STUDY">Yildirim 2005</LINK>); lack of appropriate fracture data (i.e. reported as adverse events or unspecified)(8), (<LINK REF="STD-Adami-1995" TYPE="STUDY">Adami 1995</LINK>; <LINK REF="STD-Bell-2002" TYPE="STUDY">Bell 2002</LINK>; <LINK REF="STD-Bone-2000" TYPE="STUDY">Bone 2000</LINK>; <LINK REF="STD-Bonnick-1998" TYPE="STUDY">Bonnick 1998</LINK>; <LINK REF="STD-Downs-2000" TYPE="STUDY">Downs 2000</LINK>; <LINK REF="STD-Greenspan-2003" TYPE="STUDY">Greenspan 2003</LINK>; <LINK REF="STD-Hosking-2003" TYPE="STUDY">Hosking 2003</LINK>; <LINK REF="STD-Murphy-2001" TYPE="STUDY">Murphy 2001</LINK>); lack of randomization (2), (<LINK REF="STD-Heijckmann-2002" TYPE="STUDY">Heijckmann 2002</LINK>; <LINK REF="STD-Sawka-2003" TYPE="STUDY">Sawka 2003</LINK>); extension/discontinuation studies (6)(<LINK REF="STD-Bone-2004" TYPE="STUDY">Bone 2004</LINK>; <LINK REF="STD-Greenspan-2002a" TYPE="STUDY">Greenspan 2002a</LINK>; <LINK REF="STD-McClung-2004" TYPE="STUDY">McClung 2004</LINK>; <LINK REF="STD-Ravn-1999c" TYPE="STUDY">Ravn 1999c</LINK>; <LINK REF="STD-Ravn-2000" TYPE="STUDY">Ravn 2000</LINK>; <LINK REF="STD-Sambrook-2004b" TYPE="STUDY">Sambrook 2004b</LINK>); duplicate report or earlier report of another study (7)(<LINK REF="STD-Adami-1993" TYPE="STUDY">Adami 1993</LINK>; <LINK REF="STD-Bettembuk-1999" TYPE="STUDY">Bettembuk 1999</LINK>; <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Devogelaer-1996" TYPE="STUDY">Devogelaer 1996</LINK>; <LINK REF="STD-Hochberg-1999" TYPE="STUDY">Hochberg 1999</LINK>; <LINK REF="STD-Seeman-1999" TYPE="STUDY">Seeman 1999</LINK>; <LINK REF="STD-Tucci-1996" TYPE="STUDY">Tucci 1996</LINK>); duration of therapy less than one year (7)(<LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Chesnut-1993" TYPE="STUDY">Chesnut 1993</LINK>; <LINK REF="STD-Greenspan-2002b" TYPE="STUDY">Greenspan 2002b</LINK>; <LINK REF="STD-Harris-1993" TYPE="STUDY">Harris 1993</LINK>; <LINK REF="STD-Malavolta-1999" TYPE="STUDY">Malavolta 1999</LINK>; <LINK REF="STD-Payer-2000" TYPE="STUDY">Payer 2000</LINK>; <LINK REF="STD-Rossini-1994" TYPE="STUDY">Rossini 1994</LINK>). If we found duplicate reports of the same study in preliminary abstracts and articles, we analyzed the data from the most complete data set. In total, 11 trials met the selection criteria for inclusion in this report (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>, <LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Chestnut-1995" TYPE="STUDY">Chestnut 1995</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>). </P>
<P>
<B>Trial characteristics<BR/>
</B>The characteristics of the 11 selected trials are provided in the 'Characteristics of included studies' table. A total of 12,068 women were enrolled; of these, 5525 received placebo. Three trials were in primary prevention (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>), and the other eight involved women with low BMD on densitometry and/or high prevalence of vertebral fracture (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Chestnut-1995" TYPE="STUDY">Chestnut 1995</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>). Three trials (including the largest secondary prevention trial--the Fracture Intervention Trial or FIT), used an initial dose of 5 mg and then switched to 10 mg for the final years (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>). Two trials (<LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>) evaluated only doses of 5 mg or less, four trials (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>) used only the 10 mg dose and two trials (<LINK REF="STD-Chestnut-1995" TYPE="STUDY">Chestnut 1995</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>) evaluated 5, 10 and 20 mg doses. For some endpoints, studies which administered both 5 and 10 mg did not report the results separately by dose (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK> ). To err on the conservative side, these endpoints were included in the 10 mg analysis.<BR/> <BR/>Length of follow up ranged from one to four years, and mean age was 53 to 78 years. Eight trials excluded women with a history of gastrointestinal disease (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>) and three trials evaluated fractures as the stated primary outcome (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>). All trials administered at least 500 mg of calcium to all patients and vitamin D, at daily doses ranging from 125-400 IU, was administered in four trials (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>). We did not include data from the HRT arm of the Hosking et al trial (<LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Four trials concealed allocation (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>) and for the remainder it was unclear. Two trials achieved a loss to follow up of less than 5% (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>); five trials had losses to follow up from 5% to 20% (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Chestnut-1995" TYPE="STUDY">Chestnut 1995</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>); three trials had losses to follow up over 20% (<LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>) and one trial did not report losses to follow up (<LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>). All studies but one were double blind (<LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>Effect on fractures<BR/>
</B>A summary of the overall review of fractures for the base case (i.e. the longest treatment duration and use of the baseline denominators for the number of patients in the trial) for the standard 10 mg dose of alendronate is provided in <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>. In general, for vertebral, non-vertebral, hip and wrist fractures, the pooled estimate of the RR was significant for secondary prevention but not for primary prevention (with the exception of vertebral fractures).</P>
<P>
<B>Vertebral fractures</B>
<BR/>Vertebral fractures were reported in eight of 11 trials (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>; <LINK REF="STD-Chestnut-1995" TYPE="STUDY">Chestnut 1995</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>). In two trials, no fractures occurred in either treatment group (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Chestnut-1995" TYPE="STUDY">Chestnut 1995</LINK>) and two trials (<LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>) evaluated only the 5 mg dose The pooled estimate of RR of vertebral fractures from the four trials (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>) that could be analyzed for the 10 mg dose demonstrated a reduction (45%) in vertebral fractures (RR 0.55, 95%, CI 0.45 to 0.67). For details, please refer to <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and Comparison 01.01. This supports a fracture risk reduction with alendronate and results were consistent across the four trials (P = 0.61). There was a significant reduction in vertebral fractures for both primary and secondary prevention trials. Estimates for the risk reduction were similar for the primary (RR 0.55, 95% CI, 0.38 to 0.80) and secondary (RR 0.55, 95% CI 0.43 to 0.69) prevention trials. </P>
<P>Corresponding to the significant RRR of 45% for the primary or secondary prevention of vertebral fractures, the absolute measures ARR and NNT of the 5-year risk of vertebral fracture after treatment with alendronate were calculated for different levels of increasing risk as given by the FI. Results are provided in <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>, as well as for increasing age in <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>. For the illustrative case of the patient with a FI of 6-7, the ARR in vertebral fracture was 3.2% (i.e. a reduction in risk from 7.1% to 3.9%) and the NNT was 31 (i.e. 31 patients would need to be treated to avoid one vertebral fracture). Across the range of increasing FI risk, the ARR for vertebral fracture ranged from 0.5% to 5.0%, and the NNT to avoid one vertebral fracture ranged from 200 to 20. For the illustrative patient in the age group 60-64 years, the ARR for the first vertebral fracture was 0.5% (i.e. a reduction in risk from 1.0% to 0.55%) and the NNT was 222 patients treated to avoid the first fracture. The ARR for a subsequent fracture was 4.4% (i.e. a reduction in risk from 9.7% to 5.3%) and the NNT was 23 patients treated to avoid one subsequent fracture. For increasing age, the 5-year age-specific ARR for the first vertebral fracture increased from 0.1% for the youngest age group (50-54 years) to 2.1% in the highest age group (90+ years). Accordingly, the NNT decreased from 1111 to 47. For the subsequent fracture, ARR increased from 0.2% to 12.6% and the NNT decreased from 444 to 8. </P>
<P>
<B>Non-vertebral fractures<BR/>
</B>Non-vertebral fractures were reported in nine trials (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Chestnut-1995" TYPE="STUDY">Chestnut 1995</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>, <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>). One trial did not report fractures separately by treatment groups (<LINK REF="STD-Chestnut-1995" TYPE="STUDY">Chestnut 1995</LINK>); one trial reported that no fractures occurred in either treatment group (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>) and two trials evaluated only the 2.5 and 5 mg doses. (<LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>). The pooled estimate of the RR of non-vertebral fractures from the five trials (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>) that could be analyzed for the 10 mg dose demonstrated a significant reduction (16%) in non-vertebral fractures (RR: 0.84, 95% CI 0.74 to 0.94). Details can be found in (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and Comparison 02.01) and results were consistent across the five trials (p = 0.29). Although the primary and secondary prevention trials differed in significance of the reduction in risk of non-vertebral fractures, the non-significant reduction (RR 0.89, 95% CI 0.76 to 1.04) in the one primary was not clearly different from the significant reduction (RR 0.77, 95% CI 0.64 to 0.92) in the four secondary prevention trials. </P>
<P>Corresponding to the significant RRR of 23% for the secondary prevention of non-vertebral fractures, the absolute measures ARR and NNT of the five-year risk of non-vertebral fracture after treatment with alendronate were calculated for different levels of increasing risk as measured by the FI (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>) and for increasing age (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). For the illustrative case of the patient with a FI of 6-7, the ARR in non-vertebral fracture was 4.6% (i.e. a reduction in risk from 19.8% to 15.2%) and the NNT was 22 (i.e. 22 patients need to be treated to avoid one non-vertebral fracture). Across the range of increasing FI risk, ARR for non-vertebral fracture ranged from 2.0% to 6.3% and NNT to avoid one non-vertebral fracture ranged from 50 to 16. For the illustrative patient in the age group 60-64 years, the ARR for the first non-vertebral fracture was 0.7% (i.e. a reduction in risk from 3.1% to 2.4%) and the NNT was 140 patients treated to avoid the first fracture. The ARR for a subsequent fracture was 1.4% (i.e. a reduction in risk from 6.2% to 4.8%) and the NNT was 70 patients treated to avoid one subsequent fracture. For increasing age, the five-year age-specific ARR for the first non-vertebral fracture increased from 0.4% for the youngest age group (50-54 years) to 8.1% in the highest age group (90+ years) and the NNT decreased from 272 to 12. The ARR for subsequent fracture increased from 0.6% to 8.7% and the NNT decreased from 167 to 12.</P>
<P>
<B>Hip fractures</B>
<BR/>Hip fractures were reported in seven trials (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>), with one trial reporting that no fractures occurred in either treatment group (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>). The pooled estimate of the RR of hip fractures from the six trials resulted in a significant reduction (39%) in hip fractures (RR 0.61, 95% CI 0.40 to 0.92) as presented in (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and Comparison 03.01). The results were consistent across the six trials (p = 0.84). The reduction in the risk of hip fractures for the one primary prevention trial (<LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>) was not significant (RR 0.79, 95% CI 0.44 to 1.44) compared to the significant reduction demonstrated by the five secondary prevention trials (RR 0.47, 95% CI 0.26 to 0.85).<BR/> <BR/>Corresponding to the significant RRR of 53% for the secondary prevention of hip fractures, the absolute measures: ARR and NNT of the five-year risk of hip fracture after treatment with alendronate were calculated for different levels of increasing risk as measured by the FI. Results are provided in <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK> in addition to those for increasing age in <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>. For the illustrative case of the patient with a FI of 6-7, the ARR in hip fracture was 2.1% (i.e. a reduction in risk from 3.9% to 1.8%) and the NNT was 48 (i.e. 48 patients need to be treated to avoid one hip fracture). Across the range of increasing FI risk, the ARR for hip fracture ranged from 0.2% to 4.6% and the NNT to avoid one hip fracture ranged from 500 to 22. For the illustrative patient in the age group 60-64 years, the ARR for the first hip fracture was 0.1% (i.e. a reduction in risk from 0.2% to 0.1%) and the NNT was 943 patients treated to avoid the first fracture. The ARR for a subsequent fracture was 0.1% (i.e. a reduction in risk from 0.2% to 0.1%) and the NNT was 943 patients treated to avoid one subsequent fracture. For increasing age, the five-year age-specific ARR for the first hip fracture increased from less than 0.05% for the youngest age group (50-54 years) to 11.1% in the highest age group (90+ years) and the NNT decreased from more than 272 to 9. For the subsequent fracture, the ARR increased from less than 0.05% to 12.1% and the NNT decreased from more than 472 to 8.</P>
<P>
<B>Wrist fractures<BR/>
</B>Wrist fractures were reported in five trials (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>) and one trial (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>) reported that no fractures occurred in either treatment group. Results were not consistent across the five trials which reported wrist fractures (p = 0.0007)(<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). The pooled estimate of the RR of wrist fracture from these five trials resulted in a non-significant reduction in fractures, either using the random effects (RR 0.68, 95% CI 0.34 to 1.37)(<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) or fixed effect (RR 0.83, 95%CI 0.65, 1.05) approach. We also could not identify a statistically significant effect of alendronate when used for the primary prevention of wrist fractures (RR 1.19, 95%CI 0.87 to 1.62)(<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and Comparison 04.01). In the case of the four secondary prevention trials, a statistically significant effect was observed (RR 0.50, 95%CI 0.34 to 0.73). </P>
<P>
<B>Additional analysis<BR/>
</B>
<BR/>
<B>
<I>Person years</I>
</B>
<I>
<BR/>
</I>Results were similar for vertebral, non-vertebral, hip and wrist fractures when person years were used, as illustrated in <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>. Notably, the pooled estimates of the RR for the secondary prevention trials all showed a significant risk reduction of fracture for all fractures sites. Due to lack of consistency among the trials, a random-effects estimate was used for the pooled estimate for vertebral fractures; however, for wrist fractures, there was no inconsistency among the secondary prevention trials. The risk estimates obtained from the one primary prevention trial for vertebral fracture remained significant although results were non-significant for the other fracture sites.</P>
<P>
<B>
<BR/>Subgroup analysis<BR/>
</B>
<BR/>
<B>
<I>Treatment duration<BR/>
</I>
</B>There were no trends over years of treatments that deviated from the overall RR estimates (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK> and Comparisons 05.01; 06.01; 07.01; 08.01; 09.01), with the possible exception of hip fracture risk reduction being greater in later years.</P>
<P>
<B>
<I>Treatment dose<BR/>
</I>
</B>For the 5 mg dose of alendronate, fracture data were available for vertebral and non-vertebral sites for secondary prevention trials, as well as non-vertebral for primary prevention. (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>; <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>; <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>; Comparison 12.01) For vertebral fractures, the decrease in risk of fracture was statistically significant and there was a further slight decrease in risk with the 5 mg dose (RR 0.40, 95%CI 0.29 to 0.55), compared to 10 mg (RR 0.55, 95%CI 0.43 to 0.69). For non-vertebral fractures, no significant difference was found.</P>
<P>
<B>Sensitivity analysis<BR/>
</B>
<BR/>
<B>
<I>Baseline versus follow-up denominators<BR/>
</I>
</B>By using the data available for longest treatment duration, standard dose of alendronate (10 mg) and follow-up denominators for the number of patients in the trials, a summary of the overall review of fractures was prepared (<LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>). These data are also provided by years of treatment. (<LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>). The pooled estimates of the RR of fracture after alendronate were essentially the same as those obtained using the baseline denominators.</P>
<P>
<B>
<I>Random versus fixed effects model<BR/>
</I>
</B>There were a few instances where heterogeneity of the trial results was such that a random-effects model was required. In general, results obtained using the random- and fixed-effects models were similar. </P>
<P>
<B>
<I>Baseline vertebral fracture rate<BR/>
</I>
</B>Using different baseline vertebral fracture rates (i.e. 100%, &gt; 80%, &gt; 60%, &gt; 40%, &gt; 20%) for defining secondary trials, a summary of the overall review of fractures was prepared (<LINK REF="FIG-16" TYPE="FIGURE">Figure 16</LINK>). For vertebral fractures, the pooled estimates of the RR of fracture after alendronate were essentially the same as those obtained using the definition of secondary trials with the &gt; 20% baseline fracture rate. Although the result for non-vertebral and hip fractures became non-significant when the criteria increased from &gt; 20% to &gt; 40% and &gt; 40% to &gt; 60% respectively, the relative risk of fracture was exactly the same but the confidence intervals were now slightly wider with the exclusion of the study by Liberman et al (<LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>) for non-vertebral fractures and Greenspan et al (<LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>) for hip fractures. For wrist fractures, the non-significant result was now significant when a &gt; 20% baseline fracture rate was used (without the BMD and age criteria) since a fixed-effects model could now be used.</P>
<P>
<B>Adverse events<BR/>
</B>A summary of the adverse drug events reported in the 11 randomized placebo-controlled trials of alendronate is provided in <LINK REF="FIG-17" TYPE="FIGURE">Figure 17</LINK>, <LINK REF="FIG-18" TYPE="FIGURE">Figure 18</LINK>, <LINK REF="FIG-19" TYPE="FIGURE">Figure 19</LINK> and <LINK REF="FIG-20" TYPE="FIGURE">Figure 20</LINK>. In general, the reported events were similar between alendronate and placebo. In particular, there were seven studies (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>; <LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>) reporting 'any upper gastrointestinal events' resulting in an overall RR 1.03 (95% CI 0.98 to 1.08) and two studies (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>) reporting 'esophageal ulcer', resulting in an overall RR 1.16 (95% CI 0.39 to 3.45). </P>
<P>
<B>Toxicity and withdrawals<BR/>
</B>Discontinuations due to adverse events or dropouts overall were available and analyzed for six (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>) and five (<LINK REF="STD-Ascott-Evans-2003" TYPE="STUDY">Ascott Evans 2003</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Greenspan-1998" TYPE="STUDY">Greenspan 1998</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>) of the alendronate trials respectively. The pooled estimate demonstrated no statistical difference between alendronate and placebo for the risk of discontinuing medication due to adverse events (RR 0.95, 95% CI 0.83 to 1.09) or for dropouts overall (RR 1.10, 95% CI 0.94 to 1.29)(Comparison 13.01 and 13.02). Results were consistent across the trials.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>
<B>Summary of results<BR/>
</B>Based on the longest treatment duration and use of baseline denominators for the number of patients in the included trials, the main benefit of alendronate was found to be in the secondary prevention of osteoporotic fractures. At a dose of 10 mg per day, alendronate results in a statistically significant and clinically important reduction in vertebral, non-vertebral, hip and wrist fractures (gold level evidence). We also found that the use of alendronate 10 mg per day for the primary prevention of osteoporotic fractures is not associated with statistically significant reductions in risk, with the exception of vertebral fractures for which the reduction was clinically important (gold level evidence). </P>
<P>Secondary analyses showed that a dose of 5 mg, for secondary prevention resulted in a statistically significant and clinically important reduction in vertebral fractures that is comparable to that of the 10 mg dose (RR 0.40, 95% CI 0.27 to 0.52 versus RR 0.55, 95% CI 0.43 to 0.69). It is worth noting that these results were driven primarily by the large Black trial (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>). In Black, the 5 mg data represented the first two years of follow up of the treatment group which was switched to 10 mg for the third year. No trials were available to assess the effectiveness of the 5 mg dose for the primary prevention of vertebral fractures. For non-vertebral fractures, no statistically significant reductions were shown for primary or secondary prevention. There were no trials available to assess the efficacy of the 5 mg dose for hip and wrist fractures. </P>
<P>There were no substantive differences in the results whether baseline, end of study or person year denominators were used. Sensitivity analyses indicated that there were no major differences based on the percentage of baseline vertebral fractures. Further, no trends were found for years of treatment. </P>
<P>Adverse drug events were similar between alendronate and placebo. There were also no statistically significant difference in either the rate of treatment discontinuation due to adverse events (RR 0.95, 95% CI 0.83 to 1.09) or the overall withdrawal rate (RR 1.10, 95% CI 0.94 to 1.29), compared to placebo. Thus, it was concluded that study participants tolerated their alendronate treatment. Although no increased incidence of adverse effects was detected with alendronate, external to the randomized controlled trials, concerns exist regarding the potential risk of upper gastrointestinal events and osteonecrosis of the jaw.</P>
<P>
<B>Study limitations<BR/>
</B>The results of this systematic review are believed to be robust, as a comprehensive literature search was performed, inclusion and exclusion criteria were specified and a rigorous data analysis was conducted. A potential limitation of our approach may be that the update search (i.e. 2000 to 2004) did not include non-MEDLINE® indexed journals. Recent empirical evidence indicates that this approach may have introduced a slight risk of bias into our meta-analysis. On average, such bias is estimated to result in a 6% variation in the pooled results (<LINK REF="REF-Egger-2003" TYPE="REFERENCE">Egger 2003</LINK>; <LINK REF="REF-Sampson-2003" TYPE="REFERENCE">Sampson 2003</LINK>). Accordingly, given that the initial literature search (i.e. 1966 to 2000) was very extensive, the impact of only using MEDLINE® for the search update is expected to be minimal, if any. This was confirmed by a parallel literature search update (i.e. 1999 to July 2004) that was conducted for an economic report published by The Canadian Agency for Drugs and Technologies in Health (<LINK REF="REF-CADTH-2006" TYPE="REFERENCE">CADTH 2006</LINK>). The search update included etidronate, alendronate and risedronate (daily dose regimen only) in addition to teriparatide. A number of databases were searched (i.e. the Cochrane Library, MEDLINE®, EMBASE®, BIOSIS Previews®, Toxfile and PubMed) and no additional articles meeting the inclusion criteria were identified. </P>
<P>While our methodology was robust, the results of our meta-analysis, however, are only as strong as the primary studies included. In keeping with this, the main limitations with regard to study quality were fracture assessment and classification, the lack of clarity of the concealment of allocation and large losses to follow up (primarily in the smaller studies).</P>
<P>A potential source of heterogeneity is the lack of uniform definition of non-vertebral fracture. While some researchers may use a rather liberal definition (any fracture other than vertebral fracture), others may use a more conservative definition which includes only fractures of the hip, clavicle, humerus, wrist, pelvis or leg (<LINK REF="REF-Mayo-Clin-Proc-2005" TYPE="REFERENCE">Mayo Clin Proc 2005</LINK>). Another consideration is the fact that fracture data was not the primary outcome for many of the trials. In particular, three of the 11 alendronate trials (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>) had fractures as the primary outcome. There is another source of heterogeneity, and possible bias, related to some of the secondary prevention studies. It concerns the inclusion of participants with a low BMD but no proven fractures, and the difficulty in discriminating between fracture types (traumatic versus pathological).<BR/> <BR/>Another methodological limitation concerns the approach used for concealment of treatment allocation which was not reported for most trials. Four of the 11 trials (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>) concealed allocation, and for the remainder it was unclear. </P>
<P>An additional limitation is the length of follow up in the studies. It is difficult to extrapolate beyond the duration of the follow-up trials in the review with respect to the long-term impact on fractures. Ultimately, data from longer-term trials will help establish if the effect on fractures is maintained, increased or diminished. </P>
<P>In regards to our own methodology, we acknowledge that the approach used to evaluate the effect of bisphosphonates over time may result in some estimates that are not robust. In particular, in order to determine the effect on the five-year risk of fracture, we based our evaluation on the FRACTURE Index by Black et al (<LINK REF="REF-Black-2001" TYPE="REFERENCE">Black 2001</LINK>), and for lifetime and five-year age-specific risks, we used an existing model from Doherty et al (<LINK REF="REF-Doherty-2001" TYPE="REFERENCE">Doherty 2001</LINK>). Although this latter approach allowed us to estimate the variation in risks between younger and older postmenopausal women, these estimates may be associated with a certain level of uncertainty. Nonetheless, we believe such information may be useful to decision-makers.</P>
<P>Lastly, a limitation of evaluating data on adverse effects from summary meta-analyses is that participants in RCTs tend to be healthier, with fewer co-morbid diseases, and therefore the results may not be generalizable to clinical practice. For alendronate, eight trials (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Bone-1997" TYPE="STUDY">Bone 1997</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>; <LINK REF="STD-Durson-2001" TYPE="STUDY">Durson 2001</LINK>; <LINK REF="STD-Greenspan-2002" TYPE="STUDY">Greenspan 2002</LINK>; <LINK REF="STD-Hosking-1998" TYPE="STUDY">Hosking 1998</LINK>; <LINK REF="STD-Liberman-1995" TYPE="STUDY">Liberman 1995</LINK>; <LINK REF="STD-Pols-1999" TYPE="STUDY">Pols 1999</LINK>) excluded patients with pre-existing gastrointestinal (GI) disorders. Furthermore, RCTs are underpowered for rare effects and meta-analyses of these trials generally cannot provide conclusive information pertaining to drug toxicity. In addition, the heterogeneity of the adverse drug effects (ADEs) reported in the RCTs described in this review, including their nature, low occurrence and way they were assessed by investigators, made these improper for meta-analysis. Although a number of trials reported composite endpoints such as "any GI event", as well as a number of individual GI events, only the two largest trials (<LINK REF="STD-Black-1996" TYPE="STUDY">Black 1996</LINK>; <LINK REF="STD-Cummings-1998" TYPE="STUDY">Cummings 1998</LINK>), for example, specifically reported esophageal ulcers (an endpoint of particular interest, for which there were no statistically significant differences between treatment and control). As well, the follow up for the included trials, which ranged between one and four years, does not allow for the assessment of long-term toxicity associated with alendronate. </P>
<P>Recently, there have been concerns regarding the potential risk of over suppressing bone turnover resulting in osteonecrosis of the jaw (ONJ)(<LINK REF="REF-Khosla-2007" TYPE="REFERENCE">Khosla 2007</LINK>; <LINK REF="REF-Woo-2006" TYPE="REFERENCE">Woo 2006</LINK>). Although the majority of reported cases of ONJ have occurred in cancer patients receiving the intravenous bisphosphonates zolendrate or pamidronate (at higher cumulative doses than used in the treatment of postmenopausal osteoporosis), some osteoporosis patients receiving oral bisphosphonates have developed the condition as well. In a systematic review of cases reported in the medical literature, 13 of 368 bisphosphonate treated ONJ patients had received alendronate and one risedronate (<LINK REF="REF-Woo-2006" TYPE="REFERENCE">Woo 2006</LINK>). Since that publication, a review conducted by the American Society for Bone and Mineral Research (ASBMR) Task Force on Bisphosphonate-Associated ONJ has identified studies reporting a total of 67 cases (64 alendronate, two risedronate and one etidronate) among osteoporosis and Paget's disease patients (<LINK REF="REF-Khosla-2007" TYPE="REFERENCE">Khosla 2007</LINK>). Most notably, an Australian study reported 30 of 114 ONJ cases related to alendronate (22 of whom were under treatment for osteoporosis) and two related to risedronate. The median time to onset, for alendronate, was 24 months. The most common triggering factor was dental extraction (<LINK REF="REF-Mavrokokki-2007" TYPE="REFERENCE">Mavrokokki 2007</LINK>). The ASBMR task force has pointed out that the incidence of ONJ in the general population not exposed to bisphosphonates is unknown, information on the incidence of ONJ is rapidly evolving and that ,often, the case ascertainment has been inadequate . They recommend that a hierarchy of evidence quality, based on the completeness of information across seven categories related to diagnosis and history, should be established for all future studies reporting cases of ONJ (<LINK REF="REF-Khosla-2007" TYPE="REFERENCE">Khosla 2007</LINK>). </P>
<P>No cases of ONJ were explicitly reported in any of the alendronate trials in our review. As well, a recent 10-year follow up of patients from the Black and Cummings trials (The Fracture Intervention Trial Long-term Extension (FLEX) reported that no cases were observed among the 662 women who were continued on alendronate at 5 or 10 mg for a total of 10 years or the 437 women who were switched to placebo following five years of alendronate treatment (<LINK REF="REF-Black-2006" TYPE="REFERENCE">Black 2006</LINK>). No difference between treatment groups were found for any other adverse events in FLEX.</P>
<P>Finally, because RCTs are not designed to measure ADEs, particularly rare ones, it is common practice to include sources of information other than RCTs. While some reviewers include ADEs reported in observational studies, we elected to obtain information from the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) (<LINK REF="REF-Health-Canada-2005" TYPE="REFERENCE">Health Canada 2005</LINK>). </P>
<P>
<B>Generalizability of findings<BR/>
</B>Generalizability of our findings is limited by the controlled design of the trials included in our review. Study participants were carefully selected in these trials, and so utilization of the drugs in real life may vary substantially from study conditions. Furthermore, study participants were observed for periods of time varying from one to four years. Consequently, while our results provide support for efficacy (i.e. can the intervention have an effect on outcome?), they may possibly only provide partial information on the long-term effectiveness (i.e. does the intervention have an effect on outcome?) of alendronate in preventing osteoporotic fractures. </P>
<P>From a safety perspective, we could not find any statistically significant difference in either the rates of adverse drug events or withdrawal rates due to adverse drug events between patients receiving a bisphosphonate or patients receiving a placebo. However, outside controlled trials, concerns exist regarding the safe use of alendronate, for which esophageal ulcers and gastritis have been reported (<LINK REF="REF-Kherani-2002" TYPE="REFERENCE">Kherani 2002</LINK>). While such adverse events have mainly been identified through case reports and endoscopic studies, similar concerns are also reflected in the proportions of gastrointestinal adverse drug reactions associated with the use of bisphosphonates reported to the CADRMP (<LINK REF="REF-Health-Canada-2005" TYPE="REFERENCE">Health Canada 2005</LINK>). Indeed, GI adverse drug reactions represented 38% of all reactions reported for alendronate (<LINK REF="FIG-21" TYPE="FIGURE">Figure 21</LINK>). These proportions should, however, be interpreted with caution, as adverse drug reactions are reported to CADRMP on a volunteer basis by health professionals, which means that several reactions may be unreported. Indeed, it is estimated that less than 10% of adverse reactions are reported to Health Canada (<LINK REF="REF-Health-Canada-2005c" TYPE="REFERENCE">Health Canada 2005c</LINK>). Also, a definite cause-effect relationship has not been established for these adverse drug reactions.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Alendronate demonstrated a clinically important benefit in the secondary prevention of all osteoporotic fractures. At a dose of 10 mg per day, statistically significant reductions in vertebral, non-vertebral, hip and wrist were observed. The secondary prevention population was defined as having a bone density of at least 2 SD values below peak bone mass or one or more vertebral compression fractures, or both. There were no statistically significant reductions found for the primary prevention of osteoporotic fractures, with the exception of vertebral fractures, for which the reduction was clinically important. No increased incidence of adverse effects were detected with alendronate, but clinicians should be aware that outside of randomized controlled trials, concerns exist regarding the potential risk of upper gastrointestinal events and, less commonly, osteonecrosis of the jaw.</P>
<P>The prevention of osteoporotic fractures is an important public health intervention. This is particularly true for hip and clinical vertebral fractures (i.e. fractures of the spine that present for medical attention). The RR of death following such fractures is six- to nine-fold greater in postmenopausal women aged 55 to 81 years with low BMD, which represents a typical postmenopausal population (<LINK REF="REF-Cauley-2000" TYPE="REFERENCE">Cauley 2000</LINK>). In most cases, the mortality increase reflects poor underlying health status and comorbidity, in addition to the fracture itself (<LINK REF="REF-Cauley-2000" TYPE="REFERENCE">Cauley 2000</LINK>). Osteoporotic fractures are also associated with increase in morbidity, as it is reported that 50% of women who sustain a hip fracture do not return to their usual daily activities (<LINK REF="REF-Brown-2002" TYPE="REFERENCE">Brown 2002</LINK>), while 33% will require long-term care. Accordingly, reducing the incidence of such fractures can potentially increase the quality of life of patients with osteoporosis. Such interventions may also potentially decrease mortality.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>It has been suggested from clinical trials with the bisphosphonates (<LINK REF="REF-Black-2000b" TYPE="REFERENCE">Black 2000b</LINK>; <LINK REF="REF-Harris-1999" TYPE="REFERENCE">Harris 1999</LINK>; <LINK REF="REF-McClung-2001" TYPE="REFERENCE">McClung 2001</LINK>) that their effect in reducing non-vertebral fractures may be greater in patients with lower BMD who initiate treatment. The existing data have not fully resolved the question of whether important differences in risk reduction across groups of patients with varying degrees of osteoporosis exist. The impact of the bisphosphonates on the RR of non-vertebral fractures in populations without osteoporosis also merits further investigation. Additional research is needed to clarify the role of bisphosphonates in the primary prevention of osteoporotic fractures. There is also a need for further post-marketing safety. Finally, research into combination therapy with higher doses of vitamin D or anabolic agents would be merited as would research concerning adherence to bisphosphonate therapy. </P>
<P>Given the morbidity consequences associated with osteoporotic fractures, preventing their recurrence can potentially lessen the need for community-based health services (e.g. home care). It may also reduce or delay the demand for long-term care beds. However, very little comparative information is currently available to support this (<LINK REF="REF-Hodsman-2002" TYPE="REFERENCE">Hodsman 2002</LINK>). There is also a lack of studies which evaluated the effect of bisphosphonates on hospital admissions (<LINK REF="REF-Hodsman-2002" TYPE="REFERENCE">Hodsman 2002</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Thank you to Lara Maxwell and Marie Andree Nowlan from the Cochrane Musculoskeletal Group for their editorial assistance, and Tamara Rader for her assistance with the Consumer Summary. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>George Wells was involved in the conception, design and implementation of the project and contributed significantly to the writing of the report. </P>
<P>Ann Cranney was involved with the conception of the review, data abstraction, analysis, interpretation and revision of the final report.</P>
<P>Joan Peterson screened the literature, was involved in the data abstraction, quality assessment and analysis of the primary trials and contributed significantly to the writing of the report.</P>
<P>Michel Boucher assisted in the design of the analysis, reporting and interpretation of the findings and was involved in the writing of the report. </P>
<P>Beverley Shea was involved in developing the protocol and conducting the systematic review.</P>
<P>Vivian Robinson was involved in developing the protocol and conducting the systematic review.</P>
<P>Douglas Coyle assisted with the design of the review and reviewed the analysis.</P>
<P>Peter Tugwell provided clinical rheumatology expertise and methodological guidance.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-12 15:36:14 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-08-12 14:38:38 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-08-12 14:00:10 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ascott-Evans-2003" NAME="Ascott Evans 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, et al</AU>
<TI>Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>7</NO>
<PG>789-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-1996" NAME="Black 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al</AU>
<TI>Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.[see comment]</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9041</NO>
<PG>1535-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bone-1997" NAME="Bone 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bone HG, Downs RW Jr, Tucci JR, Harris ST, Weinstein RS, Licata AA, et al</AU>
<TI>Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1997</YR>
<VL>82</VL>
<NO>1</NO>
<PG>265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chestnut-1995" NAME="Chestnut 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al</AU>
<TI>Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling</TI>
<SO>American Journal of Medicine</SO>
<YR>1995</YR>
<VL>99</VL>
<NO>2</NO>
<PG>144-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cummings-1998" NAME="Cummings 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al</AU>
<TI>Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. [see comment]</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>280</VL>
<NO>24</NO>
<PG>2077-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Durson-2001" NAME="Durson 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dursun N, Dursun E, Yalcin S</AU>
<TI>Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2001</YR>
<VL>55</VL>
<NO>8</NO>
<PG>505-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenspan-1998" MODIFIED="2008-08-12 14:00:10 -0400" MODIFIED_BY="[Empty name]" NAME="Greenspan 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-08-12 14:00:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB</AU>
<TI>Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>9</NO>
<PG>1431-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenspan-2002" NAME="Greenspan 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, et al</AU>
<TI>Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. [see comment]</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2002</YR>
<VL>77</VL>
<NO>10</NO>
<PG>1044-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hosking-1998" NAME="Hosking 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, et al</AU>
<TI>Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>8</NO>
<PG>485-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liberman-1995" NAME="Liberman 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al</AU>
<TI>Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. [see comment]</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<NO>22</NO>
<PG>1437-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pols-1999" NAME="Pols 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, et al</AU>
<TI>Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group</TI>
<SO>Osteoporosis International</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>5</NO>
<PG>461-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-08-12 14:38:38 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adami-1993" NAME="Adami 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, et al</AU>
<TI>Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin</TI>
<SO>Osteoporosis International</SO>
<YR>1993</YR>
<VL>3 Suppl 3</VL>
<PG>S21-S27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adami-1995" NAME="Adami 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, et al</AU>
<TI>Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis</TI>
<SO>Bone</SO>
<YR>1995</YR>
<VL>17</VL>
<NO>4</NO>
<PG>383-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aki-2003" MODIFIED="2008-08-12 14:04:44 -0400" MODIFIED_BY="[Empty name]" NAME="Aki 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-12 14:04:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aki S, Gulbaba RG, Eskiyurt N</AU>
<TI>Effect of alendronate on bone density and bone markers in postmenopausal osteoporosis</TI>
<SO>Journal of Back &amp; Musculoskeletal Rehabilitation</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="669"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bell-2002" NAME="Bell 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bell NH, Bilezikian JP, Bone HG III, Kaur A, Maragoto A, Santora AC, Study Group.</AU>
<TI>Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>6</NO>
<PG>2792-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bettembuk-1999" NAME="Bettembuk 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bettembuk P, Balogh A</AU>
<TI>[The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungarian of an international multicenter clinical study)]</TI>
<SO>Orvosi Hetilap</SO>
<YR>1999</YR>
<VL>140</VL>
<NO>50</NO>
<PG>2799-803</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2000" NAME="Black 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al</AU>
<TI>Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. [erratum appears in J Clin Endocrinol Metab 2001 Feb;86(2):938]</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>11</NO>
<PG>4118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2003" NAME="Black 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al</AU>
<TI>The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. [see comment]</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>13</NO>
<PG>1207-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Body-2002" NAME="Body 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al</AU>
<TI>A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone (1-34)) with alendronate in postmenopausal women with osteoporosis. [see comment]</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>10</NO>
<PG>4528-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boivin-2000" NAME="Boivin 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ</AU>
<TI>Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women</TI>
<SO>Bone</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>5</NO>
<PG>687-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bone-2000" NAME="Bone 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, et al</AU>
<TI>Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>2</NO>
<PG>720-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bone-2004" NAME="Bone 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al</AU>
<TI>Ten years' experience with alendronate for osteoporosis in postmenopausal women. [see comment]</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<NO>12</NO>
<PG>1189-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonnick-1998" NAME="Bonnick 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonnick S, Rosen C, Mako B, DeLucca P, Byrned C, Melton M</AU>
<TI>Alendronate vs calcium for treatment of osteoporosis in postmenopausal women.</TI>
<SO>Bone</SO>
<YR>1998</YR>
<VL>350</VL>
<NO>5S</NO>
<PG>S476</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bouxsein-1999" NAME="Bouxsein 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bouxsein ML, Parker RA, Greenspan SL</AU>
<TI>Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women</TI>
<SO>Osteoporosis International</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>6</NO>
<PG>505-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chailurkit-2003" NAME="Chailurkit 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R</AU>
<TI>Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis</TI>
<SO>Journal of Bone &amp; Mineral Metabolism</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>6</NO>
<PG>421-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chailurkit-2004" NAME="Chailurkit 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chailurkit LO, Aunphongpuwanart S, Ongphiphadhanakul B, Jongjaroenprasert W, Sae-tung S, Rajatanavin R</AU>
<TI>Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis</TI>
<SO>Endocrine Research</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>1</NO>
<PG>29-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chavassieux-1997" NAME="Chavassieux 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ</AU>
<TI>Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1997</YR>
<VL>100</VL>
<NO>6</NO>
<PG>1475-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2002" NAME="Cheng 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng ZQ, Yin W, Fan JY, Ma TJ</AU>
<TI>[The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis]. [Chinese]</TI>
<SO>Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>3</NO>
<PG>306-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chesnut-1993" NAME="Chesnut 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chesnut CH, Harris ST</AU>
<TI>Short term effect of alendronate on bone mass and bone remodeling in postmenopausal women</TI>
<SO>Osteoporosis International</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>Suppl 3</NO>
<PG>S17-S19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cummings-2000" NAME="Cummings 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al</AU>
<TI>Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>10</NO>
<PG>1318-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davas-2003" NAME="Davas 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davas I, Altintas A, Yoldemir T, Varolan A, Yazgan A, Baksu B</AU>
<TI>Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>2003</YR>
<VL>80</VL>
<NO>3</NO>
<PG>536-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Devogelaer-1996" NAME="Devogelaer 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, et al</AU>
<TI>Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. [erratum appears in Bone 1996 Jul;19(1):78]</TI>
<SO>Bone</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>2</NO>
<PG>141-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobnig-2006" NAME="Dobnig 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A, Dobnig H, et al</AU>
<TI>Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients</TI>
<SO>Osteoporosis International</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>5</NO>
<PG>693-703</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="13"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Downs-2000" NAME="Downs 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Downs RW Jr, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, et al</AU>
<TI>Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>5</NO>
<PG>1783-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evio-2004" NAME="Evio 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evio S, Tiitinen A, Laitinen K, Ylikorkala O, Valimaki MJ</AU>
<TI>Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>2</NO>
<PG>626-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonnelli-2002" NAME="Gonnelli 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonnelli S, Cepollaro C, Montagnani A, Martini S, Gennari L, Mangeri M, et al</AU>
<TI>Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study</TI>
<SO>Osteoporosis International</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>5</NO>
<PG>415-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenspan-2002a" NAME="Greenspan 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, et al</AU>
<TI>Significant differential effects of alendronate, estrogen or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. [summary for patients in Ann Intern Med. 2002 Dec 3;137(11):I31; PMID: 12459003]</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2002</YR>
<VL>137</VL>
<NO>11</NO>
<PG>875-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenspan-2002b" NAME="Greenspan 2002b" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R, et al</AU>
<TI>Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. [summary for patients in Ann Intern Med. 2002 May 21;136(10):I54; PMID: 12020160]</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2002</YR>
<VL>136</VL>
<NO>10</NO>
<PG>742-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenspan-2003" NAME="Greenspan 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan SL, Resnick NM, Parker RA</AU>
<TI>Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>19</NO>
<PG>2525-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1993" NAME="Harris 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, et al</AU>
<TI>The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1993</YR>
<VL>76</VL>
<NO>6</NO>
<PG>1399-1406</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heijckmann-2002" NAME="Heijckmann 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijckmann AC, Juttmann JR, Wolffenbuttel BH</AU>
<TI>Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. [see comment]</TI>
<SO>Netherlands Journal of Medicine</SO>
<YR>2002</YR>
<VL>60</VL>
<NO>8</NO>
<PG>315-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ho-2005" NAME="Ho 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ho AY, Kung AW, Ho AYY, Kung AWC</AU>
<TI>Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>9</NO>
<PG>1428-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="109"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hochberg-1999" NAME="Hochberg 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, et al</AU>
<TI>Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>6</NO>
<PG>1246-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hosking-2003" NAME="Hosking 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L, et al</AU>
<TI>Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>5</NO>
<PG>383-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwamoto-2004" NAME="Iwamoto 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwamoto J, Takeda T, Sato Y, Uzawa M</AU>
<TI>Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis</TI>
<SO>Yonsei Medical Journal</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>4</NO>
<PG>676-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnell-2002" NAME="Johnell 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E</AU>
<TI>Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. [see comment]</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>3</NO>
<PG>985-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kung-2000" NAME="Kung 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kung AW, Yeung SS, Chu LW</AU>
<TI>The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study</TI>
<SO>Calcified Tissue International</SO>
<YR>2000</YR>
<VL>67</VL>
<NO>4</NO>
<PG>286-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kushida-2004" NAME="Kushida 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, et al</AU>
<TI>Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study</TI>
<SO>Journal of Bone &amp; Mineral Metabolism</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>5</NO>
<PG>462-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-2000" NAME="Lau 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau EM, Woo J, Chan YH, Griffith J</AU>
<TI>Alendronate prevents bone loss in Chinese women with osteoporosis</TI>
<SO>Bone</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>5</NO>
<PG>677-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luckey-2004" NAME="Luckey 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, et al</AU>
<TI>Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis</TI>
<SO>Menopause</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>4</NO>
<PG>405-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malavolta-1999" NAME="Malavolta 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malavolta N, Zanardi M, Veronesi M, Ripamonti C, Gnudi S</AU>
<TI>Calcitriol and alendronate combination treatment in menopausal women with low bone mass</TI>
<SO>International Journal of Tissue Reactions</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>2</NO>
<PG>51-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McClung-1998" NAME="McClung 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, et al</AU>
<TI>Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. [see comment]</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1998</YR>
<VL>128</VL>
<NO>4</NO>
<PG>253-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McClung-2004" NAME="McClung 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McClung MR, Wasnich RD, Hosking DJ, Christiansen C, Ravn P, Wu M, et al</AU>
<TI>Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>10</NO>
<PG>4879-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="190"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-2001" NAME="Murphy 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, et al</AU>
<TI>Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2001</YR>
<VL>86</VL>
<NO>3</NO>
<PG>1116-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nenonen-2005" NAME="Nenonen 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, et al</AU>
<TI>Serum TRACP 5b is a useful marker for monitoring alendronate treatment: Comparison with other markers of bone turnover</TI>
<SO>Journal of Bone &amp; Mineral Research</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>8</NO>
<PG>1804-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="576"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palomba-2002" NAME="Palomba 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palomba S, Orio F Jr, Colao A, di Carlo C, Sena T, Lombardi G, et al</AU>
<TI>Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>4</NO>
<PG>1502-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Payer-2000" NAME="Payer 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payer J Jr, Killinger Z, Masaryk P, Tomkova S, Kmecova Z, Ondrejkova J, et al</AU>
<TI>[Effect of alendronate therapy on bone turnover--results of a multicenter study]. [Slovak]</TI>
<SO>Vnitrni Lekarstvi</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>10</NO>
<PG>689-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravn-1999a" NAME="Ravn 1999a" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravn P, Clemmesen B, Christiansen C</AU>
<TI>Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group</TI>
<SO>Bone</SO>
<YR>1999</YR>
<VL>24</VL>
<NO>3</NO>
<PG>237-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravn-1999b" NAME="Ravn 1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, et al</AU>
<TI>Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>7</NO>
<PG>2363-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravn-1999c" NAME="Ravn 1999c" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al</AU>
<TI>Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. [see comment]</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>131</VL>
<NO>12</NO>
<PG>935-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravn-2000" NAME="Ravn 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, et al</AU>
<TI>Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>4</NO>
<PG>1492-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rhee-2006" NAME="Rhee 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rhee Y, Kang M, Min Y, Byun D, Chung Y, Ahn C, et al</AU>
<TI>Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study</TI>
<SO>Osteoporosis International</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>12</NO>
<PG>1801-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rittmaster-2000" NAME="Rittmaster 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al</AU>
<TI>Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. [see comment]</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>6</NO>
<PG>2129-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rizzoli-2002" NAME="Rizzoli 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rizzoli R, Greenspan SL, Bone G III, Schnitzer TJ, Watts NB, Adami S, et al</AU>
<TI>Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis</TI>
<SO>Journal of Bone &amp; Mineral Research</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>11</NO>
<PG>1988-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossini-1994" NAME="Rossini 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S</AU>
<TI>Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis</TI>
<SO>Journal of Bone &amp; Mineral Research</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>11</NO>
<PG>1833-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossini-2000" NAME="Rossini 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossini M, Gatti D, Girardello S, Braga V, James G, Adami S</AU>
<TI>Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis</TI>
<SO>Bone</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>1</NO>
<PG>119-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rozkydal-2003" NAME="Rozkydal 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rozkydal Z, Janicek P</AU>
<TI>The effect of alendronate in the treatment of postmenopausal osteoporosis</TI>
<SO>Bratislavske Lekarske Listy</SO>
<YR>2003</YR>
<VL>104</VL>
<NO>10</NO>
<PG>309-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sahota-2000" NAME="Sahota 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahota O, Fowler I, Blackwell PJ, Lawson N, Cawte SA, San P, et al</AU>
<TI>A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial</TI>
<SO>Osteoporosis International</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>11</NO>
<PG>959-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sambrook-2004a" NAME="Sambrook 2004a" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, et al</AU>
<TI>Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2004</YR>
<VL>255</VL>
<NO>4</NO>
<PG>503-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sambrook-2004b" NAME="Sambrook 2004b" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sambrook PN, Rodriguez JP, Wasnich RD, Luckey MM, Kaur A, Meng L, et al</AU>
<TI>Alendronate in the prevention of osteoporosis: 7-year follow-up</TI>
<SO>Osteoporosis International</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>6</NO>
<PG>483-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawka-2003" NAME="Sawka 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawka AM, Adachi JD, Ioannidis G, Olszynski WP, Brown JP, Hanley DA, et al</AU>
<TI>What predicts early fracture or bone loss on bisphosphonate therapy?</TI>
<SO>Journal of Clinical Densitometry</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>4</NO>
<PG>315-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1999" NAME="Schneider 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider PF, Fischer M, Allolio B, Felsenberg D, Schroder U, Semler J, et al</AU>
<TI>Alendronate increases bone density and bone strength at the distal radius in postmenopausal women</TI>
<SO>Journal of Bone &amp; Mineral Research</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>8</NO>
<PG>1387-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schnitzer-2000" NAME="Schnitzer 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al</AU>
<TI>Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group</TI>
<SO>Aging-Clinical &amp; Experimental Research</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seeman-1999" NAME="Seeman 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seeman E</AU>
<TI>The antifracture efficacy of alendronate</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>1999</YR>
<VL>Supplement. 101</VL>
<PG>40-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-2002" NAME="Simon 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ</AU>
<TI>Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>11</NO>
<PG>1871-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sosa-2002" NAME="Sosa 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sosa M, Hernandez D, Segarra MC, Gomez A, de la PE, Betancor P</AU>
<TI>Effect of two forms of alendronate administration upon bone mass after two years of treatment</TI>
<SO>Journal of Clinical Densitometry</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>1</NO>
<PG>27-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stepan-1999" NAME="Stepan 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stepan JJ, Vokrouhlicka J</AU>
<TI>Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis</TI>
<SO>Clinica Chimica Acta</SO>
<YR>1999</YR>
<VL>288</VL>
<NO>1-2</NO>
<PG>121-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tiras-2000" NAME="Tiras 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tiras MB, Noyan V, Yildiz A, Yildirim M, Daya S</AU>
<TI>Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study</TI>
<SO>Human Reproduction</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>10</NO>
<PG>2087-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tucci-1996" NAME="Tucci 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC</AU>
<TI>Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis</TI>
<SO>American Journal of Medicine</SO>
<YR>1996</YR>
<VL>101</VL>
<NO>5</NO>
<PG>488-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tutuncu-2005" MODIFIED="2008-08-12 14:38:38 -0400" MODIFIED_BY="[Empty name]" NAME="Tutuncu 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-12 14:38:38 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tutuncu L, Arslanhan N, Mungen E, Yilmaz S, Yergok YZ</AU>
<TI>Combined usage of raloxifene and alendronate: Effects on biochemical markers. [Turkish]</TI>
<SO>Nobel Medicus</SO>
<YR>2005</YR>
<VL>1</VL>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="519"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uusi_x002d_Rasi-2003" NAME="Uusi-Rasi 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uusi-Rasi K, Kannus P, Cheng S, Sievanen H, Pasanen M, Heinonen A, et al</AU>
<TI>Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial</TI>
<SO>Bone</SO>
<YR>2003</YR>
<VL>33</VL>
<NO>1</NO>
<PG>132-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Poest-2000" NAME="van der Poest 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Poest CE, Patka P, Vandormael K, Haarman H, Lips P</AU>
<TI>The effect of alendronate on bone mass after distal forearm fracture</TI>
<SO>Journal of Bone &amp; Mineral Research</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>3</NO>
<PG>586-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vasikaran-1995" NAME="Vasikaran 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vasikaran SD, Khan S, McCloskey EV, Kanis JA</AU>
<TI>Sustained response to intravenous alendronate in postmenopausal osteoporosis</TI>
<SO>Bone</SO>
<YR>1995</YR>
<VL>17</VL>
<NO>6</NO>
<PG>517-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yen-2000" NAME="Yen 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yen ML, Yen BL, Jang MH, Hsu SH, Cheng WC, Tsai KS</AU>
<TI>Effects of alendronate on osteopenic postmenopausal Chinese women</TI>
<SO>Bone</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>5</NO>
<PG>681-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yildirim-2005" MODIFIED="2008-08-12 14:02:22 -0400" MODIFIED_BY="[Empty name]" NAME="Yildirim 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-12 14:02:22 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yildirim K, Gureser G, Karatay S, Melikoglu MA, Ugur M, Erdal A, et al</AU>
<TI>Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis</TI>
<SO>Journal of Back &amp; Musculoskeletal Rehabilitation</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>3-4</NO>
<PG>85-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="540"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-12 15:36:14 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-12 15:36:14 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Black-2000b" NAME="Black 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC</AU>
<TI>Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group</TI>
<SO>J Clin Endocrinol Metab</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>11</NO>
<PG>4118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-2001" NAME="Black 2001" TYPE="JOURNAL_ARTICLE">
<AU>Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, et al</AU>
<TI>An assessment tool for predicting fracture risk in postmenopausal women</TI>
<SO>Osteoporosis International</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>7</NO>
<PG>519-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-2006" NAME="Black 2006" TYPE="JOURNAL_ARTICLE">
<AU>Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al</AU>
<TI>Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>296</VL>
<NO>24</NO>
<PG>2927-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2002" NAME="Brown 2002" TYPE="JOURNAL_ARTICLE">
<AU>Brown JP, Josse RG</AU>
<TI>2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada</TI>
<SO>CMAJ</SO>
<YR>2002</YR>
<VL>167</VL>
<NO>10 Suppl</NO>
<PG>S1-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Browner-1996" NAME="Browner 1996" TYPE="JOURNAL_ARTICLE">
<AU>Browner WS, Pressman AR, Nevitt MC, Cummings SR</AU>
<TI>Mortality following fractures in older women. The study of osteoporotic fractures</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>14</NO>
<PG>1521-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CADTH-2006" NAME="CADTH 2006" TYPE="OTHER">
<AU>Coyle D, Hadj Tahar A, Murphy G, Perras C, Skidmore B, Boucher M, et al</AU>
<TI>Teriparatide and bisphosphonates of treatment of osteoporosis in women: a clinical and economic analysis</TI>
<SO>Canadian Agency for Drugs and Technologies in Health</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2004" NAME="Cates 2004" TYPE="COMPUTER_PROGRAM">
<AU>Cates C</AU>
<TI>Visual Rx NNT Calculator 2.0</TI>
<YR>2004</YR>
<PB>Dr. Chris Cates EBM website. Available from: URL: http://www.nntonline.net/</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cauley-2000" NAME="Cauley 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D</AU>
<TI>Risk of mortality following clinical fractures</TI>
<SO>Osteoporosis International</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>7</NO>
<PG>556-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1993" NAME="Cooper 1993" TYPE="JOURNAL_ARTICLE">
<AU>Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ III</AU>
<TI>Population-based study of survival after osteoporotic fractures</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1993</YR>
<VL>137</VL>
<NO>9</NO>
<PG>1001-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cranney-2002" NAME="Cranney 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al</AU>
<TI>Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women</TI>
<SO>Endocrine Reviews</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>4</NO>
<PG>508-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cummings-1989" NAME="Cummings 1989" TYPE="JOURNAL_ARTICLE">
<AU>Cummings SR, Black DM, Rubin SM</AU>
<TI>Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1989</YR>
<VL>149</VL>
<NO>11</NO>
<PG>2445-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doherty-2001" NAME="Doherty 2001" TYPE="JOURNAL_ARTICLE">
<AU>Doherty DA, Sanders KM, Kotowicz MA, Prince RL</AU>
<TI>Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women</TI>
<SO>Osteoporosis International</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>1</NO>
<PG>16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2003" NAME="Egger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Juni P, Bartlett C, Holenstein F, Sterne J</AU>
<TI>How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study</TI>
<SO>Health Technology Assessment</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>1</NO>
<PG>1-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleiss-1993" NAME="Fleiss 1993" TYPE="JOURNAL_ARTICLE">
<AU>Fleiss JL</AU>
<TI>The statistical basis of meta-analysis</TI>
<SO>Statistical Methods in Medical Research</SO>
<YR>1993</YR>
<VL>2</VL>
<NO>2</NO>
<PG>121-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-2004" NAME="GRADE 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al</AU>
<TI>Grading quality of evidence and strength of recommendations.</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>1490</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hanley-2003" NAME="Hanley 2003" TYPE="BOOK_SECTION">
<AU>Hanley DA</AU>
<TI>Osteoporosis</TI>
<SO>Therapeutic Choices</SO>
<YR>2003</YR>
<PG>637-46</PG>
<EN>4th</EN>
<ED>Gray J</ED>
<PB>Canadian Pharmaceutical Association</PB>
<CY>Ottawa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-1999" MODIFIED="2008-08-12 14:20:57 -0400" MODIFIED_BY="[Empty name]" NAME="Harris 1999" TYPE="JOURNAL_ARTICLE">
<AU>Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al</AU>
<TI>Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>14</NO>
<PG>1344-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Health-Canada-2005" MODIFIED="2008-08-12 15:36:14 -0400" MODIFIED_BY="[Empty name]" NAME="Health Canada 2005" TYPE="OTHER">
<AU>Health Canada, editors</AU>
<TI>Canadian Adverse Drug Reaction Monitoring Program. Alendronate</TI>
<SO>Adverse Reaction Database. Ottawa,</SO>
<YR>2005</YR>
<ED>Health Canada</ED>
<CY>Ottawa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Health-Canada-2005c" NAME="Health Canada 2005c" TYPE="OTHER">
<AU>Health Canada</AU>
<TI>Medeffect [website]</TI>
<SO>Health Canada</SO>
<YR>2005</YR>
<PB>Ottawa</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hodsman-2002" NAME="Hodsman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hodsman AB, Hanley DA, Josse R</AU>
<TI>Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date</TI>
<SO>CMAJ</SO>
<YR>2002</YR>
<VL>166</VL>
<NO>11</NO>
<PG>1426-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kanis-1994" NAME="Kanis 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N</AU>
<TI>The diagnosis of osteoporosis</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kherani-2002" NAME="Kherani 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kherani RB, Papaioannou A, Adachi JD</AU>
<TI>Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review</TI>
<SO>Drug Safety</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>11</NO>
<PG>781-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khosla-2007" NAME="Khosla 2007" TYPE="JOURNAL_ARTICLE">
<AU>Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al</AU>
<TI>Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>Khosla 2007</NO>
<PG>1479-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mavrokokki-2007" NAME="Mavrokokki 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mavrokokki T, Cheng A, Stein B, Gross A</AU>
<TI>Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia</TI>
<SO>Journal of Oral and Maxillofacial Surgery</SO>
<YR>2007</YR>
<VL>65</VL>
<PG>415-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayo-Clin-Proc-2005" NAME="Mayo Clin Proc 2005" TYPE="OTHER">
<TI>Alendronate and vertebral fracture risk [multiple letters].</TI>
<SO>Mayo Clin Proc YR:2005</SO>
<VL>80</VL>
<PG>1233-41</PG>
<EN>80</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McClung-2001" NAME="McClung 2001" TYPE="JOURNAL_ARTICLE">
<AU>McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al</AU>
<TI>Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. [see comment]</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>5</NO>
<PG>333-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melton-1989" NAME="Melton 1989" TYPE="JOURNAL_ARTICLE">
<AU>Melton LJ III, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL</AU>
<TI>Epidemiology of vertebral fractures in women</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1989</YR>
<VL>129</VL>
<NO>5</NO>
<PG>1000-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH-Consensus-2001" NAME="NIH Consensus 2001" TYPE="JOURNAL_ARTICLE">
<AU>NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy</AU>
<TI>Osteoporosis prevention, diagnosis, and therapy</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>6</NO>
<PG>785-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodan-1993" NAME="Rodan 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rodan GA, Seedor JG, Balena R</AU>
<TI>Preclinical phamacology of alendronate</TI>
<SO>Osteoporosis International</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>Suppl 3</NO>
<PG>S7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sampson-2003" NAME="Sampson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sampson M, Barrowman NJ, Moher D, Klassen TP, Pham B, Platt R, et al</AU>
<TI>Should meta-analysts search Embase in addition to Medline?</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2003</YR>
<VL>56</VL>
<NO>10</NO>
<PG>943-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shukla-2003" MODIFIED="2008-08-12 14:30:59 -0400" MODIFIED_BY="[Empty name]" NAME="Shukla 2003" TYPE="OTHER">
<AU>Shukla V</AU>
<TI>Treating osteoporosis with teriparatide: many unknowns? [Issues in emerging health technologies issue 51]</TI>
<SO>Canadian Coordinating Office of Health Technology Assessment.</SO>
<YR>2003</YR>
<PB>Canadian Coordinating Office of health Technology Assessment</PB>
<CY>Ottawa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2004" MODIFIED="2008-08-12 14:19:46 -0400" MODIFIED_BY="[Empty name]" NAME="Tugwell 2004" TYPE="BOOK">
<AU>Tugwell P, Shea B, Boers M, Brooks P, Simon S, Strand V, Wells G, editors</AU>
<SO>Evidence-Based Rheumatology</SO>
<YR>2004</YR>
<ED>Tugwell P, Shea B, Boers M, Brooks P, Simon S, Strand V, Wells G</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1994" MODIFIED="2008-08-12 14:22:00 -0400" MODIFIED_BY="[Empty name]" NAME="WHO 1994" TYPE="OTHER">
<TI>Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group</TI>
<SO>World Health Organ Tech Rep Ser</SO>
<YR>1994</YR>
<VL>843</VL>
<PG>1-129</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woo-2006" NAME="Woo 2006" TYPE="JOURNAL_ARTICLE">
<AU>Woo SB, Hellstein JW, Kalmar JR</AU>
<TI>Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2006</YR>
<VL>144</VL>
<NO>10</NO>
<PG>753-61</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-CADTH-2006b" NAME="CADTH 2006b" TYPE="OTHER">
<AU>Wells GA, Cranney A, Bouchere M, Peterson J, Shea B, Robinson V, et al</AU>
<TI>Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no 69]</TI>
<SO>Ottawa: Canadian Agency for Drugs and Technologies in Health</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Ascott-Evans-2003">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Primary prevention<BR/>Duration: 1 year<BR/>Blinding: double blind matching placebo, all study personnel blinded<BR/>Withdrawals:<BR/>Alendronate: 12/95 (12.6%)<BR/>Placebo: 13/49 (26.5%)<BR/>Total: 25/144 (17.4%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: 18 centres in 9 countries.</P>
<P>Inclusion Criteria: Women under 80 yrs old who had been postmenopausal for at least 3 years. Previous HRT for at least 1 yr which had been discontinued at least 3 months prior to study. Low bone density between -3.5 and -1.5 of young normal. </P>
<P>Exclusion Criteria: History of osteoporotic fracture or metabolic bone disease. Recent bisphosphonate or other treatment known to affect bone metabolism.</P>
<P>Treatment N = 95<BR/>Control N = 49<BR/>Age: 67.3 (6.6); YSM: 11.5 (7.3)<BR/>Calcium: not reported<BR/>BMD: not reported<BR/>T-score: -2.27 (0.65)<BR/>Vertebral Fractures: 0%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 10 mg x 1 year vs placebo<BR/>(Calcium 500mg/day)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Vertebral, Non Vertebral, Hip and Wrist Fractures: Adverse experiences were recorded by blinded study personnel at each visit using non leading questions. No fractures were reported.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Black-1996">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Secondary prevention<BR/>Blinding: double blind identical placebo, blinded radiologist<BR/>Duration: 3 years<BR/>Withdrawals:<BR/>Alendronate (available radiographs): 44 (4.2%)<BR/>Placebo (available radiographs): 37/1005 (3.7%)<BR/>Total (available radiographs): 81/2027 (4.0%)<BR/>Total (lost to follow up at close out): 78/2027 (3.8%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: Population-based listings in 11 metropolitan areas of the USA. Fracture Intervention Trial.</P>
<P>Inclusion Criteria: Age 55-81, postmenopausal for at least 2 years, femoral neck BMD 0.68 g/cm² Hologic<BR/> (2.1 SD below peak bone mass) or less.</P>
<P>Exclusion Criteria: Peptic ulcer disease (single hospital admission for upper GI bleeding or 2 or more documented ulcers in previous 5 years), dyspepsia requiring daily treatment, abnormal renal function, major medical problems, severe malabsorption, uncontrolled hypertension, MI in previous 6 months, unstable angina, thyroid or parathyroid dysfunction, estrogen or calcitonin in previous 6 months, bisphosphonates or fluorides at any time. </P>
<P>Treatment N = 1022<BR/>Control N = 1005<BR/>Age: 71.0 (5.6); YSM: not reported<BR/>Calcium: 636 (407) mg/day<BR/>BMD (hip): 0.57 g/cm 2 (0.07)<BR/>T-score (hip): -3.3<BR/>Vertebral Fractures : 100% <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 5 mg x 2 years then 10 mg x 1 year vs placebo<BR/>(If intake &lt; 1000 mg then received 500 mg Ca and 250 IU Vitamin D)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Morphometric Vertebral Fractures:<BR/>Lateral radiographs were taken at baseline 24 and 36 months intervals. Morphometry was performed with a translucent digitizer and cursor marking anterior, posterior and middle heights for each vertebra. Baseline fractures were defined a height of &gt; 3 SD below the mean population level for that vertebrae. Incident fractures were defined as a decrease of 20% and at least 4 mm from baseline. Any questionable fractures were reviewed by the study radiologist. Technicians and radiologist were all blinded. </P>
<P>Clinical Vertebral Fractures: Fractures that came to medical attention and were reported by participants. Copy of radiograph was obtained and compared with baseline study radiograph. Incident clinical fracture was defined by a semiquantitative reading by the study radiologist.</P>
<P>Non Vertebral, Hip and Wrist Fractures: Clinical fractures were initially reported by participants and confirmed by a written radiological report. Excluded pathological fractures e.g. malignancies, excessive trauma, face and skull.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bone-1997">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Secondary prevention<BR/>Blinding: double blind<BR/>Duration: 2 years<BR/>Withdrawals:<BR/>Total (for BMD analysis):<BR/>131/359 (36.5%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: 15 clinical sites in USA. Subjects stratified so that 2/3 would be age 70-85.</P>
<P>Inclusion Criteria: Women age 60-85 in good health apart from osteoporosis. Lumbar spine &lt; -2.00 SD of peak bone mass (BMD 0.824g/cm² or less by Hologic DXA or 9.44 g/cm² or less by Lunar DXA).</P>
<P>Exclusion Criteria: More than 1 spinal crush fracture or spinal anatomy otherwise unsuitable for DXA, history of recent major GI disease - peptic ulcer, esophageal ulcer, malabsorption, use of drug to inhibit gastric acid secretion for &gt; 2 wks, chronic NSAID therapy, agents known to affect bone metabolism, unstable dose thyroid hormone replacement, uncorrected vitamin D deficiency.<BR/>Treatment N = 86, 89, 93<BR/>Control N = 91<BR/>Age: 70.4 (5.6); YSM: 24.2 (9.9)<BR/>Calcium: 891(629) mg/day<BR/>BMD: 0.71 g/cm 2 (0.08)<BR/>T-score: -3.1<BR/>Vertebral Fractures: 37.4% <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 1, 2.5, or 5 mg placebo.<BR/>(500 mg calcium/day)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Vertebral Fractures: Lateral thoracic and lumbar radiographs obtained at baseline and annual visits were sent to a central evaluation facility where they were evaluated by a single radiologist. Prevalent and incident fractures were scored using a semiquantitative scale as being intact (unfractured or questionably fractured), or fractured (mild - 20 to 25% height loss; moderate - 25-40% or severe - &gt;40%).</P>
<P>Non-vertebral Fractures: Reported at each centre based on clinical presentation and confirmatory radiographs<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chestnut-1995">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Secondary prevention<BR/>Blinding: double blind unspecified<BR/>Duration: 2 years<BR/>Withdrawals:<BR/>Total: 34/188 (18%)<BR/>Loss to follow up: 34/188 (18.09%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: Recruited by advertisements and medical announcements through seven centres in the USA. </P>
<P>Inclusion Criteria: Healthy women age 42 to 75 who were at least 5 years postmenopausal. BMD = 2 SD below young normal (0.88g/cm²).</P>
<P>Exclusion Criteria: Presence of spine or hip fractures attributable to osteoporosis. Any disease or drug therapy potentially affecting bone metabolism<BR/>Treatment N = 32, 30, 32, 32<BR/>Control N = 31<BR/>Age: 63.04 (6.27); YSM: 15.6 (7.3)<BR/>Calcium: 853 (516) mg/day<BR/>BMD: 0.75 g/cm 2 (0.09)<BR/>T-score: -2.7<BR/>Vertebral Fractures : 0%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 5mg/day, or 10 mg/day, for 2 years 20 mg/day or 40 mg/day for 1 year followed by 1 year of placebo or 40 mg for 3 months followed by 2.5 mg for 21 months vs placebo for 2 years<BR/>(500 mg calcium/day)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Vertebral Fractures: Lateral thoracic and lumbar radiographs were evaluated at each centre for presence of prevalent and incident fractures at baseline and completion of treatment.</P>
<P>Non-vertebral Fractures: Ascertainment not specified but patients were questioned about intercurrent health problems at each visit. This outcome was not included in the meta-analysis as non vertebral fractures weren't broken down by study group.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cummings-1998">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Primary prevention<BR/>Blinding: double blind, collection and review of data was blinded<BR/>Study duration: 4 years<BR/>Withdrawals:<BR/>Total (lost to follow at close out)<BR/>160/4432 (3.6 %)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: Recruited principally though mass mailings from 11 community-based clinical research centres in the USA. Fracture Intervention Trial.</P>
<P>Inclusion Criteria: Age 55-80, postmenopausal for at least 2 years, femoral neck BMD 0.68 g/cm² or less Hologic. At the time of study this was thought to correspond to -2 SD below peak mass but subsequently found to correspond to a t-score of -1.6 based on the Third National Health and Nutritional Examination Survey. Consequently 1/3 of participants had higher BMD than expected. </P>
<P>Exclusion Criteria: Vertebral fractures, Peptic ulcer disease (single hospital admission for upper GI bleeding or 2 or more documented ulcers in previous 5 years), dyspepsia requiring daily treatment, abnormal renal function, major medical problems, severe malabsorption, uncontrolled hypertension, MI in previous 6 mos, unstable angina, thyroid or parathyroid dysfunction, estrogen or calcitonin in previous 6 mos, bisphosphonates or fluorides at any time. </P>
<P>Treatment N = 2214<BR/>Control N = 2218<BR/>Age : 67.6 (6.1); YSM: not reported<BR/>Calcium: 636 (400) mg/day<BR/>BMD: 0.84 g/cm2 (0.13)<BR/>T-score: -1.9<BR/>Vertebral Fractures : 0% <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 5 mg for 2 yrs then increased to 10 mg for 2 years vs placebo<BR/>(If intake &lt; 1000 mg then received 500 mg Ca and 250 IU Vitamin D)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Vertebral Morphometric Fractures: Lateral spine radiographs were obtained at baseline and 4 years. An incident fracture was defined as a decrease of 20% and 4 mm or more in any vertebral height which was confirmed by repeat measurement. All assessments were blinded. </P>
<P>Clinical Fractures: Defined as a fractured diagnosed by a physician. Self reports were confirmed by written reports of radiographs or other tests. Excluded pathologic fractures, trauma sufficient to fracture a young adult bone, facial and skull fractures. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Durson-2001">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Secondary prevention<BR/>Blinding: no blinding reported<BR/>Duration: 1 year<BR/>Withdrawals:<BR/>Alendronate: 13/51 (25.5%)<BR/>Control: 15/50 (30.0%)<BR/>Total: 28/101 (28%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: Postmenopausal women applying to one centre's department of physical medicine and rehabilitation in Turkey.</P>
<P>Inclusion Criteria: BMD of 2 SD or more below young adult mean at either lumbar spine or femoral neck. </P>
<P>Exclusion Criteria: Drug or alcohol abuse, bone metabolism disorder, active GI or liver disease, renal failure or calculi, treatment with specific therapy for osteoporosis, corticosteroids, malignancy, disorder of calcium metabolism, lumbar vertebrae abnormalities preventing evaluation of BMD. <BR/>Treatment N = 51 <BR/>Control N = 50<BR/>Age: 61 (7.8); YSM: 15.59 (8.04)<BR/>Calcium: not reported<BR/>BMD: 0.84 g/cm (0.08)<BR/>T-score: -1.9<BR/>Vertebral Fractures: not reported<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 10 mg/day plus calcium 1000 mg/day x 1 yr vs calcium 1000 mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Vertebral Fractures: Lateral and anteroposterior X-rays of thoracic and lumbar vertebrae were performed at baseline, 6 months and 12 months. A new vertebral fracture was defined as a decrease of 20% and at least 4 mm of height in any vertebrae. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Greenspan-1998">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Secondary prevention<BR/>Blinding: double blind, matching placebo<BR/>Study duration: 2.5 years<BR/>Loss to follow up: Alendronate:14/60 (23.3%)<BR/>Placebo:15/60 (25.0%)<BR/>Total: 29/120 (24.2%)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: Unselected women from one city (Boston) in the USA were recruited by advertisement. </P>
<P>Inclusion Criteria: Healthy ambulatory community dwelling age 65 or older. Criteria not based on BMD.</P>
<P>Exclusion Criteria: History of any illness affecting bone and mineral metabolism - (renal, malignancy, hyperthyroidism, hyperparathyroidism, malabsorption), medications affecting bone metabolism, treatment for osteoporosis (bisphosphonates, HRT, calcitonin) within 1 year.<BR/>Treatment N = 60<BR/>Control N = 60<BR/>Age: 70 (4.6); YSM: not reported<BR/>Calcium: 719 (465) mg/day<BR/>BMD: 0.57 g/cm2 (0.11)<BR/>T-score: -4.3<BR/>Vertebral Fractures: not reported <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 5 mg for year 1, 10 mg for year 2 vs placebo,<BR/>(if Ca intake &lt; 1000 mg - 250 mg Ca and/or 125 IU vitamin D/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Non-vertebral Hip and Wrist: Ascertainment not described. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Greenspan-2002">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Secondary prevention<BR/>Blinding: double blind matching placebo<BR/>Duration: 2 years<BR/>Withdrawals:<BR/>Not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: Female residents in long term care facilities in 25 centre in USA.</P>
<P>Inclusion Criteria: Ambulatory, age 65 or older with BMD T-score of -2 or less at lumbar spine or hip. <BR/>Exclusion Criteria: Disorders of bone mineralization, 25-hydroxycholecalciferol &lt; 25 nmol/L, untreated hyperthyroidism, recent major upper GI mucosal erosive disease, or use of bone active agents<BR/>Treatment N = 163<BR/>Control N = 164<BR/>Age: 78.5 (range 65-91); YSM: not reported<BR/>Calcium: not reported<BR/>BMD: not reported<BR/>T-score: (mean range hip and spine) -3.5 to-2.4 <BR/>Fractures: (history of any) 55%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 10 mg/day x 2yrs vs placebo<BR/>(Vitamin D 400 IU/day and if dietary calcium was &lt; 1500 mg/day they received calcium 500mg/day.)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Hip Fractures: Ascertainment not reported. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hosking-1998">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Primary prevention<BR/>Blinding: double blind, blinded BMD measurement and analysis <BR/>Duration: 2 years<BR/>Withdrawals: Alendronate:2.5mg 92/499 (18.4%)<BR/>Alendronate 5mg: 102/498 (20.5%) <BR/>Placebo: 93/502 (18.5%)<BR/>Total: 287/1499 (19.1%)</P>
<P>Withdrawals</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: Recruited by direct mailing, advertisements or telephone. Multicentre - USA, UK and Denmark.</P>
<P>Inclusion Criteria: Postmenopausal at least 6 months (confirmed by FSH) and in good health. Only 10% of women at each centre were allowed to have a lumbar-spine BMD below 0.8 g/square metre<BR/>(DEXA). </P>
<P>Exclusion Criteria: Abnormal renal function, cancer, peptic ulcer or esophageal disease requiring prescription medication within the previous five years, previous treatment with bisphosphonate or fluoride, therapy with phosphate-binding antacid, HRT within previous 3 months, therapy with any drug which affects the skeleton. <BR/>Treatment N = 499, 498<BR/>Control N = 502 <BR/>Age: 53 (4); YSM: 6 (5)<BR/>Calcium: 923 (505) mg/day<BR/>BMD: 0.94 g/cm 2 (0.12)<BR/>T-score: -1.0<BR/>Vertebral Fractures: NR <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 2.5 or 5mg vs placebo <BR/>(&lt; 500mg calcium intake encouraged to increase)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Vertebral and Non-Vertebral Fractures: <BR/>Women were questioned about any symptoms at clinic visits every 3 months. All unfavourable clinical effects including fractures were evaluated with respect to severity, duration, seriousness, relation to study drug and outcome. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liberman-1995">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Secondary prevention<BR/>Blinding: double blind, blinded radiologists<BR/>Withdrawals:<BR/>Alendronate: 97/597 (16.2%)<BR/>Placebo: 65/397 (16.5%)<BR/>Total: 162/994 (16.3 %)</P>
<P>Duration: 3 years<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: Two multicentre studies, one in the US, and the other in Australia, Canada, Europe, Israel, Mexico, New Zealand, South America. </P>
<P>Inclusion Criteria: Postmenopausal (= 5 yrs) women age 45-80 with lumbar BMD at least 2.5 SD below premenopausal mean. </P>
<P>Exclusion Criteria: Other causes for osteoporosis (glucocorticoids, vitamin D deficiency, Pagets, hyperparathyroidism), active peptic ulcer disease, abnormal renal or hepatic function, abnormalities of spine precluding assessment of BMD for 3 lumbar vertebrae, history or hip fracture, prior bisphosphonates, HRT, calcitonin, fluoride, or anabolic steroid in previous 12 months. <BR/>Treatment N = 597<BR/>Control N = 397<BR/>Age:64 (7); YSM: 16.5<BR/>Calcium: 739 (537) mg/day<BR/>BMD: 0.71 <BR/>T-score: -3.1<BR/>Vertebral Fractures: 21% <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 5, 10 or 20/5 mg vs placebo<BR/>(500 mg calcium/day)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Vertebral fractures, vertebral deformities and height loss. (Deformities and height loss not included in this review.)</P>
<P>Vertebral Fractures: Lateral thoracic and lumbar spine films were obtained at baseline, one, two, and three years. Standard values for target-to-film distance and centering were used at each centre. Vertebral heights were determined at a radiology centre by observers blinded to both treatment and sequence. All films from each woman were digitized at the same time and anterior, middle and posterior vertebral heights were calculated with using computer software. Prevalent fractures were determined by comparing baseline vertebral height ratios to a reference group. A ratio of &gt; -3 SD was considered a fracture. Incident fractures were defined as a reduction of at least 20% and 4 mm between baseline and follow up.</P>
<P>Non-Vertebral Fractures, Hip and Wrist: All reported symptomatic fractures were recorded with no attempt to exclude fractures on the basis of degree of trauma. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pols-1999">
<CHAR_METHODS>
<P>Randomized controlled trial<BR/>Secondary prevention<BR/>Blinding: double blind matching placebo<BR/>Duration: 1 year<BR/>Withdrawals:<BR/>Alendronate: 118/950 (12.4%)<BR/>Control: 93/958 (9.7%)<BR/>Total: 211/1908 (11.1 %)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Source: 153 centres in 34 countries in Europe, Latin America, Australia, Canada, South Africa and China.<BR/>.<BR/>Inclusion Criteria: Postmenopausal for at least 3 years, not older than age 85, lumbar BMD (L2-4) at least 2 SD below the premenopausal mean (=0.86 g/cm² (DXA) or =0.98 g/cm² (Hologic)). At lease 3 vertebrae from L1-L4 had to be evaluable by DXA to determine BMD. In good health and between 20% below and 50% above ideal body weight. </P>
<P>Exclusion Criteria: Other metabolic bone disease, disturbed parathyroid or thyroid, major GI disease (peptic ulcer or malabsorption, drug to inhibit gastric &gt; 2 week within past 3 mos), MI within 1 year, uncontrolled hypertension or angina, impaired renal function, bisphosphonates or fluoride within 6 months, estrogen ipriflavone or calcitonin within 4 months, anabolic steroids, glucocorticoid or progestin within 6 months, medication influencing bone metabolism - vitamin A &gt; 10,000 IU/day, vitamin D &gt; 1000 IU/day, anticonvulsants, phosphate-binding antacids, <BR/>Treatment N = 950<BR/>Control N = 958<BR/>Age: 62.8 (7.4); YSM: 15.9 (1.5)<BR/>Calcium: Not available<BR/>BMD: 0.72 g/cm2 (0.08)<BR/>T-score: -2.97<BR/>Vertebral Fractures: not reported <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Alendronate 10 mg, vs placebo<BR/>(500mg calcium/day)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Non- Vertebral, Hip, Wrist: Clinical fractures were assessed through adverse event reporting. Supporting documentation for each fracture i.e. radiographs and/or radiology reports, hospital discharge reports with clinical diagnosis or confirmation by investigator/treating physician.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>t-score calculated using the lumbar spine BMD [(LS BMD -1.047)/0.110];<BR/>YSM=Years Since Menopause;<BR/>BMD=Bone Mineral Density; <BR/>Txt=Treatment; <BR/>HRT=Hormone Replacement Therapy</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adami-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate or earlier report of another study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Adami-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of appropriate fracture data (i.e. reported as adverse events or unspecified).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aki-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bell-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of appropriate fracture data (i.e. reported as adverse events or unspecified).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bettembuk-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate or earlier report of another study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Black-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate or earlier report of another study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Black-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Body-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boivin-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bone-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of appropriate fracture data (i.e. reported as adverse events or unspecified).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bone-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Extension/discontinuation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonnick-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of appropriate fracture data (i.e. reported as adverse events or unspecified).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bouxsein-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chailurkit-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chailurkit-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chavassieux-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cheng-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of therapy &lt; 1 year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chesnut-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of therapy &lt; 1 year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cummings-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davas-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Devogelaer-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate or earlier report of another study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dobnig-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Downs-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of appropriate fracture data (i.e. reported as adverse events or unspecified).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Evio-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gonnelli-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greenspan-2002a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Extension/discontinuation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greenspan-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of therapy &lt; 1 year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greenspan-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of appropriate fracture data (i.e. reported as adverse events or unspecified).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harris-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of therapy &lt; 1 year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heijckmann-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ho-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hochberg-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate or earlier report of another study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hosking-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of appropriate fracture data (i.e. reported as adverse events or unspecified).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iwamoto-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johnell-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kung-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kushida-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lau-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Luckey-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malavolta-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of therapy &lt; 1 year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McClung-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McClung-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Extension study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murphy-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of appropriate fracture data (i.e. reported as adverse events or unspecified).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nenonen-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Palomba-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Payer-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of therapy &lt; 1 year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ravn-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ravn-1999b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ravn-1999c">
<CHAR_REASON_FOR_EXCLUSION>
<P>Extension/discontinuation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ravn-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Extension/discontinuation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rhee-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rittmaster-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rizzoli-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rossini-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of therapy &lt; 1 year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rossini-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rozkydal-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sahota-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sambrook-2004a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sambrook-2004b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Extension/discontinuation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sawka-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schneider-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schnitzer-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seeman-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate or earlier report of another study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simon-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sosa-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stepan-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tiras-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tucci-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate or earlier report of another study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tutuncu-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uusi_x002d_Rasi-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Poest-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vasikaran-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of an appropriate control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yen-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yildirim-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of fracture outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ascott-Evans-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Black-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bone-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chestnut-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cummings-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Durson-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Greenspan-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Greenspan-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hosking-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Liberman-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pols-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-01-13 16:51:59 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-01-13 16:51:59 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Clinical Relevance Table for Fracture - Primary Prevention Trials</TITLE>
<TABLE COLS="8" ROWS="26">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P># Patients # Trials</P>
</TH>
<TH>
<P>Control Event Rate</P>
</TH>
<TH>
<P>Wt Absolute RD</P>
</TH>
<TH>
<P>Wt Rel % Change</P>
</TH>
<TH>
<P>NNT B</P>
</TH>
<TH>
<P>Statistical Sig</P>
</TH>
<TH>
<P>Quality of Evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Vertebral Fractures (Trial Populations)- Primary Prevention (alendronate 10 mg/day for 1-4 yrs)</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>3.4% (3 out of 100)</P>
</TD>
<TD>
<P>-2% 2 fewer patients out of 100</P>
</TD>
<TD>
<P>-45% (I)</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-2, -1)</P>
</TD>
<TD>
<P>(-62, -20)</P>
</TD>
<TD>
<P>(48, 148)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Vertebral Fractures (Low Risk Woman) - Primary Prevention (alendronate 10 mg/day for 1-4 yrs)</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>1.2 % (1 out of 100)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>-45% (I)</P>
</TD>
<TD>
<P>186</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-62, -20)</P>
</TD>
<TD>
<P>(135, 417)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Vertebral Fractures (Moderate Risk Woman) - Primary Prevention (alendronate 10 mg/day for 1-4 yrs)</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>5.3 % (5 out of 100)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>-45% (I)</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-62, -20)</P>
</TD>
<TD>
<P>(31, 95)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Non Vertebral Fractures (Trial Populations) - Primary Prevention (alendronate 10mg/day for 1-4 years)</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>13.0% (13 out of 100 patients)</P>
</TD>
<TD>
<P>-1% 1 fewer patient out of 100</P>
</TD>
<TD>
<P>-11% (I)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-3, 0)</P>
</TD>
<TD>
<P>(-24, 4)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Non Vertebral Fractures (Low Risk Woman) - Primary Prevention (alendronate 10mg/day for 1-4 years)</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>8.6% (9 out of 100)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>-11% (I)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-24, 4)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Non Vertebral Fractures (Moderate Risk Woman)- Primary Prevention (alendronate 10mg/day for 1-4 years)</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>16.5% (17 out of 100)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>-11% (I)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-24, 4)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hip Fractures (Trial Populations)- Primary Prevention (alendronate 10mg/day for 1-4 yrs</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>1.1% (1 out of 100)</P>
</TD>
<TD>
<P>0% fewer patients out of 100</P>
</TD>
<TD>
<P>-21% (I)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-1, 0)</P>
</TD>
<TD>
<P>(-56, 44)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hip Fractures (Low Risk Woman)- Primary Prevention (alendronate 10mg/day for 1-4 yrs</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>0.4% (0 out of 100)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>-21% (I)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-56, 44)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hip Fractures (Moderate Risk Woman)- Primary Prevention (alendronate 10mg/day for 1-4 yrs</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>1.9% (2 out of 100)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>-21% (I)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-56, 44)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wrist Fractures (Trial Populations)- Primary Prevention (alendronate 10 mg/day for 1-4 yrs)</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>3.1% (3 out of 100)</P>
</TD>
<TD>
<P>1 1 more patient out of 100</P>
</TD>
<TD>
<P>19% (W)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(0, 2)</P>
</TD>
<TD>
<P>(-13, 38)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wrist Fractures (Low Risk Woman)- Primary Prevention (alendronate 10 mg/day for 1-4 yrs)</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>19% (W)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-13, 38)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wrist Fractures (Moderate Risk Woman)- Primary Prevention (alendronate 10 mg/day for 1-4 yrs)</P>
</TD>
<TD>
<P>4,576 (2)</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>19% (W)</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
<TD>
<P>Not statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-13, 38)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Legend</P>
</TD>
<TD>
<P>Primary prevention = bone density &lt; 2 SD values below peak bone mass and/or no history of vertebral compression fractures.</P>
</TD>
<TD>
<P>For Trial Population rates are based on the event rate in the control group. Low and Moderate Risk, are 5 year community population risks derived from the following variables from the FRACTURE Index: age, fracture after 50 yrs., maternal hip fracture after 50 yrs., weight &lt; 125 lbs, smoking, using arms to assist standing and BMD. Low = FRACTURE Index score 1-2, Moderate = FRACTURE Index score 5 (Black 2001) see Figure 1</P>
</TD>
<TD>
<P>Wt = weighted, RD = risk difference</P>
</TD>
<TD>
<P>Wt Rel = weighted relative percent change, I = improvement</P>
</TD>
<TD>
<P>NNT B = number needed to benefit</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Gold level: At least one randomised clinical trial meets all of the following criteria for the major outcome(s) as reported: Sample sizes of at least 50 per group. If a statistically significant difference is not found they must be powered for 20% relative difference in the relevant outcome. Blinding of patients and assessors for outcomes. Handling of withdrawals &gt; 80% follow up (imputations based on methods such as Last Observation Carried Forward (LOCF) acceptable). Concealment of treatment allocation. Silver level: Randomised trial does not meet the above criteria.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-01-13 16:47:25 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Clinical Relevance Table for Fracture - Secondary Prevention Trials</TITLE>
<TABLE COLS="8" ROWS="25">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P># Patients # Trials</P>
</TH>
<TH>
<P>Control Event Rate</P>
</TH>
<TH>
<P>Wt Absolute RD</P>
</TH>
<TH>
<P>Wt Rel % Change</P>
</TH>
<TH>
<P>NNT B</P>
</TH>
<TH>
<P>Statistical Sig</P>
</TH>
<TH>
<P>Quality of Evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Vertebral Fractures (Trial populations) - Secondary Prevention (alendronate 10 mg for 1-3 yrs)</P>
</TD>
<TD>
<P>2,785 (4)</P>
</TD>
<TD>
<P>12.2% (12 out of 100)</P>
</TD>
<TD>
<P>-6% 6 fewer patients out of 100</P>
</TD>
<TD>
<P>-45% (I)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-8, -4)</P>
</TD>
<TD>
<P>(-57, -31)</P>
</TD>
<TD>
<P>(15, 25)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Vertebral Fractures (Moderate Risk Woman) - Secondary Prevention (alendronate 10 mg for 1-3 yrs)</P>
</TD>
<TD>
<P>2,785 (4)</P>
</TD>
<TD>
<P>5.3% (5 out of 100)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>-45% (I)</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-57, -31)</P>
</TD>
<TD>
<P>(34, 61)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Vertebral Fractures (High Risk Woman) - Secondary Prevention (alendronate 10 mg for 1-3 yrs)</P>
</TD>
<TD>
<P>2,785 (4)</P>
</TD>
<TD>
<P>11.2% (11 out of 100)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>-45% (I)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-57, -31)</P>
</TD>
<TD>
<P>(16, 29)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Non Vertebral Fractures (Trial Population)- Secondary Prevention (alendronate 10mg/day for 1 - 3 yrs)</P>
</TD>
<TD>
<P>5049 (4)</P>
</TD>
<TD>
<P>9.3% (9 out of 100)</P>
</TD>
<TD>
<P>-2% 2 fewer patients out of 100</P>
</TD>
<TD>
<P>-23% (I)</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-4, -1)</P>
</TD>
<TD>
<P>(-36, -8)</P>
</TD>
<TD>
<P>(30, 135)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Non Vertebral Fractures (Moderate Risk Woman) - Secondary Prevention (alendronate 10mg/day for 1 - 3 yrs)</P>
</TD>
<TD>
<P>5049 (4)</P>
</TD>
<TD>
<P>16.5% (17 out of 100)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>-23% (I)</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-36, -8)</P>
</TD>
<TD>
<P>(17, 76)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Non Vertebral Fractures (High Risk Woman) - Secondary Prevention (alendronate 10mg/day for 1 - 3 yrs)</P>
</TD>
<TD>
<P>5049 (4)</P>
</TD>
<TD>
<P>27.5% (28 out of 100)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>-23%</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-36, -8) (I)</P>
</TD>
<TD>
<P>(11, 46)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hip Fractures (Trial Population) - Secondary Prevention (alendronate 10mg/day for 1-3 yrs)</P>
</TD>
<TD>
<P>5,376 (5)</P>
</TD>
<TD>
<P>1.3% ( out of 100)</P>
</TD>
<TD>
<P>-1% 1 fewer patients out of 100</P>
</TD>
<TD>
<P>-53% ( -74, -15) (I)</P>
</TD>
<TD>
<P>146</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-1, 0)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(104, 513)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hip Fractures (Moderate Risk Woman) - Secondary Prevention (alendronate 10mg/day for 1-3 yrs)</P>
</TD>
<TD>
<P>5,376 (5)</P>
</TD>
<TD>
<P>1.9% (2 out of 100)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>-53% ( -74, -15) (I)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(72, 351)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hip Fractures (High Risk Woman) - Secondary Prevention (alendronate 10mg/day for 1-3 yrs)</P>
</TD>
<TD>
<P>5,376 (5)</P>
</TD>
<TD>
<P>8.9% (9 out of 100)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>-53% ( -74, -15) (I)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(16, 75)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wrist Fractures (Trial Population) - Secondary Prevention (alendronate 10mg/day for 1-3 yrs)</P>
</TD>
<TD>
<P>5,153 (4)</P>
</TD>
<TD>
<P>2.9% (3 out of 100)</P>
</TD>
<TD>
<P>-1% 1 fewer patients out of 100</P>
</TD>
<TD>
<P>-50% (-66, -27) (I)</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(-2, -1)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(53, 128)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wrist Fractures - Secondary Prevention (alendronate 10mg/day for 1-3 yrs)</P>
</TD>
<TD>
<P>5,153 (4)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>-50% (-66, -27) (I)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>95% confidence interval</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wrist Fractures - Secondary Prevention (alendronate 10mg/day for 1-3 yrs)</P>
</TD>
<TD>
<P>5,153 (4)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>-50% (-66, -27) (I)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>Statistically significant</P>
</TD>
<TD>
<P>Gold</P>
</TD>
</TR>
<TR>
<TD>
<P>Legend</P>
</TD>
<TD>
<P>Secondary prevention = bone density of at least 2 SD values below peak bone mass and/or one or more vertebral compression fractures.</P>
</TD>
<TD>
<P>For Trial Population rates are based on the event rate in the control group. Moderate and High Risk, are 5 year community population risks derived from the following variables in the FRACTURE Index: age, fracture after 50 yrs., maternal hip fracture after 50 yrs., weight &lt; 125 lbs, smoking, using arms to assist standing and BMD. Moderate = FRACTURE Index score 5, High = FRACTURE Index score 8-13 (Black 2001) see Figure 1</P>
</TD>
<TD>
<P>Wt = weighted, RD = risk difference</P>
</TD>
<TD>
<P>Wt Rel = weighted relative percent change, I = improvement</P>
</TD>
<TD>
<P>NNT B = number needed to benefit</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Gold level:<BR/>At least one randomised clinical trial meets all of the following criteria for the major outcome(s) as reported:<BR/>Sample sizes of at least 50 per group. If a statistically significant difference is not found they must be powered for 20% relative difference in the relevant outcome.<BR/>Blinding of patients and assessors for outcomes.<BR/>Handling of withdrawals &gt; 80% follow up (imputations based on methods such as Last Observation Carried Forward (LOCF) acceptable).<BR/>Concealment of treatment allocation.<BR/>
<BR/>Silver level:<BR/>Randomised trial does not meet the above criteria.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-08-12 13:44:50 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Alendronate 10 mg vs Control - all years baseline denominators</NAME>
<DICH_OUTCOME CHI2="1.805756761007737" CI_END="0.6698970820522357" CI_START="0.4502020134950404" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.549171207524911" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="259" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.17399191391120208" LOG_CI_START="-0.3465925669813675" LOG_EFFECT_SIZE="-0.2602922404462848" METHOD="MH" NO="1" P_CHI2="0.6136831501839716" P_Q="0.9707813072443005" P_Z="3.390292498630469E-9" Q="0.0013416392322384083" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3611" TOTAL_2="3750" WEIGHT="99.99999999999999" Z="5.911488834547657">
<NAME>Vertebral Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7976234183048383" CI_START="0.3823998030250023" DF="0" EFFECT_SIZE="0.5522780441479629" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="78" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.09820210357896997" LOG_CI_START="-0.4174823401019433" LOG_EFFECT_SIZE="-0.2578422218404566" NO="1" P_CHI2="1.0" P_Z="0.001547477591065127" STUDIES="2" TAU2="0.0" TOTAL_1="2309" TOTAL_2="2267" WEIGHT="30.805188583997197" Z="3.1656295046919976">
<NAME>Vertebral primary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17286" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7976234183048383" CI_START="0.38239980302500237" EFFECT_SIZE="0.5522780441479629" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="78" LOG_CI_END="-0.09820210357896997" LOG_CI_START="-0.41748234010194324" LOG_EFFECT_SIZE="-0.2578422218404566" ORDER="17287" O_E="0.0" SE="0.18754679139625466" STUDY_ID="STD-Cummings-1998" TOTAL_1="2214" TOTAL_2="2218" VAR="0.03517379896303026" WEIGHT="30.805188583997197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.809215253070662" CI_END="0.6935729730248206" CI_START="0.4326462671756042" DF="2" EFFECT_SIZE="0.5477880591917595" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="181" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.15890783867901334" LOG_CI_START="-0.36386703897779515" LOG_EFFECT_SIZE="-0.26138743882840426" NO="2" P_CHI2="0.40470069231071915" P_Z="5.758629561805376E-7" STUDIES="4" TAU2="0.0" TOTAL_1="1302" TOTAL_2="1483" WEIGHT="69.19481141600279" Z="4.999140954570593">
<NAME>Vertebral secondary</NAME>
<DICH_DATA CI_END="0.686793298814153" CI_START="0.4074342027906647" EFFECT_SIZE="0.5289830622849045" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="145" LOG_CI_END="-0.16317395099253298" LOG_CI_START="-0.3899425161808285" LOG_EFFECT_SIZE="-0.2765582335866807" ORDER="17288" O_E="0.0" SE="0.13320497771410628" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.017743566087815552" WEIGHT="57.7984981347105"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17289" O_E="0.0" SE="0.0" STUDY_ID="STD-Chestnut-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6341909947917648" CI_START="0.43211890233106215" EFFECT_SIZE="0.8403361344537815" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.21330281298997472" LOG_CI_START="-0.3643967357750363" LOG_EFFECT_SIZE="-0.07554696139253075" ORDER="17290" O_E="0.0" SE="0.3393435746034539" STUDY_ID="STD-Durson-2001" TOTAL_1="51" TOTAL_2="50" VAR="0.11515406162464988" WEIGHT="5.588924493068341"/>
<DICH_DATA CI_END="1.179417149933243" CI_START="0.17430187910688136" EFFECT_SIZE="0.45340338053905893" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="0.07166743857424544" LOG_CI_START="-0.7586979308398034" LOG_EFFECT_SIZE="-0.343515246132779" ORDER="17291" O_E="0.0" SE="0.4877607283686822" STUDY_ID="STD-Liberman-1995" TOTAL_1="199" TOTAL_2="397" VAR="0.23791052813874736" WEIGHT="5.807388788223951"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Alendronate 10 mg vs Control - all years baseline denominators</NAME>
<DICH_OUTCOME CHI2="4.9717812039732365" CI_END="0.9416798236967319" CI_START="0.7425565029427703" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8362119807656487" ESTIMABLE="YES" EVENTS_1="450" EVENTS_2="518" I2="19.54593663930002" I2_Q="28.391690834816604" ID="CMP-002.01" LOG_CI_END="-0.026096734614855493" LOG_CI_START="-0.12927049422271011" LOG_EFFECT_SIZE="-0.0776836144187828" METHOD="MH" NO="1" P_CHI2="0.2902052592919858" P_Q="0.23731303117695335" P_Z="0.00316266094617991" Q="1.3964859827834184" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4938" TOTAL_2="4687" WEIGHT="100.0" Z="2.951469191942084">
<NAME>Non Vertebral Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4643626504272223E-30" CI_END="1.0394441044089022" CI_START="0.7609446431553619" DF="0" EFFECT_SIZE="0.8893589956307727" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="294" I2="100.0" ID="CMP-002.01.01" LOG_CI_END="0.01680114032505723" LOG_CI_START="-0.11864693593193525" LOG_EFFECT_SIZE="-0.05092289780343904" NO="1" P_CHI2="0.0" P_Z="0.1405539084516278" STUDIES="2" TAU2="0.0" TOTAL_1="2309" TOTAL_2="2267" WEIGHT="55.79359358155112" Z="1.4737314614020118">
<NAME>Non-vertebral primary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17292" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.039444104408902" CI_START="0.7609446431553617" EFFECT_SIZE="0.8893589956307726" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="294" LOG_CI_END="0.016801140325057137" LOG_CI_START="-0.1186469359319354" LOG_EFFECT_SIZE="-0.050922897803439095" ORDER="17293" O_E="0.0" SE="0.0795628704721482" STUDY_ID="STD-Cummings-1998" TOTAL_1="2214" TOTAL_2="2218" VAR="0.0063302503577678335" WEIGHT="55.79359358155112"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6679287290892146" CI_END="0.9241348433387363" CI_START="0.640131237447126" DF="3" EFFECT_SIZE="0.7691343061094279" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="224" I2="18.209970215399153" ID="CMP-002.01.02" LOG_CI_END="-0.034264654921379055" LOG_CI_START="-0.19373097936583467" LOG_EFFECT_SIZE="-0.11399781714360686" NO="2" P_CHI2="0.2996266938687545" P_Z="0.005074878988436124" STUDIES="4" TAU2="0.0" TOTAL_1="2629" TOTAL_2="2420" WEIGHT="44.20640641844887" Z="2.8022419993191305">
<NAME>Non vertebral secondary</NAME>
<DICH_DATA CI_END="1.0134222360737097" CI_START="0.6483897389234528" EFFECT_SIZE="0.8106124715713757" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="148" LOG_CI_END="0.005790429161446899" LOG_CI_START="-0.1881638666862377" LOG_EFFECT_SIZE="-0.09118671876239538" ORDER="17294" O_E="0.0" SE="0.1139297134701785" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.01297997961139697" WEIGHT="28.347711344478345"/>
<DICH_DATA CI_END="28.031112609677763" CI_START="0.3210718077916301" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.447640336099703" LOG_CI_START="-0.49339782666037835" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="17295" O_E="0.0" SE="1.140175425099138" STUDY_ID="STD-Greenspan-1998" TOTAL_1="60" TOTAL_2="60" VAR="1.3" WEIGHT="0.18994555883818695"/>
<DICH_DATA CI_END="1.1898477678759476" CI_START="0.5211932534343561" EFFECT_SIZE="0.7874900819888918" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.07549140021552862" LOG_CI_START="-0.2830012146309696" LOG_EFFECT_SIZE="-0.10375490720772051" ORDER="17296" O_E="0.0" SE="0.2105803365278964" STUDY_ID="STD-Liberman-1995" TOTAL_1="597" TOTAL_2="397" VAR="0.0443440781322021" WEIGHT="8.670231283306055"/>
<DICH_DATA CI_END="0.8938265110251987" CI_START="0.3000090319417781" EFFECT_SIZE="0.5178378378378379" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="37" LOG_CI_END="-0.04874676824669984" LOG_CI_START="-0.5228656704022389" LOG_EFFECT_SIZE="-0.28580621932446937" ORDER="17297" O_E="0.0" SE="0.27849979005258" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.07756213305933116" WEIGHT="6.99851823182628"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Alendronate 10 mg vs Control - all years baseline denominators</NAME>
<DICH_OUTCOME CHI2="2.0576478111249" CI_END="0.9158051228530733" CI_START="0.3997206589993801" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.605034071124791" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="57" I2="0.0" I2_Q="31.65625686552201" ID="CMP-003.01" LOG_CI_END="-0.038196931434442166" LOG_CI_START="-0.39824340526110225" LOG_EFFECT_SIZE="-0.2182201683477722" METHOD="MH" NO="1" P_CHI2="0.8411122948338052" P_Q="0.22642327111663596" P_Z="0.017509774496694074" Q="1.4631917336343858" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5101" TOTAL_2="4851" WEIGHT="100.0" Z="2.3758247990386576">
<NAME>Hip Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4436421213395543" CI_START="0.43570548176487733" DF="0" EFFECT_SIZE="0.7930969587473653" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.1594595450406052" LOG_CI_START="-0.3608069760172848" LOG_EFFECT_SIZE="-0.10067371548833977" NO="1" P_CHI2="1.0" P_Z="0.448138426282064" STUDIES="2" TAU2="0.0" TOTAL_1="2309" TOTAL_2="2267" WEIGHT="41.170426271841606" Z="0.7585222133677242">
<NAME>Hip primary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17298" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4436421213395543" CI_START="0.43570548176487733" EFFECT_SIZE="0.7930969587473653" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.1594595450406052" LOG_CI_START="-0.3608069760172848" LOG_EFFECT_SIZE="-0.10067371548833977" ORDER="17299" O_E="0.0" SE="0.3056071298302187" STUDY_ID="STD-Cummings-1998" TOTAL_1="2214" TOTAL_2="2218" VAR="0.09339571780306416" WEIGHT="41.170426271841606"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6435679523691942" CI_END="0.8482699637122543" CI_START="0.26421923367622246" DF="4" EFFECT_SIZE="0.47342289737887505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="33" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-0.07146591060645749" LOG_CI_START="-0.5780355713717031" LOG_EFFECT_SIZE="-0.3247507409890803" NO="2" P_CHI2="0.9581014080582663" P_Z="0.011971606370296494" STUDIES="5" TAU2="0.0" TOTAL_1="2792" TOTAL_2="2584" WEIGHT="58.829573728158394" Z="2.512980170702562">
<NAME>Hip secondary</NAME>
<DICH_DATA CI_END="1.0086241471311288" CI_START="0.23968506817875357" EFFECT_SIZE="0.4916829745596869" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="0.0037293612455512382" LOG_CI_START="-0.620359020657886" LOG_EFFECT_SIZE="-0.3083148297061674" ORDER="17300" O_E="0.0" SE="0.36659260481739286" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.13439013790680115" WEIGHT="38.09044838522404"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="17302" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Greenspan-1998" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="2.5754760788844004"/>
<DICH_DATA CI_END="2.708645201468076" CI_START="0.09343301735774216" EFFECT_SIZE="0.5030674846625767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4327521216312133" LOG_CI_START="-1.0294996256716957" LOG_EFFECT_SIZE="-0.2983737520202411" ORDER="17301" O_E="0.0" SE="0.858933914628615" STUDY_ID="STD-Greenspan-2002" TOTAL_1="163" TOTAL_2="164" VAR="0.7377674696992369" WEIGHT="6.846933347329782"/>
<DICH_DATA CI_END="2.1233949448091476" CI_START="0.0231397713219528" EFFECT_SIZE="0.2216638749302066" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3270307790925038" LOG_CI_START="-1.6356409372643368" LOG_EFFECT_SIZE="-0.6543050790859165" ORDER="17303" O_E="0.0" SE="1.1528830815696918" STUDY_ID="STD-Liberman-1995" TOTAL_1="597" TOTAL_2="397" VAR="1.3291393997696288" WEIGHT="6.187361042631738"/>
<DICH_DATA CI_END="4.0142993074220605" CI_START="0.11258785340588227" EFFECT_SIZE="0.6722807017543859" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6036097504922032" LOG_CI_START="-0.9485084610241724" LOG_EFFECT_SIZE="-0.1724493552659846" ORDER="17304" O_E="0.0" SE="0.9117219205537777" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.8312368604182689" WEIGHT="5.1293548740884285"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Alendronate 10 mg vs Control - all years baseline denominators</NAME>
<DICH_OUTCOME CHI2="19.207198423861783" CI_END="1.062229145976028" CI_START="0.6645090750001375" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8401552875693375" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="142" I2="79.17447452913977" I2_Q="91.01322127080506" ID="CMP-004.01" LOG_CI_END="0.026218213636403694" LOG_CI_START="-0.17749908365191766" LOG_EFFECT_SIZE="-0.07564043500775701" METHOD="MH" NO="1" P_CHI2="7.155910218606953E-4" P_Q="8.506038445420527E-4" P_Z="0.14553831767595912" Q="11.127457681263975" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4938" TOTAL_2="4791" WEIGHT="99.99999999999997" Z="1.4554731518975972">
<NAME>Wrist Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6237043399421989" CI_START="0.8690024558108225" DF="0" EFFECT_SIZE="1.1878564976125952" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="70" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.2105069514929633" LOG_CI_START="-0.060978996228454624" LOG_EFFECT_SIZE="0.07476397763225433" NO="1" P_CHI2="1.0" P_Z="0.28036437454725394" STUDIES="2" TAU2="0.0" TOTAL_1="2309" TOTAL_2="2267" WEIGHT="47.99825385284189" Z="1.0795012024013968">
<NAME>Wrist primary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17305" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6237043399421989" CI_START="0.8690024558108225" EFFECT_SIZE="1.1878564976125952" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="70" LOG_CI_END="0.2105069514929633" LOG_CI_START="-0.060978996228454624" LOG_EFFECT_SIZE="0.07476397763225433" ORDER="17306" O_E="0.0" SE="0.1594721895686759" STUDY_ID="STD-Cummings-1998" TOTAL_1="2214" TOTAL_2="2218" VAR="0.0254313792458277" WEIGHT="47.99825385284189"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.078053654611723" CI_END="0.7535637698437487" CI_START="0.35775644073159807" DF="3" EFFECT_SIZE="0.519222777007697" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="72" I2="57.615466816285824" ID="CMP-004.01.02" LOG_CI_END="-0.12287998990623356" LOG_CI_START="-0.44641253884278176" LOG_EFFECT_SIZE="-0.28464626437450763" NO="2" P_CHI2="0.06945120931523452" P_Z="5.631235652765877E-4" STUDIES="4" TAU2="0.0" TOTAL_1="2629" TOTAL_2="2524" WEIGHT="52.00174614715809" Z="3.448780831120131">
<NAME>Wrist secondary</NAME>
<DICH_DATA CI_END="0.8792452479793448" CI_START="0.3166634582463592" EFFECT_SIZE="0.5276597775762494" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="41" LOG_CI_END="-0.055889970218213944" LOG_CI_START="-0.49940204966121693" LOG_EFFECT_SIZE="-0.27764600993971544" ORDER="17307" O_E="0.0" SE="0.2605211908850205" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.06787129090014929" WEIGHT="28.374651571439372"/>
<DICH_DATA CI_END="361.2528774781699" CI_START="0.9924142311153011" EFFECT_SIZE="18.934426229508198" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.5578113150529473" LOG_CI_START="-0.0033070166181552053" LOG_EFFECT_SIZE="1.277252149217396" ORDER="17308" O_E="0.0" SE="1.5044135857638115" STUDY_ID="STD-Greenspan-1998" TOTAL_1="60" TOTAL_2="164" VAR="2.263260237030729" WEIGHT="0.1852426280185669"/>
<DICH_DATA CI_END="0.7695233501044795" CI_START="0.1436648611707586" EFFECT_SIZE="0.3324958123953099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.1137781975769193" LOG_CI_START="-0.8426494424835511" LOG_EFFECT_SIZE="-0.47821382003023516" ORDER="17309" O_E="0.0" SE="0.4281425772290064" STUDY_ID="STD-Liberman-1995" TOTAL_1="597" TOTAL_2="397" VAR="0.18330606643629568" WEIGHT="13.190384725412718"/>
<DICH_DATA CI_END="1.0351897922469133" CI_START="0.15717512317169804" EFFECT_SIZE="0.4033684210526316" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.01501998087418534" LOG_CI_START="-0.8036161906388671" LOG_EFFECT_SIZE="-0.39429810488234096" ORDER="17310" O_E="0.0" SE="0.4808709394611709" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.23123686041826907" WEIGHT="10.251467222287431"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Alendronate 10 mg vs Control - 1 year baseline denominators</NAME>
<DICH_OUTCOME CHI2="1.9905741877808178" CI_END="0.8254068992374044" CI_START="0.3879689139082311" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5658906415814777" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.08333190535415455" LOG_CI_START="-0.4112030709495316" LOG_EFFECT_SIZE="-0.2472674881518431" METHOD="MH" NO="1" P_CHI2="0.5743654026821596" P_Q="0.5825919550900236" P_Z="0.003113996117791446" Q="1.9512246839153051" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3311" TOTAL_2="3151" WEIGHT="400.0" Z="2.9562549085111147">
<NAME>Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6341909947917648" CI_START="0.4321189023310622" DF="0" EFFECT_SIZE="0.8403361344537815" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.21330281298997472" LOG_CI_START="-0.36439673577503623" LOG_EFFECT_SIZE="-0.07554696139253075" NO="1" P_CHI2="1.0" P_Z="0.6082192159272655" STUDIES="3" TAU2="0.0" TOTAL_1="176" TOTAL_2="130" WEIGHT="100.0" Z="0.5126170646570054">
<NAME>Vertebral</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17311" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17312" O_E="0.0" SE="0.0" STUDY_ID="STD-Chestnut-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6341909947917648" CI_START="0.43211890233106215" EFFECT_SIZE="0.8403361344537815" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.21330281298997472" LOG_CI_START="-0.3643967357750363" LOG_EFFECT_SIZE="-0.07554696139253075" ORDER="17313" O_E="0.0" SE="0.3393435746034539" STUDY_ID="STD-Durson-2001" TOTAL_1="51" TOTAL_2="50" VAR="0.11515406162464988" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8938265110251987" CI_START="0.3000090319417781" DF="0" EFFECT_SIZE="0.5178378378378379" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="37" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-0.04874676824669984" LOG_CI_START="-0.5228656704022389" LOG_EFFECT_SIZE="-0.28580621932446937" NO="2" P_CHI2="1.0" P_Z="0.018127996953969105" STUDIES="2" TAU2="0.0" TOTAL_1="1045" TOTAL_2="1007" WEIGHT="100.0" Z="2.3629933077409633">
<NAME>Nonvertebral fractures</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17314" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8938265110251987" CI_START="0.3000090319417781" EFFECT_SIZE="0.5178378378378379" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="37" LOG_CI_END="-0.04874676824669984" LOG_CI_START="-0.5228656704022389" LOG_EFFECT_SIZE="-0.28580621932446937" ORDER="17315" O_E="0.0" SE="0.27849979005258" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.07756213305933116" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.336400551970358E-32" CI_END="4.0142993074220605" CI_START="0.11258785340588222" DF="0" EFFECT_SIZE="0.6722807017543858" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="99.99999999999999" ID="CMP-005.01.03" LOG_CI_END="0.6036097504922032" LOG_CI_START="-0.9485084610241726" LOG_EFFECT_SIZE="-0.17244935526598468" NO="3" P_CHI2="0.0" P_Z="0.663180104245028" STUDIES="2" TAU2="0.0" TOTAL_1="1045" TOTAL_2="1007" WEIGHT="100.0" Z="0.43552678265178213">
<NAME>Hip fractures</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17316" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.0142993074220605" CI_START="0.11258785340588227" EFFECT_SIZE="0.6722807017543859" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6036097504922032" LOG_CI_START="-0.9485084610241724" LOG_EFFECT_SIZE="-0.1724493552659846" ORDER="17317" O_E="0.0" SE="0.9117219205537777" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.8312368604182689" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.035189792246913" CI_START="0.15717512317169804" DF="0" EFFECT_SIZE="0.4033684210526316" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="0.015019980874185246" LOG_CI_START="-0.8036161906388671" LOG_EFFECT_SIZE="-0.39429810488234096" NO="4" P_CHI2="1.0" P_Z="0.05902019828410227" STUDIES="2" TAU2="0.0" TOTAL_1="1045" TOTAL_2="1007" WEIGHT="100.0" Z="1.8880428489091348">
<NAME>Wrist fractures</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17318" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0351897922469133" CI_START="0.15717512317169804" EFFECT_SIZE="0.4033684210526316" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.01501998087418534" LOG_CI_START="-0.8036161906388671" LOG_EFFECT_SIZE="-0.39429810488234096" ORDER="17319" O_E="0.0" SE="0.4808709394611709" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.23123686041826907" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Alendronate 10 mg vs Control - 1 year baseline denominators</NAME>
<DICH_OUTCOME CHI2="1.9905741877808178" CI_END="0.8254068992374044" CI_START="0.3879689139082311" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5658906415814777" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.08333190535415455" LOG_CI_START="-0.4112030709495316" LOG_EFFECT_SIZE="-0.2472674881518431" METHOD="MH" NO="1" P_CHI2="0.5743654026821596" P_Q="0.5825919550900236" P_Z="0.003113996117791446" Q="1.9512246839153051" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3311" TOTAL_2="3151" WEIGHT="400.0" Z="2.9562549085111147">
<NAME>Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Vertebral primary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17320" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6341909947917648" CI_START="0.4321189023310622" DF="0" EFFECT_SIZE="0.8403361344537815" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.21330281298997472" LOG_CI_START="-0.36439673577503623" LOG_EFFECT_SIZE="-0.07554696139253075" NO="2" P_CHI2="1.0" P_Z="0.6082192159272655" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="81" WEIGHT="100.0" Z="0.5126170646570054">
<NAME>Vertebral secondary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17321" O_E="0.0" SE="0.0" STUDY_ID="STD-Chestnut-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6341909947917648" CI_START="0.43211890233106215" EFFECT_SIZE="0.8403361344537815" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.21330281298997472" LOG_CI_START="-0.3643967357750363" LOG_EFFECT_SIZE="-0.07554696139253075" ORDER="17322" O_E="0.0" SE="0.3393435746034539" STUDY_ID="STD-Durson-2001" TOTAL_1="51" TOTAL_2="50" VAR="0.11515406162464988" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Nonvertebral primary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17323" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8938265110251987" CI_START="0.3000090319417781" DF="0" EFFECT_SIZE="0.5178378378378379" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="37" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="-0.04874676824669984" LOG_CI_START="-0.5228656704022389" LOG_EFFECT_SIZE="-0.28580621932446937" NO="4" P_CHI2="1.0" P_Z="0.018127996953969105" STUDIES="1" TAU2="0.0" TOTAL_1="950" TOTAL_2="958" WEIGHT="100.0" Z="2.3629933077409633">
<NAME>Non vertebral secondary</NAME>
<DICH_DATA CI_END="0.8938265110251987" CI_START="0.3000090319417781" EFFECT_SIZE="0.5178378378378379" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="37" LOG_CI_END="-0.04874676824669984" LOG_CI_START="-0.5228656704022389" LOG_EFFECT_SIZE="-0.28580621932446937" ORDER="17324" O_E="0.0" SE="0.27849979005258" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.07756213305933116" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Hip primary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17325" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.336400551970358E-32" CI_END="4.0142993074220605" CI_START="0.11258785340588222" DF="0" EFFECT_SIZE="0.6722807017543858" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="99.99999999999999" ID="CMP-006.01.06" LOG_CI_END="0.6036097504922032" LOG_CI_START="-0.9485084610241726" LOG_EFFECT_SIZE="-0.17244935526598468" NO="6" P_CHI2="0.0" P_Z="0.663180104245028" STUDIES="1" TAU2="0.0" TOTAL_1="950" TOTAL_2="958" WEIGHT="100.0" Z="0.43552678265178213">
<NAME>Hip secondary</NAME>
<DICH_DATA CI_END="4.0142993074220605" CI_START="0.11258785340588227" EFFECT_SIZE="0.6722807017543859" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6036097504922032" LOG_CI_START="-0.9485084610241724" LOG_EFFECT_SIZE="-0.1724493552659846" ORDER="17326" O_E="0.0" SE="0.9117219205537777" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.8312368604182689" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Wrist primary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17327" O_E="0.0" SE="0.0" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.035189792246913" CI_START="0.15717512317169804" DF="0" EFFECT_SIZE="0.4033684210526316" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="0.0" ID="CMP-006.01.08" LOG_CI_END="0.015019980874185246" LOG_CI_START="-0.8036161906388671" LOG_EFFECT_SIZE="-0.39429810488234096" NO="8" P_CHI2="1.0" P_Z="0.05902019828410227" STUDIES="1" TAU2="0.0" TOTAL_1="950" TOTAL_2="958" WEIGHT="100.0" Z="1.8880428489091348">
<NAME>Wrist secondary</NAME>
<DICH_DATA CI_END="1.0351897922469133" CI_START="0.15717512317169804" EFFECT_SIZE="0.4033684210526316" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.01501998087418534" LOG_CI_START="-0.8036161906388671" LOG_EFFECT_SIZE="-0.39429810488234096" ORDER="17328" O_E="0.0" SE="0.4808709394611709" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.23123686041826907" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Alendronate 10 mg vs Control - 2 years baseline denominators</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.708645201468076" CI_START="0.09343301735774216" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5030674846625767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.4327521216312133" LOG_CI_START="-1.0294996256716957" LOG_EFFECT_SIZE="-0.2983737520202411" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.42378917513925707" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="193" TOTAL_2="195" WEIGHT="100.0" Z="0.7998647414447093">
<NAME>Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Vertebral secondary</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17329" O_E="0.0" SE="0.0" STUDY_ID="STD-Chestnut-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.708645201468076" CI_START="0.09343301735774216" DF="0" EFFECT_SIZE="0.5030674846625767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="0.4327521216312133" LOG_CI_START="-1.0294996256716957" LOG_EFFECT_SIZE="-0.2983737520202411" NO="2" P_CHI2="1.0" P_Z="0.42378917513925707" STUDIES="1" TAU2="0.0" TOTAL_1="163" TOTAL_2="164" WEIGHT="100.0" Z="0.7998647414447093">
<NAME>Hip secondary</NAME>
<DICH_DATA CI_END="2.708645201468076" CI_START="0.09343301735774216" EFFECT_SIZE="0.5030674846625767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4327521216312133" LOG_CI_START="-1.0294996256716957" LOG_EFFECT_SIZE="-0.2983737520202411" ORDER="17330" O_E="0.0" SE="0.858933914628615" STUDY_ID="STD-Greenspan-2002" TOTAL_1="163" TOTAL_2="164" VAR="0.7377674696992369" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Alendronate 10 mg vs Control - 3 years baseline denominators</NAME>
<DICH_OUTCOME CHI2="19.05694337244402" CI_END="0.7485860891508" CI_START="0.5654016315987556" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6505780477375438" ESTIMABLE="YES" EVENTS_1="298" EVENTS_2="437" I2="47.52568759552589" I2_Q="69.99548724475329" ID="CMP-008.01" LOG_CI_END="-0.12575824756781517" LOG_CI_START="-0.24764294258630498" LOG_EFFECT_SIZE="-0.1867005950770601" METHOD="MH" NO="1" P_CHI2="0.03954537583011197" P_Q="0.018578963098528245" P_Z="1.9195897128422564E-9" Q="9.998495974494396" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6258" TOTAL_2="5892" WEIGHT="400.0" Z="6.004469095774871">
<NAME>Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0933337435929493" CI_END="0.6718945230244835" CI_START="0.40567389422160954" DF="1" EFFECT_SIZE="0.5220824337798707" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="167" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="-0.17269889906495925" LOG_CI_START="-0.3918229389564807" LOG_EFFECT_SIZE="-0.2822609190107199" NO="1" P_CHI2="0.7599810346907248" P_Z="4.432258655489408E-7" STUDIES="2" TAU2="0.0" TOTAL_1="1221" TOTAL_2="1402" WEIGHT="100.0" Z="5.049388791645712">
<NAME>Vertebral secondary</NAME>
<DICH_DATA CI_END="0.686793298814153" CI_START="0.4074342027906647" EFFECT_SIZE="0.5289830622849045" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="145" LOG_CI_END="-0.16317395099253298" LOG_CI_START="-0.3899425161808285" LOG_EFFECT_SIZE="-0.2765582335866807" ORDER="17331" O_E="0.0" SE="0.13320497771410628" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.017743566087815552" WEIGHT="90.86973066618779"/>
<DICH_DATA CI_END="1.179417149933243" CI_START="0.17430187910688136" EFFECT_SIZE="0.45340338053905893" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="0.07166743857424544" LOG_CI_START="-0.7586979308398034" LOG_EFFECT_SIZE="-0.343515246132779" ORDER="17332" O_E="0.0" SE="0.4877607283686822" STUDY_ID="STD-Liberman-1995" TOTAL_1="199" TOTAL_2="397" VAR="0.23791052813874736" WEIGHT="9.130269333812203"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3361415658714433" CI_END="0.9924676282917019" CI_START="0.6715695012115442" DF="2" EFFECT_SIZE="0.8164012433236874" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="187" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="-0.003283649888336255" LOG_CI_START="-0.17290903522054685" LOG_EFFECT_SIZE="-0.08809634255444154" NO="2" P_CHI2="0.5126967676952107" P_Z="0.041765729930978095" STUDIES="3" TAU2="0.0" TOTAL_1="1679" TOTAL_2="1462" WEIGHT="100.00000000000001" Z="2.035846913340758">
<NAME>Nonvertebral secondary</NAME>
<DICH_DATA CI_END="1.0134222360737097" CI_START="0.6483897389234528" EFFECT_SIZE="0.8106124715713757" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="148" LOG_CI_END="0.005790429161446899" LOG_CI_START="-0.1881638666862377" LOG_EFFECT_SIZE="-0.09118671876239538" ORDER="17333" O_E="0.0" SE="0.1139297134701785" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.01297997961139697" WEIGHT="76.18736973809293"/>
<DICH_DATA CI_END="28.031112609677763" CI_START="0.3210718077916301" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.447640336099703" LOG_CI_START="-0.49339782666037835" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="17334" O_E="0.0" SE="1.140175425099138" STUDY_ID="STD-Greenspan-1998" TOTAL_1="60" TOTAL_2="60" VAR="1.3" WEIGHT="0.5104980908496667"/>
<DICH_DATA CI_END="1.1898477678759476" CI_START="0.5211932534343561" EFFECT_SIZE="0.7874900819888918" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.07549140021552862" LOG_CI_START="-0.2830012146309696" LOG_EFFECT_SIZE="-0.10375490720772051" ORDER="17335" O_E="0.0" SE="0.2105803365278964" STUDY_ID="STD-Liberman-1995" TOTAL_1="597" TOTAL_2="397" VAR="0.0443440781322021" WEIGHT="23.302132171057423"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.47026828519597497" CI_END="0.8696301510551343" CI_START="0.23009271139292675" DF="2" EFFECT_SIZE="0.4473204213595846" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="26" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="-0.06066541118272514" LOG_CI_START="-0.6380971381847556" LOG_EFFECT_SIZE="-0.3493812746837403" NO="3" P_CHI2="0.79046499947704" P_Z="0.017701930171699597" STUDIES="3" TAU2="0.0" TOTAL_1="1679" TOTAL_2="1462" WEIGHT="100.0" Z="2.371794562824287">
<NAME>Hip secondary</NAME>
<DICH_DATA CI_END="1.0086241471311288" CI_START="0.23968506817875357" EFFECT_SIZE="0.4916829745596869" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="0.0037293612455512382" LOG_CI_START="-0.620359020657886" LOG_EFFECT_SIZE="-0.3083148297061674" ORDER="17336" O_E="0.0" SE="0.36659260481739286" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.13439013790680115" WEIGHT="81.29728358056013"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="17337" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Greenspan-1998" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="5.496895363963109"/>
<DICH_DATA CI_END="2.1233949448091476" CI_START="0.0231397713219528" EFFECT_SIZE="0.2216638749302066" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3270307790925038" LOG_CI_START="-1.6356409372643368" LOG_EFFECT_SIZE="-0.6543050790859165" ORDER="17338" O_E="0.0" SE="1.1528830815696918" STUDY_ID="STD-Liberman-1995" TOTAL_1="597" TOTAL_2="397" VAR="1.3291393997696288" WEIGHT="13.205821055476765"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.9256075751137125" CI_END="0.8217215793620102" CI_START="0.36501702579884476" DF="2" EFFECT_SIZE="0.5476699434271068" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="57" I2="71.12166725722744" ID="CMP-008.01.04" LOG_CI_END="-0.0852753077996684" LOG_CI_START="-0.437686877905064" LOG_EFFECT_SIZE="-0.26148109285236615" NO="4" P_CHI2="0.03134179367354317" P_Z="0.003631737760524646" STUDIES="3" TAU2="0.0" TOTAL_1="1679" TOTAL_2="1566" WEIGHT="100.0" Z="2.9084943180244633">
<NAME>Wrist secondary</NAME>
<DICH_DATA CI_END="0.8792452479793448" CI_START="0.3166634582463592" EFFECT_SIZE="0.5276597775762494" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="41" LOG_CI_END="-0.055889970218213944" LOG_CI_START="-0.49940204966121693" LOG_EFFECT_SIZE="-0.27764600993971544" ORDER="17339" O_E="0.0" SE="0.2605211908850205" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.06787129090014929" WEIGHT="67.96278324870444"/>
<DICH_DATA CI_END="361.2528774781699" CI_START="0.9924142311153011" EFFECT_SIZE="18.934426229508198" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.5578113150529473" LOG_CI_START="-0.0033070166181552053" LOG_EFFECT_SIZE="1.277252149217396" ORDER="17340" O_E="0.0" SE="1.5044135857638115" STUDY_ID="STD-Greenspan-1998" TOTAL_1="60" TOTAL_2="164" VAR="2.263260237030729" WEIGHT="0.4436919531769111"/>
<DICH_DATA CI_END="0.7695233501044795" CI_START="0.1436648611707586" EFFECT_SIZE="0.3324958123953099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.1137781975769193" LOG_CI_START="-0.8426494424835511" LOG_EFFECT_SIZE="-0.47821382003023516" ORDER="17341" O_E="0.0" SE="0.4281425772290064" STUDY_ID="STD-Liberman-1995" TOTAL_1="597" TOTAL_2="397" VAR="0.18330606643629568" WEIGHT="31.593524798118658"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Alendronate 10 mg vs Control - 4 years baseline denominators</NAME>
<DICH_OUTCOME CHI2="9.843622757627491" CI_END="0.9909888371383748" CI_START="0.768739721152765" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8728186995746924" ESTIMABLE="YES" EVENTS_1="406" EVENTS_2="466" I2="69.52341557710142" I2_Q="69.50907502308876" ID="CMP-009.01" LOG_CI_END="-0.003931237539457883" LOG_CI_START="-0.11422067814527978" LOG_EFFECT_SIZE="-0.05907595784236883" METHOD="MH" NO="1" P_CHI2="0.01994328683859825" P_Q="0.01998555093386256" P_Z="0.03575622845779935" Q="9.83899308489887" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8856" TOTAL_2="8872" WEIGHT="400.0" Z="2.099688765982143">
<NAME>Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7976234183048383" CI_START="0.3823998030250023" DF="0" EFFECT_SIZE="0.5522780441479629" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="78" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="-0.09820210357896997" LOG_CI_START="-0.4174823401019433" LOG_EFFECT_SIZE="-0.2578422218404566" NO="1" P_CHI2="1.0" P_Z="0.001547477591065127" STUDIES="1" TAU2="0.0" TOTAL_1="2214" TOTAL_2="2218" WEIGHT="100.0" Z="3.1656295046919976">
<NAME>Vertebral primary</NAME>
<DICH_DATA CI_END="0.7976234183048383" CI_START="0.38239980302500237" EFFECT_SIZE="0.5522780441479629" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="78" LOG_CI_END="-0.09820210357896997" LOG_CI_START="-0.41748234010194324" LOG_EFFECT_SIZE="-0.2578422218404566" ORDER="17342" O_E="0.0" SE="0.18754679139625466" STUDY_ID="STD-Cummings-1998" TOTAL_1="2214" TOTAL_2="2218" VAR="0.03517379896303026" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4643626504272223E-30" CI_END="1.0394441044089022" CI_START="0.7609446431553619" DF="0" EFFECT_SIZE="0.8893589956307727" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="294" I2="100.0" ID="CMP-009.01.02" LOG_CI_END="0.01680114032505723" LOG_CI_START="-0.11864693593193525" LOG_EFFECT_SIZE="-0.05092289780343904" NO="2" P_CHI2="0.0" P_Z="0.1405539084516278" STUDIES="1" TAU2="0.0" TOTAL_1="2214" TOTAL_2="2218" WEIGHT="100.0" Z="1.4737314614020118">
<NAME>Nonvertebral primary</NAME>
<DICH_DATA CI_END="1.039444104408902" CI_START="0.7609446431553617" EFFECT_SIZE="0.8893589956307726" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="294" LOG_CI_END="0.016801140325057137" LOG_CI_START="-0.1186469359319354" LOG_EFFECT_SIZE="-0.050922897803439095" ORDER="17343" O_E="0.0" SE="0.0795628704721482" STUDY_ID="STD-Cummings-1998" TOTAL_1="2214" TOTAL_2="2218" VAR="0.0063302503577678335" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4436421213395543" CI_START="0.43570548176487733" DF="0" EFFECT_SIZE="0.7930969587473653" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" I2="0.0" ID="CMP-009.01.03" LOG_CI_END="0.1594595450406052" LOG_CI_START="-0.3608069760172848" LOG_EFFECT_SIZE="-0.10067371548833977" NO="3" P_CHI2="1.0" P_Z="0.448138426282064" STUDIES="1" TAU2="0.0" TOTAL_1="2214" TOTAL_2="2218" WEIGHT="100.0" Z="0.7585222133677242">
<NAME>Hip primary</NAME>
<DICH_DATA CI_END="1.4436421213395543" CI_START="0.43570548176487733" EFFECT_SIZE="0.7930969587473653" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.1594595450406052" LOG_CI_START="-0.3608069760172848" LOG_EFFECT_SIZE="-0.10067371548833977" ORDER="17344" O_E="0.0" SE="0.3056071298302187" STUDY_ID="STD-Cummings-1998" TOTAL_1="2214" TOTAL_2="2218" VAR="0.09339571780306416" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6237043399421989" CI_START="0.8690024558108225" DF="0" EFFECT_SIZE="1.1878564976125952" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="70" I2="0.0" ID="CMP-009.01.04" LOG_CI_END="0.2105069514929633" LOG_CI_START="-0.060978996228454624" LOG_EFFECT_SIZE="0.07476397763225433" NO="4" P_CHI2="1.0" P_Z="0.28036437454725394" STUDIES="1" TAU2="0.0" TOTAL_1="2214" TOTAL_2="2218" WEIGHT="100.0" Z="1.0795012024013968">
<NAME>Wrist primary</NAME>
<DICH_DATA CI_END="1.6237043399421989" CI_START="0.8690024558108225" EFFECT_SIZE="1.1878564976125952" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="70" LOG_CI_END="0.2105069514929633" LOG_CI_START="-0.060978996228454624" LOG_EFFECT_SIZE="0.07476397763225433" ORDER="17345" O_E="0.0" SE="0.1594721895686759" STUDY_ID="STD-Cummings-1998" TOTAL_1="2214" TOTAL_2="2218" VAR="0.0254313792458277" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2008-08-12 13:44:50 -0400" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Alendronate 5 mg vs Control - all years baseline denominators</NAME>
<DICH_OUTCOME CHI2="14.41543597285796" CI_END="0.6697547051134072" CI_START="0.4000329596312018" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5176137139928183" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="167" I2="72.25196652025383" I2_Q="85.3652427164515" ID="CMP-010.01" LOG_CI_END="-0.17408422673414417" LOG_CI_START="-0.39790422468141" LOG_EFFECT_SIZE="-0.28599422570777705" METHOD="MH" NO="1" P_CHI2="0.00608066700135268" P_Q="0.0010775730706337194" P_Z="5.476135164199925E-7" Q="13.666096138459903" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1905" TOTAL_2="2085" WEIGHT="300.0" Z="5.008831983867059">
<NAME>Fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7663054794038813" CI_END="0.5472433296505849" CI_START="0.29234195812863795" DF="2" EFFECT_SIZE="0.3999777325838123" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="137" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="-0.26181952334358194" LOG_CI_START="-0.5341088484262986" LOG_EFFECT_SIZE="-0.3979641858849403" NO="1" P_CHI2="0.6817089395134842" P_Z="1.0092515908850516E-8" STUDIES="3" TAU2="0.0" TOTAL_1="1314" TOTAL_2="1493" WEIGHT="99.99999999999997" Z="5.729166732734289">
<NAME>Vertebral secondary</NAME>
<DICH_DATA CI_END="0.5350969073841103" CI_START="0.2683140878127672" EFFECT_SIZE="0.3789116501193917" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="109" LOG_CI_END="-0.2715675590423716" LOG_CI_START="-0.5713565241274472" LOG_EFFECT_SIZE="-0.42146204158490946" ORDER="17346" O_E="0.0" SE="0.17609752207028387" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.031010337279294115" WEIGHT="84.11541357267633"/>
<DICH_DATA CI_END="2.2355698627467713" CI_START="0.19034703797767832" EFFECT_SIZE="0.6523297491039427" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.34938824634957605" LOG_CI_START="-0.7204538769266216" LOG_EFFECT_SIZE="-0.18553281528852272" ORDER="17347" O_E="0.0" SE="0.6284305590163584" STUDY_ID="STD-Bone-1997" TOTAL_1="93" TOTAL_2="91" VAR="0.3949249675056126" WEIGHT="4.641606455349324"/>
<DICH_DATA CI_END="1.179417149933243" CI_START="0.17430187910688136" EFFECT_SIZE="0.45340338053905893" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="0.07166743857424544" LOG_CI_START="-0.7586979308398034" LOG_EFFECT_SIZE="-0.343515246132779" ORDER="17348" O_E="0.0" SE="0.4877607283686822" STUDY_ID="STD-Liberman-1995" TOTAL_1="199" TOTAL_2="397" VAR="0.23791052813874736" WEIGHT="11.242979971974329"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.054114464386073" CI_START="0.8183154421284216" DF="0" EFFECT_SIZE="1.580895008605852" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" I2="0.0" ID="CMP-010.01.02" LOG_CI_END="0.4848853098388295" LOG_CI_START="-0.08707925333583678" LOG_EFFECT_SIZE="0.1989030282514964" NO="2" P_CHI2="1.0" P_Z="0.17282860364318972" STUDIES="1" TAU2="0.0" TOTAL_1="498" TOTAL_2="501" WEIGHT="100.0" Z="1.3631710664908299">
<NAME>Non vertebral primary</NAME>
<DICH_DATA CI_END="3.054114464386073" CI_START="0.8183154421284216" EFFECT_SIZE="1.580895008605852" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" LOG_CI_END="0.4848853098388295" LOG_CI_START="-0.08707925333583678" LOG_EFFECT_SIZE="0.1989030282514964" ORDER="17349" O_E="0.0" SE="0.3359748156790489" STUDY_ID="STD-Hosking-1998" TOTAL_1="498" TOTAL_2="501" VAR="0.1128790767705709" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1814023758396366" CI_START="0.25642720649079626" DF="0" EFFECT_SIZE="0.5504032258064516" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-010.01.03" LOG_CI_END="0.07239783990334857" LOG_CI_START="-0.5910358988022314" LOG_EFFECT_SIZE="-0.2593190294494414" NO="3" P_CHI2="1.0" P_Z="0.12547355632434554" STUDIES="1" TAU2="0.0" TOTAL_1="93" TOTAL_2="91" WEIGHT="100.0" Z="1.5321981038179966">
<NAME>Non vertebral secondary</NAME>
<DICH_DATA CI_END="1.1814023758396366" CI_START="0.25642720649079626" EFFECT_SIZE="0.5504032258064516" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.07239783990334857" LOG_CI_START="-0.5910358988022314" LOG_EFFECT_SIZE="-0.2593190294494414" ORDER="17350" O_E="0.0" SE="0.38970426216562876" STUDY_ID="STD-Bone-1997" TOTAL_1="93" TOTAL_2="91" VAR="0.15186941195005713" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2008-08-12 13:44:50 -0400" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Alendronate 10 mg vs Control - all years baseline denominators</NAME>
<DICH_OUTCOME CHI2="5.655310216479835" CI_END="1.0851658371846944" CI_START="0.8307175490647007" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9494557939129201" ESTIMABLE="YES" EVENTS_1="383" EVENTS_2="396" I2="29.27001619922077" I2_Q="100.0" ID="CMP-011.01" LOG_CI_END="0.03549611299619936" LOG_CI_START="-0.08054661488511924" LOG_EFFECT_SIZE="-0.02252525094445994" METHOD="MH" NO="1" P_CHI2="0.22641119496322548" P_Q="0.0" P_Z="0.44671449077939585" Q="1.0362616626413846E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4425" TOTAL_2="4371" WEIGHT="100.0" Z="0.7609038739423792">
<NAME>Withdrawals due to side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.154691402131153" CI_START="0.2303981658410388" EFFECT_SIZE="0.5157894736842106" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.0624659320557896" LOG_CI_START="-0.6375209825764576" LOG_EFFECT_SIZE="-0.28752752526033404" ORDER="17351" O_E="0.0" SE="0.41117577864609217" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.1690655209452202" WEIGHT="3.301366823685471"/>
<DICH_DATA CI_END="1.0633135631127006" CI_START="0.6003654863097267" EFFECT_SIZE="0.7989848336594912" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="96" LOG_CI_END="0.02666135356239605" LOG_CI_START="-0.22158428234494454" LOG_EFFECT_SIZE="-0.09746146439127423" ORDER="17352" O_E="0.0" SE="0.14582071536768804" STUDY_ID="STD-Black-1996" TOTAL_1="1022" TOTAL_2="1005" VAR="0.02126368103034429" WEIGHT="24.221500823089226"/>
<DICH_DATA CI_END="3.1431894650237133" CI_START="0.6355474976126378" EFFECT_SIZE="1.4133811230585425" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.49737056018853726" LOG_CI_START="-0.19685198691919645" LOG_EFFECT_SIZE="0.1502592866346704" ORDER="17353" O_E="0.0" SE="0.40778976062811345" STUDY_ID="STD-Bone-1997" TOTAL_1="93" TOTAL_2="91" VAR="0.16629248887313405" WEIGHT="2.2763566391599683"/>
<DICH_DATA CI_END="1.1625604805238239" CI_START="0.8182483304230466" EFFECT_SIZE="0.9753272128903374" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="227" LOG_CI_END="0.06541555569060477" LOG_CI_START="-0.08711487216575427" LOG_EFFECT_SIZE="-0.010849658237574767" ORDER="17354" O_E="0.0" SE="0.08959712836062027" STUDY_ID="STD-Cummings-1998" TOTAL_1="2214" TOTAL_2="2218" VAR="0.008027645410469464" WEIGHT="56.746148659045296"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17355" O_E="0.0" SE="0.0" STUDY_ID="STD-Durson-2001" TOTAL_1="51" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.624701299717871" CI_START="0.7986976931197973" EFFECT_SIZE="1.1391423001949317" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="54" LOG_CI_END="0.21077352789435966" LOG_CI_START="-0.09761756993936936" LOG_EFFECT_SIZE="0.05657797897749514" ORDER="17356" O_E="0.0" SE="0.18115045742808675" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.032815488226405065" WEIGHT="13.454627055020033"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.658482038390835" CI_END="1.293890081991258" CI_START="0.9362426840197267" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1006339642178955" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="229" I2="47.77032863759955" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.11189738389662383" LOG_CI_START="-0.028611562939768295" LOG_EFFECT_SIZE="0.04164291047842779" METHOD="MH" NO="2" P_CHI2="0.1049207015670397" P_Q="1.0" P_Z="0.24533432963782997" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1654" TOTAL_2="1619" WEIGHT="100.0" Z="1.1617566936030113">
<NAME>Withdrawals overall</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9634163398272356" CI_START="0.23529176588343223" EFFECT_SIZE="0.4761133603238866" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="-0.016185992195732895" LOG_CI_START="-0.6283932708433592" LOG_EFFECT_SIZE="-0.32228963151954604" ORDER="17357" O_E="0.0" SE="0.3596135859525199" STUDY_ID="STD-Ascott-Evans-2003" TOTAL_1="95" TOTAL_2="49" VAR="0.12932193120163044" WEIGHT="7.376290236656121"/>
<DICH_DATA CI_END="1.5985723004546526" CI_START="0.45161832907754385" EFFECT_SIZE="0.8496732026143791" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.20373228338431562" LOG_CI_START="-0.3452284404058397" LOG_EFFECT_SIZE="-0.07074807851076204" ORDER="17358" O_E="0.0" SE="0.32246224655374567" STUDY_ID="STD-Durson-2001" TOTAL_1="51" TOTAL_2="50" VAR="0.10398190045248867" WEIGHT="6.514387561390454"/>
<DICH_DATA CI_END="1.760129822088698" CI_START="0.4949129889052089" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.24554470130133685" LOG_CI_START="-0.3054711480562233" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="17359" O_E="0.0" SE="0.3236694374850749" STUDY_ID="STD-Greenspan-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.10476190476190478" WEIGHT="6.45052101667094"/>
<DICH_DATA CI_END="1.4227140098604658" CI_START="0.8591432592936519" EFFECT_SIZE="1.1055836248218682" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="93" LOG_CI_END="0.1531176081501924" LOG_CI_START="-0.06593441296362389" LOG_EFFECT_SIZE="0.043591597593284286" ORDER="17360" O_E="0.0" SE="0.12867224152724802" STUDY_ID="STD-Hosking-1998" TOTAL_1="498" TOTAL_2="502" VAR="0.016556545739646447" WEIGHT="39.83325738214639"/>
<DICH_DATA CI_END="1.6536750666318012" CI_START="0.9899921404142742" EFFECT_SIZE="1.2795019807583474" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="93" LOG_CI_END="0.21845017835315333" LOG_CI_START="-0.0043682532693795646" LOG_EFFECT_SIZE="0.1070409625418869" ORDER="17361" O_E="0.0" SE="0.13088464970410082" STUDY_ID="STD-Pols-1999" TOTAL_1="950" TOTAL_2="958" VAR="0.017130791528165178" WEIGHT="39.8255438031361"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Models for fracture risk in postmenopausal women: FRACTURE Index</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAnEAAAJYCAIAAACCTCeRAAAhFUlEQVR42u3d25ajOrIFUH/6/nN6
nNPd1S4jhUIXbC5zPtTIyjQYBI6FAKPXBgCs8NIEACBTAUCmAoBMBQBk6pO269+OfiMNDlesDM3P
7/wH/P1dnlArVMPbfmyOi71DZw6cpz4kP+C117xP/pBaoRre/ANzxN4sRMExd2+m6qdyw0z9OA+z
P4osft72kyTnsH+xDQTnzNTM53f/WY7PIdf+FLxXXD2+c0lLptLRTy3+nPll5gNZewuxCmfO1GaJ
aMZq/HZx0ci/4/nPJCtwMrWRqR9zG8vUk38M4GklonjOKf/57fpcN+MwOWeZysUyNT79IlPhsSVi
8nMdn6/qytSTn/5V4HxgGmdl42NMmQoyNageca0Y7qeet3ntYbf/zGTOnxRvz2vGsEwFmRp8/TR5
o8ZYpuqn8u2PTeamu8xdf7WDyt45nPyGPXhUZWj+6VWxpe8Yqn3wm18x2HLfRJCp/ODDoykAZCpr
YlU7AMhU9FYBZCoAyFQAQKYCgEwFAJkKAMhUAJCpACBTAUCmAgAyFQBkKgDIVACQqQCATAUAmQoA
MhUAkKkAIFMBQKYCgEwFAGQqAMhUAJCp/3kPADgH/VQA0E8FAJkKAMhUAJCpACBTAUCmAgAyFQBk
KgDIVABApgKATAUAmQoAMhUAkKkAIFMBQKYCgEwFAGQqAMhUAJCpv1zi12tsqn9r/nds/vNLSG1j
8dsNsd8uNo2PGDfJ1Jn94GPC4n/z87c7HtQUH0Vc855ns9oc99uytql+6nZopubnb1+UqTfedgJV
piJTxzN1/3PtrFfxv/EuW3zlx9nm5nnp4s9Bx3psJvt57ucTvyBYho9fZmbiA3/o5yjegeOPADKV
p2fqvjNa7JsWIyTfnd1PXntxc7bBL7tCPTmT/Tzja2nHrZ1P+6/SNNiHbReZikwdzNTgvTKniJOn
kSdTJ7MAXW9X/O9HlPYuSXJFgsDm+x+fZs21dWQqMrUapZlzwl1Fv9brbS7PCTN1YCaZrm1XN5fv
91NlqkxFph6VqfOR1rxwdb9MbZ5DVrVPm6y2jkxFpg5OnomNIEjiipPMv3ymJr9HOzyTmcOLZHff
J/z8n6bk5Q9kKpfP1GQvZzhTa7fjFq8sNm92zdwqGd8SvI/e5JwHZhLfptv8OViGoBlXbVa+8EFz
3++Nty/P7ac+oaPwkJX1kQZkKgJVpgLI1DOlyzPPvXhmLCBTAQCZCgAyFQBkKgDIVOAJn/zR8cZ9
b/U2O4BGkKnAIfV0bNhgj+m4xxEVMhX4caDKVP1UZCqopCPnb2sTqtEyFZkKz62kY+ONN4ejV6Nl
KjIVnltJu8Zxy49CiEyVqYBM/czL5njym4dNylRkKqikS/qpCrRMRaaCStodjcGEqrNMRabCc4vp
2HMbahNq0hvsA8hUAJCpACBTAQCZCgAyFQBkKgDIVOCOH/i/7X/fO+Gfv2rbK+4GmkKmAuOVtPjf
3ocr7f+rOl90N7DhZCpwYGHNPPlh/1+l+R6HWchUQKYiU2UqcPFMDYZiRabKVOCJlTSfqcNJjECV
qcBzM7V4a2ht5FS3KclUZCoopuP9VNVZoCJTQTGNvl2aHEJVgb7HPmDDyVRgfQclc/5Wpt5mB3DG
XqYCgEwFAJkKAMhUAJCpACBTAUCmAgAyFch/4FtjkgdPShobzJwz7waaQqYC45W09t+upz3kBzPn
5LuBrSZTgV8WVkPT3PgwC5kKLMjU/JlAmSpQkalAu55miqxMvc0OYJPJVODYDsrYhVWZqquKTAWV
tPqn5pjkHy9TnWUqMhVU0vF+qtIsU5GpoIwKVGw7mQocUEaTJ29rE2rSy+0ATtfLVACQqQAgUwEA
mQoAMhUAZCoAyFTgMZ/5ygOSml+uCF7jWxkX3RM0gkwF1pTRrmFQg9f4puN1D620g0wFTpSp//5Z
db7ibmCryVRgfT1NDi9TLMSqs0xFpoKS2u6D5idUna+49W01mQqcpZ9q8NSrH07ZajIVWF9Sa798
v42leA31g+a9xA5gq8lU4NuZ2tW/UZqvvjMgUwGZikyVqcBPK6lnPmCryVQAkKkAIFMBAJkKADIV
AGQqAMhUAECmAoBMBb73aU9/xz9+LoRnBdxgT7ApZSqwppjmo9cwJg8/ukKmAlPJ2nwmMAIVmQpk
k7U4xqpThXfa7jalTAV+01vVy9FhRaYCI2la7KeqxWIVmQr0pemWuC9JIZapyFRQQF+9L5Opdglk
KrCmzu5rriosUJGpwF/f9I+/9b//k5tF77cbaAqZCgAyFQBkKgAgUwFApgKATAUAmQoAyFQAkKkA
IFMBAJkKADIVAGQqAMhUAECmAoBMBQCZCgAyFQCQqQAgUwFApgIAMhUAZCoAyNTZxf2v+QmHZ/W1
Nf3yhCdcl/PsP8ctSbxPLl/gjxme/FPAEz6VMvUUO8FYrF5lrxoucyesj+dZpI8gOVtF2+/ekzt8
8q3V1mcGqu0uU2fj8EKZqp96wmOyoxvkJ5mqsOqnIlMPydTgnFjydFl+ktrP+2XbnwksTl6sks0T
icW3qK1RZgGClim+UWb+8YuD1qu9OHPStWsx9jMfWLxm1K2tgB9rOtzOyFQenam1qlrLpOQv47I4
MJ99bsXxWZxzXLKDFgi6TcVJBtala/5xHy65FfI/x1m4avvmF+mI8rfvBw+0MzKVm2Tq8LXGzHya
tTIou2sztdmrCF4T9D/eu5XJJj16XTI5Gix8cqOvnfnMfpKfz3G1L+5A97YzMhWZ2u6gDFzWiif5
TqY2876rfznQdzwiU+Pub3PJu2Ye9yx7T3LMZPP3M7WrnZGpXD5TF968MxAVl8jU5ot7c+Wcmdq7
XvOZ2uzpDuyl589UJVimcttMnbm6szxT405SPvnGTiPPxFLmWKH3UCDuNS7M1IXXU2vtMLwiMwcE
X74dt/feYyVYpnK3TG3eXpSZtvab4I7Q5qwy4V27WbSZzXH65m9XDv7avJO5eJmtq2e2duGbW6G5
wMmW6ZrzzG3JcSsd91Ea2+u4QaDarDLVAaC1vsCKq1MgUxEt1lqmAjL1TLX1gadTnETaWt9qBWQq
ACBTAUCmAoBMBU7/aU9/gac5n+Ic5i8qJyd33XrJnqAZZSowW0znI6r55KnJWG0urTBYtQ9oSZkK
rO+qLk/lJQ/lzjzQCpkqU4Ff1tPMOIDzPd3MI5G7hu/dz3k/hM7w47qeczpUpspUYHE9HR72dSBT
u8bK7eqn1p6huHyoBpmKTAVS9XRsuKSZTJ3J72RvW6bKVJkKfK+ebuHgMyfP1Hiwga4hp542+rpM
lanAIZm6/X0BcmGmzg8hvPWc+5WpMlWmAr/P1HzO5W9cmulBBt3ogRnGw8jvf5apyFQgW0yb36XJ
3G1bm+3YsKzNqYJZZQb3Ta61PQGZCpygiPzz+trPIFOBR8Tq0f+CTAX0VvVQkakAgEwFAJkKADIV
AGQqACBTAUCmAoBMBQBkKgDIVACQqQAgUwEAmQoAMhUAZCoAyFQAQKYCgEwFAJkKAMhUAJCp2+u/
5iccntUlWun7c1g1yZKNe6ddF5Cph0fFkgp+pwL3Z13mC/fAHL4zSXPFf3UI8s2tA8jUU3TFHpKp
V++nXqJT/tutA8jUHwdqM1OLp+Zq5+vef//xmuJ/iz/Xei37PzUXbP/f5FT5ZYibaKufyA16ZrV3
iV9QnP/7MtQ2TbPp8hsrWK/gKsPH0vZuFECmHhKow5laK23Fmh6fVIwniX+Zr8jFhcy8S3OqZtrt
q3zcRM1DluS7xAcKwYbo2qbNXwYbK1ivzMuCn11zBZl6ma5q8txv8vrcZMkOZt6svwPBsD+kGFuG
5Jsmt9fYivQm99jhUTBVrcfZO9vejQLI1MtkanBeLp7hfAR+LVPzbdhM5a6eaNApPzRT4wWeydTk
6ZCufB3esQGZeq5MHStzj8rUrjfNJ+5xmZpv9oWZOnPuV6aCTL1zpibzL1+RJ8+7Zpa2K/8WZmrt
bqD5TM1fT13bdMHGWnI9tdaqMhVk6vdyND6rlpm29pvila3mDSPxLcH7bOi6Ryl/d/FWudm1eY/r
2DIU76JqnvsN7r+N7x3L3Pe7JW64bTZdfmNlWi/eCslVAGTqk5pP+dO8ADJVxdfCADL1FLXeOTqN
DCBTAUCmAoBMBQCZyq7JEk9C31wO5Nx7r73UnqARZOpJ98XkExLghDuw/fOxh1baQaae9OBOpnLR
fdjOaTdApk4dmmXGGOkaHXPzBFcuW08zDwJzflimIlNTx+YDz4Vv5qgTa1zl49B1FcOeLFORqR0H
6cGDf8fmY6/lciXVeK4yFZnasQ9lhv/M72oylftlau2Do8VkKjJ1a0bd8EA3MpWHZKqdWaYiU1OZ
2jVCdT6k7VXcIFNdT5WpyNTGPlQb2DJ/o2PtT837geGEn4Xmn9z0+7QdAJmaW89/Xvuf/2+fKv3+
42cAkKmFWA3+/ROx+38BQKY2eqv/OQPyz9vJLr1VAGQqAMhUAJCpAIBMBQCZCvR/2tNfrW7OpziH
+W89Jif3xcole4JmlKnAbDGdj6jmgIaTsdpcWmGwah/QkjIVWN9VXZ7KY8U6mc2SQKbKVOAs9TSI
ruZZwa4BbYLZvj8fNIj/eM77YemKjwitPW2x9rNMRaYCHfW0OapEVx+xmXzFKG0+oL/5+9pzicdW
8yEBI1NlKnBgPc1n6ljQrs3vZG9bpspUmQp8r55u4YBuJ8/UeBioZHzu/5WpyFRgMFO3vy9ALszU
Zl9wvp868y4yVabKVGB9puZzLn/j0kwPMuhGD8wwyNSPa7HP3AdkqkwFxotp87s0mbtta7MdG+q8
OVUwq+JbJ4dVf3K0eOaDTAXOWkQqwyMe8TPIVOARsXr0vyBTAb1VPVRkKgAgUwFApgKATAUAmQoA
yFQAkKkAIFMBAJkKADIVAGQqAMhUAECmAoBMBQCZCgAyFQCQqQAgUwFApgIAMhUAZOp/F/r1Gpjk
w51WObk6+5cVW+PnrXTQ+07O9qJ7TrwW91gpzvMp43XRojC/D91ml0o2SDE7mz9faPseOtvztM/y
Yqq2PjNQbXeZ+r/P/5JMvVmsTr7sveNy1yNomXq/dUE/VaaeKFP39aV2+Pb+p/jsWe3n5qyas93P
4X3azLFnMlPj+dTeK98O8RzyG6X416Ap4tlmfnObYhQcQuXbAZnKtTN1si8VZ2rz4L34gvwvMx2F
OEHj12cap+tPzWOLsXZozqE5/6DpmgEcTBgsz/0qUe3YNNMyyFTukKnzJ6yulanFnujwO8Z/6vr9
fDuMzWFgSZp98WLPOLnutyypmZZBpnKTTJ28cXcyU4tH98MJ93HOtjnVMzN1C09oz2RqbQdr/ub2
mZppGWQql8/U+b0hc6br/Jm61S8ijmXqzOu/kKkzS9KVqb07yXMyVQmWqcjU9lTJL5bEx+xxWW/e
9JTpD2Uuaw1nanyvSrMFkpmavCS8f/HAWvdmau/11OdkquupMpUnZmr+ayTNU8eZs8pdj03IJ9zA
7cGZm4fj5Sw2yKr7fmvt0LzVeeu8CTm58Jm7tZs3u97sO80DDcXtdwCemKlPPrj7eZX3OQSQqTeJ
E5kKIFMvn6bnOVXyw+fxOmUEIFMBQKYCgEwFAJkK3PHT3hrUgUftCTa6TAVmi2nylzxhH7DpZSqw
vquqZWQqMhUYqafxszCdFZSpyFSgo57ODHCETEWmAu0BDFRbmYpMBbrr6RYOPqPaylRkKtCRqVtl
8D7VVqYiU4HuTNVPlanIVGCkmDa/S+O+3yfvCchUAJCpACBTAQCZCgAyFQBkKgDIVABApgKATAUA
mQoAMhUAkKkAIFMBQKYCADIVAGQqAMhUAJCpAIBMBQCZCgAyFQBkKgAgUwFApvYt7puZmdjwJ2yH
seWZ3x+ettHfm0vr+fjz9Ey1My1Z97NV0rHleZ9EjRjb/7XbYw+ttMPTM3VhoD52fzpzCMlU+wD6
qTL128dWk7tCMVP//PKj3BTf7v338Zm02s/xegU/v/9mv8z7+eRfUFydfMsn3zqeZ9yMwczViJnT
Fc1t7fywTOWemTq/N2QqeOZYvjaf5C8HZtW8DFYsgvsZDixkfhWCRe1ajPx6KRBrz9YUdzwtLFO5
eaZuE/ez5FMzWcEXZmp+/sX/fizwwoXsXYVmOwe/7Fov1WHtJyjT2shUZGojKQfKdJBbv8rU4eDf
WpeZm7dbx53mfKZmzujK1EMztblxkanI1EYtlqlBpg70Ymf6qVvPuWjV4QuZqpFlKjfP1PkTv12Z
OtM5a34RMD9VPlOb536Ds6wDmdp1QXT+l2rBdzLV9VSZys0zNXluMDntayfzds2Qrt3guiXOrAZT
Zb6qX7uDd//z1rrLqbaEmYbKLEZ+qi1xZ7LqsOSj1NwuPGEH4In9VAd6VgdApkogqwMgU3mLnzud
NnEWCECmAoBMBQCZCgDIVACQqcCST/vQ97C5655go8tUYLaYJn/JE/YBm16mAuu7qlpGpiJTgZF6
Gj8s2llBmYpMBTrq6eRIushUZCqop+Oj7CFTkanAVquhwYBuqq1MRaYCHZm6/X3XkmorU5GpwHim
6qfKVGQqMFJMm9+lcd/vk/cEZCoAyFQAkKkAgEwFAJkKADIVAGQqACBTAUCmAoBMBQCZCgDIVACQ
qQAgUwEAmQoAMhUAZCoAyFQAQKYCgEwFAJkKADIVAJCpACBTRxb6/w1M8u4+m/BtXb6/XndqSS0G
PC5Th0vSx4T3KG3vxwffP1a42dHJz/cKcQsy9TJFZz/tbWJVP1WmAjJ1pOIM942KU30EUm3m73/6
eFnxv0E3LnjB/l1qk9RytPiy2nrV2rP4FsXf1I5UJtsq2NC11f9YnngrBA3SXPHmfJozibe4WAWZ
+r1MLRamJZna7O3Vomv5rIL5dL1dvBi1Qp950+bZ5pm2io9s4hfHmR289VgDdm3EYthnFgmQqQf2
U2+fqb01fSxTmx3cff+p2Dc9oq0yG7f24kwPfmAfS06Vub7Q9WJApt4zU+PO4nymbqVTwXHmNd+u
dnp2ONq/01bBxo1XP3+E0dUmwXYMzoonN+tvL4cDMnVZpvZ2So7O1OZ8et/uZpmaefHYydvJyVd1
T2UqyNSrZmqyFhe7JskqH98ctO1uUWnOZyDCe/tkA9dT41t4Btrq0EzNXE/NnOIeu5665a65Kkwg
U78Uq2OnyzLPfMjceJm5WXQLb4utvSA5n1dFMIdmS8Z3+myd9/1OtlXyVtvi1qytVP722rH7foOZ
J5eweQAEyNQ7ttfrZYHv2lYAMlVICFQAmXqpcLrWebkfLrBnFwAyFQCQqQAgUwFAppJo3PSj28+w
hL9djPNcgs1/O+v869JcPBe/VSdk6mV22eGH2X7ng3GSYnqqpwhNtsklHjR4y4GEueJnX6Zyugo7
OdtTZeoNjt8vl6kKq+qETB0/Lls7qGd+pMzm85tqbzGzIltrhNQtfMBeMDJo/Jj45EioxZZJNvKW
GKe2NnnzBcVlbj4bMv8Eq1PV0/lBZJGpPLSfunZQz+HhTmsnYeLhVppvmhlbtJj0ycUYGBggs0Zb
+HTG5ICpQTz0LnPtmKCWuCe8Rp7/LGRazPP9ZSoydX2mbomrUAPjjM7kVlf0bj3jrR40KGzv8Grb
xBjsyQqyZNSgiw6D2hy9zgP9ZSoytfvwfGYAsubT/Jdn6pYYjLM5tOqjMjV51j3ZeW324G+Qqc1d
DpmKTD0kU7tq66pMzfSWjsjULTFIy9kydaDfv/UPW3v7TFWCZSoyNdqTlgzquep66lhfML5BJpmp
XZdOm5/AYDizS2Tq8FDwF61NvccTSrBMRaam9qSxQT2DqbrG7MyPhLq1RtzMD62aGZa1tgqZwUcH
7vvNNOlAC/cOmptc/Xg43vNXq7EG4WZdC5tVpk6s5z9vNeKf1/73X/756scikw8bApCpl4/VP4H6
239lKoBMvfJ6vl56qGvaMH3KyPklQKYCADIVAGQqAMhUAECmwqM+7bkvPWfmU5zD/F1pycnd+LZk
T9CMMhWYLabzEdV8HOOhY9AKg4X7gJaUqcD6ruryVB4r1slslgQyVaYCZ6mn8XOVm6O4D/wyOfb7
Pv6bD74OBrQvzmfgAaIyFZkKbHEaJX85n6nz49U35zw8IMQDA0amylTgwHo6NkruTKbO5Heyty1T
ZapMBb5XT7dwQLeTZ2o8HFAyPvf/ylRkKjCYqVt9jNvJTM2PUrytOPcrU2WqTAV+n6n5nMvfuDTT
gwy60QMzDDJ1P5ywTEWmAh3FtPldmszdtrXZzo/9HvShi7MqvnVyWPUnR4tnPshU4KxFxFCJIFOB
tbF69L8gUwG9VT1UZCoAIFMBQKYCgEwFAJkKAMhUAJCpACBTAQCZCgAyFQBkKgDIVABApgKATAUA
mQoAMhUAkKkAIFMBQKYCADIVAGTq9nqz//0R7/XoneOmLZBZrzOs+78X4LWTWcg/fwom//MWwHP7
qfsq8Kd2fOG9bhyfJ2yB4949M+f5d//Iv1XTNme7j95VSwXcPFMPLQoy9a4t8J1MHZ5bvJP/+W+x
n5rpjIpVkKnlglI7G1b8fa2UxIkSnGqOz8UVz7bV5lP76/v61hbsoyk+pgp+v9VPpwersF+woMrX
Zl5ctWAJMy3c3C7FxmxulGYbZhYm2EbJMzHFn4vxKVNBpi7rpxYrdRyTtTgpFqli0Uy+e1dvI7PA
xagIlqG4UnHANBsz2VbNFm5O3ly7ge2VX9/8ysarn98x9mndTFCZCjJ1ZaAGAZMpc5mOVGZWycBO
viB+61rHpfn6ruLebMxkW+VbOF6vZNdtOMwy2bwNXfVsHmfkT/x27fAyFWTqeKbWKldXxc8nSlcn
tasb0VWXk5F/RKbO9NTzHeL89k0ubfzifBvmXxb3lZs7QzNKM3uXTAWZ2pGpXYU1uJQY91rinlPy
gll84jffKazNuTd0kwcNyUxtXk4ePhQILtM22zmzuYN3mTnfu7W+pfOdTE0uDHDnTE3e8dt19i8f
qFvujGtv2c2cvh4I1K3nTObWc6p5oB88MP+uvnUm8scub+fP6jdPTTc3etc2TR4uNL/GLVDhoZka
37ibOdlV68Nlujv7Xkum35O5mTZ+TTxJ8ixfXIibzw1o3sc7dudz8zaiTH40z0kUG61ro2TacOu5
FzqOsWLrFWdeO94q3hif6dYDz+qnZsqBGsHldtpf7cA+LCBTG+cqlQmutd/+Kud8UkCm/qcWJL+E
AOffb3+Sdj4pIFMBQKYCgEwFAGTqlbeKa8MAMpUgJrteI1O/3BQaH5CpMlXTXeldAJl66mq7Hy8s
fs5OZszL5nArmUcyJQco/ZhJc4i3zECeQSslh/9sLsmWfkrRwICjW/0RQs0doHaA0lzZ5Mi7+WYH
ZOoluy/JZ/X1js/1kShbOLT18AClQSd17L2SrdQck653nLt4cPUtN/rpln6SXy2Ae5d/YFfJNDsg
Uy8ZqFv/sF+9mZrJj7EBSoOlHX6vTCt1xUw+XJP5NxZvvTtA8pH3A7tT5on8gEy9ZKDOdLZ6a3pm
dK2uwdTyRwC9A3nOd9OD5/Xnx6DtWp18puZXLflGvZmaWWtApl6yk5oJxfyApl19oMkBSrsydXhE
uXzfdGudK37/U37UsPzopwOZGl/zTm53mQrI1NSJ2Uw3K3OpL/PXrgFKi8G/TZ/VTLbSlh4jNpPl
XYHa2ylPDkCbX9/gyujYuK0A187U2h2nC2/63XLXI7sGKM1fcRx7r0wrZWbe7GQHC5PvUwbv2DXW
abC++e1ebMnkYLHCFbhypv7zuujPiu9xJy0AZOpUrF7xXwQqIFP1Vhf8zNpA9dQFQKYCgEwFAGQq
AMhUAJCpACBTAQCZCgAyFQBkKgDIVABApgKATAUAmQoAyFQAkKkAIFMBQKYCADIVAGQqAMhUAJCp
AMCDMvX1t1XTBjN8/9Nr5zurvLDF5he72UrFdvvhArNqd7IhbrYn+HA9PVP3QTgzh2Ks1va8hcsw
sN/PvNd+8ng+zb/WXrD//XcWmJmd6uipOH8ttVkf3U9dVa9r6dj85arkmMmYQ1us+bKjM9VH/bTJ
aovIVGTq4Zka//KjoxmfIP145X4+tWmHO6AfM4n/O5yp+4XMFPTMJs40S9BWzZWVrDJVpiJT2yU4
iIpi5e3N1DjwPmYbvHX+rwMtNvB2caYWr4PGmb2kx5xvouAA5ZklRqbKVJtVpo7vBEGXKyjQM/3U
IM5XhdxBmdr7Cezqp67N1PyGqK3mA2+Jcu5XptqsMvXamdqsa/lMHaiJA5lajJkfZmrtTO+STNU3
jZta8ZWpyNSRTN3q52a3njtx8vVo4NzvQFN84dzvl/upM53sx6aF79IgU2XqUUUhqPXJGMgkZT6z
i9cd9zcrbcdfTx243JjP1J9fT83vCchUmcrjMjX/LZHaZbPgDOfYMx8yd58Gr9lKd9MM35G71W9q
jc+m1m44ys9n31bJ+34zlzbzj+/It/zt68urIj+hinmzPUFTPD1T0dcBkKkgUwGZCosC1ekmQKYC
ADIVAGQqAMhUAJCpwAOrwGE3jrkx7bRb3HaRqcBR5fWIuPW8nvMfQtkuMhX4Xj91Vc1Vuy+36ZGp
wMrCmhz1Xe2WqchUoK+fOnPOUO2WqTIVkKkLMlXhFqgyFbhnGe0d1CifqcHIRVpepspUQD91tp+q
cAtUmQoor//70/u/XRU5OQQ9v9ritotMBRaX1+BW3pn7fntHPufLW9x2kakAIFMBQKYCADIVAGQq
AMhUAJCpwPNKwJHfqWjO3Jc67rfRZSrw3Npa/Dn+5aqZb545cMqNjkwFVpba5TX30JmzdrsgU4H1
5fXo8VOdgRSoMhV4aD/1uPFTFfefbG7NLlOBr3ZZvjZ+qvquqypTgUv2TvJDnH5t/FTFXabKVODm
hfVr46cq7jJVpgL3qarB9dSjx09V2WWqTAXuUFLjpy4sHz91yV3ErNroWkOmAoBMBQCZCgDIVACQ
qQAgUwFApgIAMhU4qEwYWvymm1UjyFTgZ5XX0OI3O07SDjIV+FlPxdDid9ruNpxMBX7ZTTG0uExF
pgKzaZrpkqrRFwpU20umAsvq6UHTKtMX2gFsLJkKHN5PNbT47be++7RlKvDVZB0LSzX6on1WZCrw
papqaHGZikwFlvVoDS0uU5GpACBTAUCmAoBMBQBkKgDIVACQqQCATAUAmQoAMhUAZCoAIFMBQKYC
gEwFAJkKAMhUAJCpACBTAQCZCgAyFQBkKgDI1In3AIA5MhUA9FMBAJkKADIVAGQqAMhUTQAAMhUA
ZCoAyFQAQKYCwIH+BbvmsRUi71isAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Five year risk of fracture by Quintiles of the FRACTURE Index: Assessment with bone mineral density</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvoAAAE9CAIAAAD1eFETAAASZ0lEQVR42u3dS5biOBAF0Nz/ynrY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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Five year risk of fracture by Quintiles of the FRACTURE Index: Assessment without bone mineral density</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArsAAAEYCAIAAADTYakIAAAQb0lEQVR42u3d7Y6jMBJG4dz/TbPS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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Estimated five year age-specific risks of first and subsequent osteoporotic fractures (from Doherty et al 2001)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwAAAAGgCAIAAACSYJceAAAl/ElEQVR42u3d0Za0qLJG0Xr/l/Zc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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-05" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Summary of literature search for alendronate</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlQAAALSCAIAAACUE9i7AAAmFElEQVR42u3dy3HbSLuAYS29VAgO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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-06" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Weighted relative risk (RR) of fracture after alendronate (10 mg)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABLAAAAJYCAIAAAD9hIhNAAA8/0lEQVR42u3dUZKzOpYu0BxaD63G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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-07" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Five year FRACTURE Index specific risk of fracture after alendronate (10 mg)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtcAAAL2CAIAAAAFHC2ZAABQAklEQVR42u3dMbLkOJIE0Lpg36MO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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-08" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Five year age-specific fisk of first and subsequent fracture after alendronate (10 mg)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4QAAAJsCAIAAAAqTPo3AABa1UlEQVR42u3dO7b0ttW1bXfQ/VAj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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-09" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Weighted relative risk (RR) of fracture after alendronate (10 mg): Person years</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuMAAAHCCAIAAADKB1D9AABJDklEQVR42u2dO3blKtOGzwQ9jz0I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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-10" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Weighted relative risk of fracture after alendronate (10 mg) by years of treatment</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABLAAAAJYCAIAAAD9hIhNAAA8G0lEQVR42u3dXY7rupkF0BpaDy3D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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-11" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Weighted relative risk of fractrue after alendronate by dose</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABLAAAAJYCAIAAAD9hIhNAABH8ElEQVR42u3dXZKkSgxY4Vmal3bX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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-12" NO="12" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Weighted relative risk of fracture after alendronate by dose: Person years</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqQAAALdCAIAAAB1Ceb3AABX10lEQVR42u3dPdacPNe166eD7ocb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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-13" NO="13" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Weighted relative risk of fracture after alendronate by years of treatment and dose</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABLAAAAJYCAIAAAD9hIhNAAA+PklEQVR42u3dQXakupYF0BzaH9ob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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-14" NO="14" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Weighted relative risk of fracture after alendronate by dose: Follow-up denominators</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAo8AAALiCAIAAAA3mKuoAABStklEQVR42u3dPbacPLSt4dNB92M3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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-15" NO="15" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Weighted relative risk of fracture after alendronate by years of treatment and dose: Follow-up denominators</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqwAAALTCAIAAABc1MdzAABP7klEQVR42u3dPbLcLNeo4XeCnocH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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-16" NO="16" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Weighted relative risk (RR) of fracture after alendronate (10 mg): sensitivity analysis by baseline prevalent vertebral fracture rate</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAn4AAALQCAIAAACBpOqpAABTGklEQVR42u3d3Y7soK627Xn+J7L2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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-17" NO="17" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Summary of adverse drug events reported in randomized placebo-controlled trials of alendronate (part 1)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA40AAALHCAIAAAClgjDQAABr+ElEQVR42u3dS67tOpOu59VY1w33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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-18" NO="18" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Summary of adverse drug events reported in randomized placebo-controlled trials of alendronate (part 2)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4QAAAKfCAIAAAC5SpGAAABWSElEQVR42u3dW9bkqBJl62x6Ne1v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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-19" NO="19" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Summary of adverse drug events reported in randomized placebo-controlled trials of alendronate (part 3)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5MAAALYCAIAAABuZTHFAABm0UlEQVR42u3dDbLsKLCd0R76G9od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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-20" NO="20" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Summary of adverse drug events reported in randomized placebo-controlled trials of alendronate (part 4)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4kAAAF2CAIAAABMF0rnAAAyZ0lEQVR42u3dXbLjLK+G4Xf+o8rI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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-21" NO="21" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Adverse drug reactions reported to CADRMP for etidronate, alendronate and risedronate</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiYAAAJYCAIAAADZhLqgAABFpElEQVR42u29Xa4srdKkuYfWQ6vR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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-22" NO="22" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Summary of Findings for Primary Prevention</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsUAAAPHCAIAAABPFqPwAABwiklEQVR42u3d67HsOJO25/ZmDJAD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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-23" NO="23" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Summary of Findings for Secondary Prevention</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAskAAAOECAIAAADc5ju8AABsUElEQVR42u3d65HsuJJo6dLmCDDq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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2011-07-08 11:44:37 -0400" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2008-08-12 15:11:34 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-08-12 14:59:50 -0400" MODIFIED_BY="[Empty name]">Feedback from Maryann Napoli</TITLE>
<DATE_SUBMITTED>
<DATE DAY="2" MONTH="6" YEAR="2008"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2008-08-12 15:11:34 -0400" MODIFIED_BY="[Empty name]">
<P>Date of Submission: 02-Jun-2008</P>
<P>Name: Maryann Napoli</P>
<P>Email Address: <A HREF="mailto:mnapoli2@ix.netcom.com">mnapoli2@ix.netcom.com</A>
</P>
<P>Personal Description: Occupation a consumer advocate</P>
<P> </P>
<P>Feedback: I like the new format of the plain language summary, particularly the way you have expressed "best estimates."  But there is a glaring omission: You should also provide an estimate of the number of hip fractures, vertebral fractures, etc out of 100 women who do NOT take alendronate. If this and future PLS do not include numerical information about the no-treatment options, then it will not be clear to readers what their chances of having a hip fracture, vertebral fracture, etc. are to begin with. People will want to know "one fewer than what?"</P>
<P>Submitter agrees with default conflict of interest statement: I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback. </P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2008-08-12 11:16:15 -0400" MODIFIED_BY="[Empty name]">
<P>Thank you for your feedback about the Plain language summary.  The CSMG has been and continues to be actively involved in research to summarise our reviews in a format that is useful and comprehensible to consumers. </P>
<P>Your feedback addresses the issues around providing absolute event rates and absolute differences to consumers, in particular for dichotomous outcomes.  In summaries that we have published in earlier reviews, review authors presented primarily absolute event rates without differences. In this review, differences were provided, but event rates were not. Unfortunately we do not have high quality evidence to determine the best presentation, but we continue to investigate and explore the options.  User testing of a variety of Plain language summary formats, which is funded by the Cochrane Collaboration Opportunity Fund, is pending and we look forward to the results.</P>
<P>As you have suggested, we have edited this Plain language summary to present absolute event rates.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2008-08-12 15:07:41 -0400" MODIFIED_BY="[Empty name]">
<P>George A. Wells, Nancy Santesso, Tamara Rader.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2011-01-13 16:53:40 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-01-13 16:35:14 -0500" MODIFIED_BY="[Empty name]">Feedback from Mark Porcheret</TITLE>
<DATE_SUBMITTED>
<DATE DAY="22" MONTH="12" YEAR="2010"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-01-13 16:53:40 -0500" MODIFIED_BY="[Empty name]">
<P>Date of Submission: 22-Dec-2010</P>
<P>Name: Mark Porcheret</P>
<P>Email Address: <A HREF="mailto:m.porcheret@keele.ac.uk">m.porcheret@keele.ac.uk</A>
</P>
<P>Personal Description: Occupation GP Research fellow</P>
<P>Feedback: In figure 6 on page 20 the "corresponding risk" for the outcome "hip fractures" for the moderate risk population is stated to be 19 per 1000 (CI 5 to 16). Could you confimr this is a typo and should be 9 per 1000.</P>
<P>Also, I am trying to interpret this data for an EBP group I facilitate and have a question: the risks in figure 6 are 5yr risks comparing people on alendronate to those not taking it. But the heading states it is for alendronate for 1-3yrs. So, I am not sure how to phrase the evidence for use in the consultation. Does that data mean, for example for vertebral factures in the moderate risk populations, that: "If you take a 1000 people like you, those at moderate risk, in 5yrs time 63 will have had a vertebral fracture, but if all 1000 took alendronate for the 5 years only 29 will have had a vertebral fracture." This is how such a comparison would normally be comminicated with the period of risk / benefit being the same as the period of treatment, but the figure presents 5yr risks for 1-3yrs of treatment, which complicates the message. Your views on this would be welcome before the meeting we have to discuss this on 12th January 2011. Many thanks Mark Porcheret</P>
<P>Submitter agrees with default conflict of interest statement:</P>
<P>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2011-01-13 16:37:05 -0500" MODIFIED_BY="[Empty name]">
<P>Many thanks for your feedback on this review. Please find below our response to your comment after consultation with the lead author, George Wells.</P>
<P>Regarding your first point, yes, we can confirm that there is a typo here and it should state 9 per 1000. We will fix this for the next issue of the Library. </P>
<P>For your second point, yes, the risks in the table are for 5 year risks and your interpretation is correct (though the '63' in your email should be '53' as from the table). The '1-3' years in the heading simply indicates that the relative risk came from studies of 1 to 3 years duration (since this is the best evidence that we have) but were modeled on a 5-year time horizon. We agree this heading is confusing so we will take the '1-3' out of the heading and explain this in a footnote in the table for the next issue. We also noticed that the high-risk population should state 62/1000 instead of 62/100.</P>
<P>Thanks again for bringing this to our attention.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2011-01-13 16:37:35 -0500" MODIFIED_BY="[Empty name]">
<P>George A Wells, Lara Maxwell.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-03" MODIFIED="2011-07-08 11:44:37 -0400" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-07-08 11:38:39 -0400" MODIFIED_BY="[Empty name]">Feedback from Aaron M Tejani</TITLE>
<DATE_SUBMITTED>
<DATE DAY="17" MONTH="12" YEAR="2010"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-07-08 11:36:32 -0400" MODIFIED_BY="[Empty name]">
<P>Date of Submission: 17-Dec-2010</P>
<P>Name: Aaron M Tejani</P>
<P>Email Address: <A HREF="mailto:aaron.tejani@fraserhealth.ca">aaron.tejani@fraserhealth.ca</A> Personal Description: Occupation a pharmacist</P>
<P> </P>
<P>Feedback: In the review, alendronate was found to have a statistically significant benefit for primary vertebral fracture prevention (45% RRR, 95% CI of 0.38 to 0.80).   The results were compiled from two studies that were conducted by Ascott-Evans et al. (2) (2003) and Cummings et al. (3) (1998) (as shown by Analysis 1.1 figure).  Based on closer inspection of these two studies we have some specific concerns.</P>
<P> </P>
<P>The review (1) cited that vertebral fractures did not occur in neither the treatment nor control group in the study by Ascott-Evans et al. (2) as shown in the Analysis 1.1 figure.  However, the study did not report the incidence of vertebral fractures. It is incorrect to assume that no vertebral fractures occurred simply because they were not reported in the trial publication. The authors of the review need to clarify if unpublished vertebral fracture information was received from Ascott-Evans et al.</P>
<P> </P>
<P>The other study that contributed to the vertebral fracture meta-analysis for alendronate was Cummings et al. 2003 (3). In this trial vertebral fractures were solely radiographically determined and not clinical fractures. The review authors should emphasize that the data used in the meta-analysis of alendronate in primary prevention from Cummings et al. 2003 was only for non-clinical vertebral fractures.</P>
<P> </P>
<P>If this review is revised, we urge the authors to also clarify whether alendronate reduces the risk of clinical vertebral fractures in secondary prevention. It would be very useful if these authors also clarify the non-clinical versus clinical fracture issue for all the oral bisphosphonate reviews.(4,5)</P>
<P> </P>
<P>1. Wells GA, Crannery A, Peterson J, Boucher M, Shea B, Welch V, Coyle D, Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD001155. DOI: 10.1002/14651858.CD001155.pub2.</P>
<P> </P>
<P>2. Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, et al. Alendronate prevents loss of bone density associated with discontinuation of homrone replacement therapy: a randomized controlled trial. Archives of Internal Medicine 2003; 163(7): 789-94.</P>
<P> </P>
<P>3. Cummings SR, Black DM, Thompson DE, Appleggate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24):2077-82.</P>
<P> </P>
<P>4. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, Coyle D, Tugwell P. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD003376. DOI: 10.1002/14651858.CD003376.pub3.</P>
<P> </P>
<P>5. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, Coyle D, Tugwell P. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD004523. DOI: 10.1002/14651858.CD004523.pub3.</P>
<P> </P>
<P>Submitter agrees with default conflict of interest statement:</P>
<P>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2011-07-08 11:44:37 -0400" MODIFIED_BY="[Empty name]">
<P>Dear Dr Tejani,</P>
<P>Thank you for your feedback regarding our review.</P>
<P>With respect to the Ascott-Evans study, we determined the absence of vertebral fractures from the information provided in the publication. (We did not request additional data from any study authors as the selective response often elicited to such a request may introduce a source of bias.) Fractures, in this paper, were assessed as adverse events. Adverse events were recorded by study personnel at each visit using non-leading questions. In reporting these events, in the results section of the paper, the authors stated that "no fractures were reported during the study". We agree that it may have been presumptuous of us to assume the absence of vertebral fractures from this report and we would not be adverse to removing this study from the analysis. Doing so, however, would not substantially alter our results or conclusions.</P>
<P>Your concern regarding the Cummings paper is a point well taken. This was the only primary prevention study which reported both radiographic and clinical fractures as separate outcomes. Since the other papers (with the exception of Ascott-Evans having 0 events) reported only radiographic vertebral fractures we decided, for the sake of consistency, to use the radiographic outcome for Cummings in the meta-analysis. (As well, all of the alendronate studies in the secondary prevention analysis reported only radiographic fractures.) Your suggestion that we clarify the issue surrounding clinical and non clinical fractures for future bisphosphonate updates is a good one and will be included in the next update of the review.</P>
<P>We hope that these responses are helpful. Please do not hesitate to contact us should you have any further questions or concerns.</P>
<P> </P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2011-07-08 11:42:01 -0400" MODIFIED_BY="[Empty name]">
<P>Geroge A. Wells, Elizabeth Ghogomu.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-04" MODIFIED="2011-07-08 11:41:53 -0400" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-07-08 11:39:50 -0400" MODIFIED_BY="[Empty name]">Feedback from George Hannah</TITLE>
<DATE_SUBMITTED>
<DATE DAY="5" MONTH="11" YEAR="2010"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-07-08 11:40:44 -0400" MODIFIED_BY="[Empty name]">
<P>Name: George hannah</P>
<P>Email Address: <A HREF="mailto:george.hannah@nhs.net">george.hannah@nhs.net</A>
</P>
<P>Personal Description: Occupation GP</P>
<P> </P>
<P>Feedback: I am uncertain what length of treatment of alendronate is being referred to in the review, to produce the NNT. When you may be treating women in their 60s to prevent fractures in their 80s? Does treatment have to be ongoing to produce the benefit? Is 5 years a standard length. How does this affect NNT? ie is the NNT in year one, less than year 2, year 3 etc of treatment.</P>
<P>Submitter has modified conflict of interest statement:</P>
<P>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2011-07-08 11:41:24 -0400" MODIFIED_BY="[Empty name]">
<P>Dear Dr Hannah,</P>
<P>The NNTs reported in our review are derived from the pooling of trials varying in length between 1 and 4 years. (The majority of subjects stemmed from trials which had follow ups of 3 or 4 years). These studies were designed to evaluate the current use of alendronate and did not provide for an off drug follow up period. The estimates reported in our review cannot be extrapolated to a future date at which the patient is no longer taking the medication. </P>
<P>You had also asked if 5 years was a standard treatment length. We did not make any recommendations in the review regarding length of treatment. We used 5 year risk estimates in our Summary of Findings tables and in Figure 9 as the FRACTURE Index (Black 2001) used to classify women according to baseline risk factors was based on 5 year community population risks.</P>
<P>With respect to the effect of length of treatment on the NNTs, we did provide a breakdown of treatment effects by year of follow up in Figure 11,which could, theoretically, be translated into NNTs. These estimates, however, should be viewed with caution as in some cases they are comprised of interim time point data.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2011-07-08 11:41:53 -0400" MODIFIED_BY="[Empty name]">
<P>George A. Wells, Elizabeth Ghogomu.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>